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The aetiology of peripheral arterial disease is likely to be multifactorial. Aside from conventional risk factors, 'endocrine'
risk factors such as glucose intolerance and steroid sex hormones may be important. These factors were investigated in
the Edinburgh Artery Study, a large prospective study on the epidemiology of peripheral arterial disease.
The prevalence of peripheral arterial disease is known to be higher in subjects with diabetes mellitus or impaired glucose
tolerance compared with non-diabetic subjects. The objective of study 1 was to determine whether this could be explained
by differing levels of'traditional' risk factors, such as smoking, hypertension, dyslipidaemia and obesity. Methods: 1,592
men and women aged 55-74 years were selected at random from the age-sex registers of 11 general practices throughout
Edinburgh, Scotland. Subjects underwent a comprehensive medical examination, including assessment for peripheral
arterial disease (positive intermittent claudication questionnaire or major asymptomatic disease on non-invasive testing), a
glucose tolerance test and measurement of cardiovascular risk factors (including smoking, blood pressure, body mass
index and serum lipids and lipoproteins). Results: 288 subjects (18.7%) were found to have diabetes or impaired glucose
tolerance (IGT). The prevalence of peripheral arterial disease was greater in subjects with diabetes or IGT (20.6%)
compared to those with normal glucose tolerance (12.5%) (age and sex-adjusted OR 1.45; 95% CI 1.03, 2.04). In subjects
with diabetes or IGT, mean levels of smoking, systolic blood pressure and serum triglycerides were significantly higher in
subjects with peripheral arterial disease than in those without disease (p<0.05). In general, levels of cardiovascular risk
factors were higher in subjects with diabetes or IGT compared with normal glucose tolerant subjects; this included systolic
blood pressure and triglycerides, but not smoking. In multivariate analysis, subjects with diabetes or IGT no longer had a
significantly higher risk of peripheral arterial disease after adjusting separately for systolic blood pressure (OR 1.22, 95% CI
0.85, 1.73) or serum triglycerides (OR 1.26, 95% CI 0.89, 1.79). Simultaneous adjustment for both risk factors reduced the
odds of disease further to 1.11 (95% CI 0.78, 1.58). Conclusions: Raised levels of serum triglycerides and systolic blood
pressure in subjects with diabetes or IGT may explain a major portion of their increased risk of peripheral arterial disease.
The objectives of study 2 were to determine whether, in non-diabetic men and women from the general population, there was
an association between peripheral arterial disease and (i) plasma insulin levels or (ii) endogenous steroid sex hormones.
Methods: 83 cases with peripheral arterial disease and 88 age and sex matched controls were selected from non-diabetic
participants in the Edinburgh Artery Study. Venous blood samples were taken for measurement of steroid sex hormones and
for plasma insulin, both in the fasting state and one hour after a standard oral glucose tolerance test. Results: Compared with
controls, cases had higher mean plasma insulin levels one hour after the oral glucose load (73.6 mU/1 vs 59.8 mU/1; p<0.05).
The relationship between one-hour insulin and disease was independent of blood pressure (OR 2.04; 95% CI 1.11,3.74;
p<0.05) and partially independent of serum low and high density lipoprotein cholesterol and triglycerides (OR 1.86; 95% CI
0.99,3.48; p<0.1). However, when smoking was added to the multivariate model, the relationship between insulin and disease
diminished (odds ratio 1.64; 95% CI 0.83,3.23; p>0.1), consistent with raised mean insulin levels in smokers. Mean plasma
oestrone levels were slightly higher in male cases than controls (101.9 pmol/1 vs 92.1 pmol/1; p=0.09), but this association
lost significance after multivariate adjustment for age and body mass index. Mean levels of plasma total and free
testosterone, oestradiol and sex hormone-binding globulin were not significantly different in cases compared with controls in
either sex (p>0.1). Conclusions: In the non-diabetic general population, peripheral arterial disease was associated with non-
fasting hyperinsulinaemia, independent of blood pressure, serum lipoproteins and triglycerides. Some of the association may
have been mediated by a relationship between hyperinsulinaemia and smoking. Peripheral arterial disease was not associated
with altered levels of individual endogenous steroid sex hormones in either men or postmenopausal women. The
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Epidemiology of peripheral arterial disease, aims and objectives
1.1 Definition and classification of peripheral arterial disease
In the strictest sense, 'peripheral arterial disease' refers to all arterial pathology occurring
outwith the coronary arteries, including the arms, carotid arteries, cerebral arteries and
renal arteries as well as the aorta and arteries of the lower limbs. However, the term is
frequently used to refer to disease of the lower limb arteries alone. Such disease includes
conditions such as inflammatory arteritis, vasospastic disorders and medial calcification,
but by far the most common cause of peripheral arterial disease is atherosclerosis.
For the purposes of this thesis, as in general parlance, the term 'peripheral arterial disease'
is used to refer to atherosclerotic disease of the lower limbs. Indeed, in most
epidemiological studies, causes of peripheral arterial disease other than atherosclerosis
cannot be easily differentiated; it is generally accepted that inclusion of these few cases
will have a minimal effect on the overall results. Also consistent with usual terminology,
'cardiovascular disease' is used to include both peripheral arterial disease and coronary
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artery disease (generally myocardial infarction and angina), a condition for which the
most common underlying pathology is also atherosclerosis.
Atherosclerotic disease of the lower limbs ranges from mild asymptomatic disease to
severe limb-threatening ischaemia. Intermittent claudication is the prime symptom,
characterised by pain in the muscles of the leg when walking which is relieved by rest and
provoked by an inadequate arterial blood flow during exercise. At the more severe end
of the spectrum of disease is critical limb ischaemia, a term used to describe those
patients whose arterial disease has led to rest pain in the foot or tissue necrosis
(ulceration or gangrene). More formal definitions of critical limb ischaemia have required
the presence of a reduced ankle systolic pressure (less than 50 mmHg) or, in diabetics,
absent peripheral pulses, in addition to rest pain or tissue necrosis (European Consensus
on Critical Limb Ischaemia 1989, 1992). However, the validity of including what are
fairly arbitrary ankle pressures in the definition of disease has been challenged (Thompson
et al 1993, Tyrell and Wolfe 1993).
1.2 Atherosclerosis
Atherosclerosis is derived from the Greek words athero (meaning gruel or paste) and
sclerosis (hardness). A normal arterial wall consists of two layers of smooth muscle, the
tunicae intima and media, which are surrounded by a layer of adventitia. Athersclerosis
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involves deposition of lipids, cellular waste products, calcium and fibrin in the tunica
intima, resulting in the formation of atherosclerotic plaque.
The earliest precursors of atherosclerotic plaque are thought to be 'fatty streaks',
deposits of lipid in the tunica intima which can be seen in the aorta and large arteries
during childhood (McGill 1968). In some people the disease progresses rapidly in their
third decade, while in others it does not become threatening until they are in their fifties
or sixties.
Exactly how atherosclerosis begins or what causes it is not known, but some theories
have been proposed. It is thought that atherosclerosis may begin because the inner lining
of the artery (endothelium) becomes damaged, resulting in denuding of the intima. Three
of the possible causes of damage to the arterial wall are;
• elevated levels of cholesterol and triglyceride in the blood
• high blood pressure
• cigarette smoke
This damage results in a proliferation of smooth muscle cells to form the simple or
fibrous plaque, which, over time, progresses to a complicated plaque. Lipids, fibrin,
platelets, cellular debris and calcium are deposited in the artery wall. These substances
may stimulate the cells of the artery wall to produce still other substances that result in
proliferation and migration of macrophages and vascular smooth muscle cells into the
forming atherosclerotic plaque. At the same time, lipids build up within and around these
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cells, which also form connective tissue (Ross 1986a, Ross 1993).
One recent theory on the early events in atherogenesis suggests that excess lipoproteins in
the blood are trapped within the arterial wall where they are subsequently oxidized.
These modified lipoproteins are taken up by macrophages or smooth muscle cells more
rapidly than normal to form cholesterol-laden foam cells (Steinberg et al 1989, Leake
1993). This, in turn, leads to the deposition of connective tissue cells and other elements
(Klatt and Esterbauer 1996). Platelets may also have a particularly important role in
atherosclerosis; one of the prostaglandins which they form may damage arteries and
platelet-derived growth factors can stimulate the growth of smooth muscle cells.
Platelets are normally present in the arterial wall, but their abnormal growth and
accumulation is believed to be one of the earliest events in the atherosclerosis process
(Ross 1986b).
Whatever the underlying cause of the atherosclerotic process, the innermost layer of the
artery becomes markedly thickened by the accumulating cells and surrounding material. If
the wall is thickened sufficiently, the diameter of the artery will be reduced and the
amount of blood decreased, thus decreasing the oxygen supply. In addition, two 'acute'
events may occur;
• haemorrhage into the plaque: intraplaque haemorrhage is clinically important as
it may erupt through the surface of the plaque, producing an embolisation of
platelets, fibrin and cholesterol
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• formation of a blood clot (thrombus) on the plaque surface following loss of
surface integrity
If either of these occurs and blocks the entire artery, an acutely ischaemic leg may result
(Badimon et al 1992).
1.3 Measurement of peripheral arterial disease
Symptomatic peripheral arterial disease is most commonly measured in epidemiological
surveys using the World Health Organisation (WHO)/Rose intermittent claudication
questionnaire (Appendix I). This questionnaire was devised in 1962 by Professor G.
Rose to diagnose intermittent claudication in epidemiological surveys, and was
subsequently adopted by the WHO for use worldwide (Rose 1962). The severity of
intermittent claudication can be graded using the questionnaire - Grade 1: symptoms
occur while walking 'at an ordinary pace on the level' and Grade 2: symptoms occur
while walking 'uphill' or in a 'hurry'. It can also be used to identify 'possible
claudicants', i.e. those with exercise leg pain not present at rest, but not otherwise fully
concordant with the full WHO criteria (Criqui et al 1985). Unfortunately, although the
WHO questionnaire is very specific, it is only moderately sensitive, and a more accurate
alternative devised in Edinburgh is now becoming more widely used (Fowkes 1988a,
Leng and Fowkes 1992).
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Peripheral arterial disease can also be measured by clinical tests such as the ankle brachial
pressure index (ABPI), the ratio of systolic blood pressure in the ankle to that in the arm.
This can be easily, quickly and reproducibly measured using a portable Doppler probe
and sphygmomanometer (Fowkes et al 1988). In small studies on hospital patients, an
ABPI of less than 0.9 has been shown to be up to 95% sensitive in detecting angiogram
positive disease (Yao et al 1969, Hummel et al 1978, Ouriel et al 1982) and a ratio of
greater than 0.9 was almost 100% specific in identifying supposedly healthy subjects
(Fowkes 1988a). However, these studies mostly used selected hospital patients who
were symptomatic and it is not known how the ABPI would correlate with disease in
asymptomatic subjects. In such subjects, the ABPI cannot be assumed to be a valid
indicator of disease on its own.
In some subjects known to have significant peripheral arterial disease, blood pressures
may be normal at rest but may become abnormal after exercise (exercise stress test) or an
equivalent stress such as that caused by obstructing blood flow (reactive hyperaemia
stress test). The exercise stress test is usually performed on a treadmill; following a
standard amount of exercise, subjects with peripheral arterial disease show a significantly
greater fall in ankle pressure and have a longer recovery time than normal subjects
(Fowkes 1988a). However, practical problems due to the use of heavy equipment and
inability of some patients with co-existing cardiac or mobility problems to complete the
test restricts the usefulness of this test in epidemiological surveys.
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In the reactive hyperaemia test, ankle systolic pressure is measured after the release of a
pneumatic cuff occluding arterial blood flow just above the knee. The systolic pressure in
patients with peripheral arterial disease is reduced two to three times further and takes
longer to return to pre-occlusion levels than in healthy subjects (Johnson 1975, Hummel
et al 1978). In general, using a cuff pressure about 50 mmHg above systolic for only 3
minutes to occlude blood flow causes minimum discomfort to the patient while still
resulting in a significant post-occlusion alteration in blood flow. Measuring the blood
pressure at between 15 and 30 seconds after the cuff has been released has been shown to
be the optimum time to distinguish between subjects with angiogram positive disease and
controls; in this situation the test is over 95% sensitive in detecting disease (Johnson
1975, Fowkes 1988a). The test may be particularly useful for detecting subjects with
peripheral arterial disease in whom the presence of medial arterial calcification (as may
occur in diabetes) can render measurement of the ABPI an unreliable marker of disease.
Techniques used to assess disease severity include angiography, duplex scanning and
walking tests. Angiography, in which injection of contrast medium into a peripheral
artery allows visualization of the lower limb arterial system, is considered the 'gold
standard' against which to evaluate all other measures of peripheral arterial disease.
However, angiography is expensive and time-consuming to perform. It is also not
without risk to the patient, and for this reason it is not suitable for use in population
surveys. Angiography and duplex scanning have the advantage of localizing abnormal
arterial segments and categorizing disease severity at specific sites. With angiography as
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the gold-standard, peak systolic velocity ratios greater than 2 on duplex are 95% specific
and at least 85% sensitive at detecting stenoses affecting more than 50% of the arterial
lumen diameter (Leng 1993).
Treadmill exercise testing, in which patients walk at a defined speed and slope until the
onset of claudication pain (claudication distance) or a maximum level of claudication pain
is reached (maximum walking distance) is well accepted by both patients and physicians
and is widely used as a clinical test of disease severity. However, the reproducibility of
treadmill testing is poor and results should be interpreted with caution (Ouriel et al 1982).
1.4 Incidence and prevalence
The incidence of intermittent claudication (the development of new cases in a population
initially free of disease) has only recently begun to be reported in samples of the general
population which were not highly selected. In middle-aged subjects, annual incidences of
1.0 to 10.1 per 1000 have been reported in four population studies (Bainton et al 1994,
Bowlin et al 1994, Leng et al 1996, Murabito et al 1997). The incidence of disease was
higher in men than in women (Murabito et al 1997) and generally increased with age
(Bainton et al 1994, Bowlin et al 1994, Murabito et al 1997).
The prevalence of intermittent claudication (the proportion of individuals with disease at
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any given time) is easier to measure and has been reported more widely. However,
comparison between populations can be difficult due to highly variable criteria used by
different studies to diagnose disease. Table 1.1 summarises prevalence figures from
population studies, all of which used the WHO or Edinburgh claudication questionnaire
as standard measures of disease, allowing reasonable inter-population comparisons. The
prevalence of intermittent claudication varied widely, ranging from 1.0% to 7.7% in
middle-aged men and from 0.4% to 4.6% in middle-aged women. Prevalence increased
with age and, although inconsistently reported, appeared to be approximately 1.5 to 2
times more common in men than in women.
Accurate figures on the incidence of critical limb ischaemia are not available. The Second
European Consensus Document on Chronic Critical Limb Ischaemia (1992) estimated an
annual incidence of between 50 and 100 per 100,000 population, whereas recent data
from Oxford suggested an incidence of 30 per 100,000 per year (Collins 1992). From a
national audit, the Vascular Surgical Society estimated that 20,000 patients presented
annually in the United Kingdom and Ireland, equating to 40 per 100,000 per year (Harris
et al 1995). Critical limb ischaemia is more common in men than women (approximately
1.5:1), and the prevalence generally increases with age (Harris et al 1995).
The wide variety of methods used to detect asymptomatic disease in population studies
makes it particularly difficult to compare figures for disease prevalence. However, in
general, the prevalence of disease detected by noninvasive procedures is at least three
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times greater than the prevalence of intermittent claudication, with a similar distribution
by age and sex (Dormandy et al 1999a).
1.5 Prognosis
Peripheral arterial disease stabilizes soon after onset in approximately 75% of patients,
and only 25% of claudicants will deteriorate to rest pain or gangrene (Dormandy et al
1999b). A subjective improvement in symptoms does not necessarily indicate regression
of atherosclerosis, but may simply represent psychological and physiological adaptation
to the ischaemia, such as the development of a collateral circulation. Only 3% to 22% of
those claudicants presenting to a doctor ever require reconstructive arterial surgery, and
as few as 1% may undergo amputation (Leng and Fowkes 1993). In addition to local
symptoms, claudicants have an increased prevalence of coronary artery disease and
cerebrovascular disease; coronary disease is the most common cause of death in subjects
with peripheral arterial disease (Dormandy et al 1999b).
More than 90% of patients with critical limb ischaemia undergo major amputation,
arterial reconstruction or angioplasty over the twelve months following presentation
(Harris et al 1995). Amputation leads to loss of mobility and independence,
psychological morbidity and reduced life expectancy. If untreated, critical limb ischaemia
is often fatal. Even if treated, patients with critical limb ischaemia have a high risk of
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dying, with a mortality in excess of 10% per year, usually from coexistent coronary artery
disease and cerebrovascular disease (Wolfe 1986, DeWeese et al 1993, Tyrell and Wolfe
1993).
1.6 Risk factors
It is likely that many of the risk factors for peripheral arterial disease are common to all
atherosclerotic conditions, including coronary artery disease and ischaemic stroke.
However, there is evidence that peripheral arterial disease has its own risk factor profile
in terms of the relative importance of such atherosclerotic risk factors.
A summary of selected risk factors implicated in the pathogenesis of peripheral arterial
disease is given in Table 1.2. For many of these, however, much of the evidence comes from
the study of coronary artery disease and their role in peripheral arterial disease is uncertain.
The impact on peripheral arterial disease of the 'traditional' cardiovascular risk factors
(smoking, hypertension and hyperlipidaemia) and/or those included as possible confounding
factors in the projects presented in this thesis are discussed below. Diabetes, plasma insulin
and steroid sex hormones are reviewed in detail in chapter 2.
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1.6.1 Smoking
Cigarette smoking is the single most powerful risk factor for peripheral arterial disease
(Schroll and Munck 1981, Fowkes 1988b, Fowkes et al 1992). Three quarters of cases of
intermittent claudication may be attributable to smoking (Kannel and McGhee 1985), which is
a more important risk factor for the development of peripheral arterial disease than it is for
ischaemic heart disease. Thus, cigarette smoking can result in a seven-fold increase in the
risk of peripheral arterial disease (Heliovaara et al 1978, Hughson et al 1978), compared
with a two-fold increase in the risk of coronary artery disease (Doll et al 1976, Doll et al
1980).
The pathophysiological mechanisms by which smoking results in the development of
atherosclerotic disease are unknown. Suggested mechanisms include endothelial
disturbance, changes in fibrin formation and turnover, altered blood rheology, changes in
lipids and lipoproteins and reduced availability of antioxidants. Thus, smokers have been
shown in some studies to have increased plasma levels of von Willebrand factor (a marker
of endothelial dysfunction), raised plasma fibrinogen (the precursor of fibrin) and elevated
haematocrit (Ogston et al 1970, Meade et al 1987, Blann 1991, Smith et al 1993),
together with altered blood lipid and lipoprotein profiles (Craig et al 1989) and reduced
circulating antioxidants (Duthie et al 1990). However, in the Edinburgh Artery Study,
the combined effect of smoking on these risk factors explained only part of its influence
on peripheral arterial disease, and the majority of the effect appeared to be due to other
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mechanisms (Price et al 1999). The latter could include a direct toxic effect of whole
smoke, nicotine and/or carbon monoxide on endothelial cells (Krupski 1991), increased
platelet reactivity and aggregability (Lassila et al 1988), and/or a detrimental effect of the
elevated white blood cell count found consistently in smokers (Corre et al 1971,
Friedeman et al 1973).
1.6.2 Hyperiipidaemia
Various lipids and lipid fractions have been implicated in the pathogenesis of peripheral arterial
disease, including total serum cholesterol, lipoprotein subtractions and plasma triglycerides. It
seems fairly certain that raised serum cholesterol increases the risk of disease. Thus in most
(Hale et al 1988, Fowkes et al 1992), though not all (Gofin et al 1987), cross-sectional
population studies, total serum cholesterol was found to be independently associated with
peripheral arterial disease. In prospective studies, serum cholesterol was found to be an
independent risk factor for intermittent claudication (Kannel and McGhee 1985) and to
correlate with ankle brachial pressure indices (Schroll and Munck 1981).
In recent years, interest has concentrated on the lipoprotein subtractions of cholesterol. Low
density lipoprotein cholesterol is the main carrier of cholesterol from the liver to hepatic and
peripheral tissues and tends to reflect the role of total cholesterol as an atherosclerotic risk
factor. High density lipoprotein cholesterol picks up cholesterol from peripheral tissues and
returns it to the liver, thus acting in opposition to low density lipoprotein cholesterol (Gotto
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1990). Reduced levels of high density lipoprotein cholesterol have been found in the vast
majority of hospital cases of peripheral arterial disease compared with control subjects (Leng
and Fowkes 1993), and are also associated with an increased severity of disease (Beach 1979,
Jacobson et al 1984). In the few community studies in which high density lipoprotein
cholesterol has been examined, there is some support for lower levels of the lipoprotein in
those with disease (Pomrehn et al 1986), but other studies have shown no significant
relationship (Gofin et al 1987). However, in the Edinburgh Artery Study there was a strong
inverse relationship between high density lipoprotein cholesterol levels and intermittent
claudication, which persisted on adjustment for other lipids, obesity, smoking, diabetes and
alcohol consumption (Fowkes et al 1992).
Elevated levels of serum triglycerides have been identified in patients with peripheral arterial
disease in numerous case control studies (Leng and Fowkes 1993). Similarly, the majority of
cross-sectional (Hughson et al 1978, Schroll and Munck 1981, Pomrehn et al 1986, Hale et al
1988, Fowkes et al 1992) and prospective (Da Silva and Widmer 1980, Schroll and Munck
1981) population studies have shown a univariate association with triglyceride levels.
However, whether serum triglycerides are important in the development of disease in their
own right is uncertain, since the relationship generally disappears when multivariate analysis is
undertaken to adjust for other risk factors, including smoking, blood pressure, and other lipids
(Schroll and Munck 1981, Pomrehn et al 1986). Evidence from the Edinburgh Artery Study
suggests that the strong univariate relationship between triglycerides and peripheral arterial
disease can mostly be explained by the correlation between triglyceride levels and non-high
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density lipoprotein cholesterol (Fowkes et al 1992), comparable with the situation for serum
triglycerides and coronary artery disease (Austin 1989).
1.6.3 Hypertension
Elevated blood pressure has been associated with the development of peripheral arterial
disease in many studies. Most case control studies and cross-sectional surveys show
associations with only systolic pressure (De Backer et al 1979, Schroll and Munck 1981,
Jacobson et al 1984, Gofin et al 1987, Hale et al 1988) although a few implicate both systolic
and diastolic pressure (Reid et al 1966, Hughson et al 1978), have conflicting results (Bothig
et al 1976) or show no association (Reunanen et al 1982). However, as elevated blood
pressure may be secondary to atherosclerotic changes in blood vessels, its role in the aetiology
of peripheral atherosclerosis can only be clearly determined in prospective studies.
Unfortunately, the results from cohort studies are not consistent: one reported a three-fold
increased risk of intermittent claudication at 26 years follow-up, primarily associated with a
raised systolic pressure (Kannel and McGhee 1985); another found that both initial systolic
and diastolic pressures were correlated with the ankle pressure index after 10 years (Schroll
and Munck 1981), whereas a third did not find any association between blood pressure and
the development of intermittent claudication (Da Silva et al 1979). Therefore, the importance
of elevated blood pressure as a risk factor for peripheral arterial disease has not been clearly
established in epidemiological studies.
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1.6.4 Obesity
It is generally assumed that people who are obese are at an increased risk of arterial disease.
This is primarily due to reported associations between body mass index (as a measure of
overall obesity) and coronary artery disease, since investigation into the relationship between
obesity and other forms of arterial disease is scarce. However, even in studies on coronary
artery disease, an elevated body mass index has often not been significantly related to the risk
of disease (Bradley 1982, Keys et al 1984) or only in very large samples (Manson et al 1990).
Recently, some studies have suggested that the localisation rather than the degree of obesity
is the important factor. Thus, in women, an increased ratio of waist circumference to hip
circumference (waist hip ratio) was a significant risk factor for subsequent mortality from
myocardial infarction independent ofbody mass index, whereas body mass index itselfwas not
a significant independent risk factor (Lapidus et al 1984, Bengtsson et al 1993). Such an
'android' distribution of adipose tissue, with relative abdominal adiposity, has now been
shown to be a risk factor for coronary artery disease in both men and women (Lapidus
and Bengtsson 1988, Larsson 1988, Thompson et al 1991). Some of this effect may be
due to the association between visceral fat accumulation and a variety of risk factors,
including raised low density lipoprotein cholesterol and triglycerides, reduced high
density lipoprotein cholesterol, hypertension, hyperinsulinaemia and insulin resistance
(Despres et al 1990). Although the waist hip ratio is often used to assess degrees of
abdominal fat, the results of computed tomography indicate that it is more likely to be the
amount of intra-abdominal or visceral fat that predicts coronary artery disease (Fujioka et
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al 1987, Peiris et al 1988).
The role of obesity and fat distribution in peripheral arterial disease is uncertain. In the
Edinburgh Artery Study, body mass index was not related to either symptomatic or
asymptomatic peripheral arterial disease (Fowkes et al 1992), This was consistent with
findings from a number ofother case control and cross-sectional studies (Reunanen et al 1982,
Pomrehn et al 1986, Vigna et al 1992, Newman et al 1993), although in Italy, the prevalence
of peripheral arterial disease was associated with a raised body mass index in women but not
in men (Novo et al 1992). In the Speedwell prospective study, body mass index did not
predict the development of intermittent claudication in middle aged men from the general
population (Bainton et al 1994). However, after 5 years of follow-up, a raised body mass
index was (weakly) associated with an increased incidence of intermittent claudication in
Israeli men (Bowlin et al 1994). Measures of adiposity other than body mass index have not
been widely considered. In a single study on elderly Japanese American men, there appeared
to be a 'U-shaped' relationship between waist hip ratio and a reduced ankle brachial pressure
index (less than 0.9), with higher abnormality rates in the lowest and highest quintiles ofwaist
hip ratio than in the midrange. However, this relationship was not statistically significant and
was similar to that found for body mass index (Curb et al 1996).
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1.7 Background to project
The Edinburgh Artery Study was established in 1988 to address the relative lack of
epidemiological research into peripheral arterial disease. The initial cross-sectional
survey involved clinical examination of 1592 men and women, aged 55 to 74 years,
selected at random from the general population of Edinburgh. In the prospective phase
of the study, subjects were followed up for cardiovascular events and death, and were
invited to a 5-year follow-up clinic where they underwent further clinical examination.
Analysis of the data collected on disease parameters and potential risk factors has led to a
greater understanding of the distribution and aetiology of peripheral arterial disease in the
general population. However, one area which has not received a great deal of attention
(either in the Edinburgh Artery Study or elsewhere), is the role of endocrine risk factors.
For example, diabetes is a particularly well-recognised risk factor for peripheral arterial
disease, but the reasons why are unknown. Whether or not hyperinsulinaemia (a
characteristic ofmany subjects with diabetes) might affect the development of peripheral
arterial disease is uncertain. Similarly, although peripheral arterial disease is more
common in men than in women, the role of endogenous steroid sex hormones in the
aetiology of peripheral arterial disease has not been investigated
In view of this lack of information, it was decided to investigate the relationship between
several endocrine risk factors (diabetes, plasma insulin and steroid sex hormones) and
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peripheral arterial disease in the Edinburgh Artery Study. Data was already available on
the diabetic status of study participants and levels of 'traditional' cardiovascular risk
factors. This allowed the author to undertake original analysis on the relationship
between these factors and the development of peripheral arterial disease without further
data collection. However, plasma insulin and steroid sex hormone levels had not
previously been measured. It was not considered practicable, on the grounds of cost and
'over-investigation' of the study population, to carry out investigations on the whole study
population. Instead, a more feasible option was to perform a case control study on
selected subjects; this was undertaken by the author during 1995, using subjects who had
attended the 5-year follow-up examination.
1.8 Aims and objectives
The overall aim of the work presented in this thesis was to investigate the association
between peripheral arterial disease and a range of endocrine risk factors (diabetes, plasma
insulin and steroid sex hormones).
The specific objectives were:
a) To determine whether the higher prevalence of peripheral arterial disease in subjects
with diabetes or impaired glucose tolerance compared with non-diabetic subjects
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could be explained by differing levels of'traditional' risk factors, including;
i) Cigarette smoking
ii) Hypertension (systolic and/or diastolic)
iii) Dyslipidaemia (hypercholesterolaemia, hypertriglyceridaemia,
raised low density lipoprotein cholesterol and/or reduced high
density lipoprotein cholesterol)
iv) Elevated body mass index
b) To determine whether the following measures of circulating insulin and/or insulin
resistance were associated with peripheral arterial disease in non-diabetic men and
women and, if so, whether this was independent of other cardiovascular risk factors;
i) Fasting plasma insulin levels
ii) Plasma insulin levels one hour after a standard oral glucose load
iii) Insulin resistance
c) To determine whether the following endogenous steroid sex hormones were
associated with peripheral arterial disease in men and/or women;
i) Total plasma testosterone
ii) Free plasma testosterone




The rationale for measuring free testosterone in addition to total concentration was that,
while there is an overall high correlation between the two measures under normal
circumstances, it is possible that the percentage of hormone which is free in the
circulation may differ between subjects with and without peripheral arterial disease (for
example, due to variations in the affinity of testosterone for sex hormone-binding
globulin). In addition, testosterone parameters have been found to change from around age
40, with a reduction in free testosterone levels and an increase in sex hormone-binding
globulin levels of about 1.2% per year, so that total testosterone levels may not adequately
reflect the true level ofbioavailable testosterone in older men (Gray et al 1991).
It was not proposed to measure free oestrone because it binds only loosely to albumin
and not at all to sex hormone-binding globulin. Neither was it proposed to measure free
oestradiol. A smaller percentage of oestradiol is bound to sex hormone-binding globulin
than is the case for testosterone and the relationship between concentration of the
globulin and bioavailable oestradiol has not been as well established. The concentration
of total oestradiol is low in postmenopausal women and men, such that any difference
between subjects with and without peripheral arterial disease in the free fraction of
hormone would be difficult to detect.
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Diabetes, insulin and steroid sex hormones
2.1 Diabetes mellitus
2.1.1 Classification and epidemiology
Diabetes mellitus is a clinical syndrome characterised by hyperglycaemia due to absolute
or relative deficiency of insulin. Since the distribution of blood glucose in populations is
unimodal, with no clear division between normal and abnormal, diagnostic criteria are
necessarily arbitrary, and have been selected according to the degree of hyperglycaemia
associated with microvascular complications (such as retinopathy, regarded as the
hallmark of diabetes). Until very recently, the diagnostic criteria for diabetes mellitus
involved a fasting plasma glucose of 7.8 mmol/l or greater and/or a level of 11.1 mmol/1
or greater two hours after administration of a standard (75g) oral glucose tolerance test
(National Diabetes Data Group 1979, WHO 1980). This World Health Organization
criteria also recognised an intermediate zone of abnormal blood glucose levels called
'impaired glucose tolerance', diagnosed when the two hour plasma glucose value was
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between 7.8 mmol/1 and 11.1 mmol/1. In 1997, the American Diabetes Association
proposed modifying the diagnostic criteria by lowering the fasting glucose at which
diabetes can be diagnosed to 7.0 mmol/1 (because a fasting value of 7.8 mmol/1 defines a
greater degree of hyperglycaemia than a 2-hour value of 11.1 mmol/1) (Report ofExpert
Committee 1997). This simple fasting sample is now preferred for diagnosis to the more
complex 75g oral glucose tolerance test.
Diabetes has a worldwide distribution, although the prevalence varies considerably
between different countries (King et al 1993, WHO 1994). Recent reports suggest that
the prevalence of known diabetes in the United Kingdom is between 1% and 2% (Zimmet
1982, Gatling et al 1985, Neil et al 1987, WHO 1994). However, this is set to increase,
since the incidence of both types of primary diabetes, type 1 diabetes (previously known
as insulin-dependent diabetes mellitus or juvenile-onset diabetes) and type 2 diabetes
(previously known as non-insulin-dependent diabetes mellitus or adult-onset diabetes) is
rising worldwide (Kurtz et al 1988, National Center for Health Statistics 1994). In
addition, almost 50% of cases of type 2 diabetes in the general population may remain
undetected (Zimmet 1982). These factors mean that diabetes is a major and escalating
public health problem.
In the United Kingdom, as in most European countries and North America, type 1
diabetes accounts for approximately 15% of all diagnosed cases of diabetes, while type 2
diabetes accounts for up to 85% (Gatling et al 1988). Other specific types of diabetes
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result from certain genetic syndromes, surgery, drugs, malnutrition, infections, and other
illnesses and account for only 1% to 2% of all diagnosed cases (National Diabetes Data
Group 1979). Gestational diabetes, which develops in 2% to 5% of all pregnancies
(Freinkel 1980), usually disappears when a pregnancy is over (Ratner 1993), although
women who have had gestational diabetes are at increased risk for later developing type 2
diabetes (Damm et al 1992, Dornhorst and Beard 1993).
The causes of type 1 diabetes appear to differ from those for type 2 diabetes. The
appearance of type 1 diabetes is suspected to follow exposure to an 'environmental
trigger', such as an unidentified virus, stimulating autoimmune destruction of the 13 cells
of the pancreas in some genetically predisposed people (Szopa et al 1993, Atkinson and
Maclaren 1994). For type 2 diabetes, risk factors include obesity, increasing age, family
history of diabetes, physical inactivity and race (DeFronzo et al 1992). Twin studies also
provide evidence for a genetic basis to the condition, but the exact mechanisms for
development are unknown (DeFronzo 1997).
Whereas in type 1 diabetes the single fundamental defect is severe insulin deficiency
(which, if untreated, results in hyperglycaemia), there appears to be two main
pathophysiological defects in type 2 diabetes, namely altered insulin secretion and insulin
resistance. Altered patterns of insulin secretion, including impaired meal-related insulin
secretion, leads to exaggerated and prolonged postprandial hyperglycaemia, which is an
important contributor to the overall loss of glycaemic control (Polonsky et al 1988).
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Insulin resistance, defined as a diminished ability of insulin to exert its biological action
across a broad range of concentrations, is high in those with type 2 diabetes (Ginsberg et
al 1975, Reaven 1988, Yki-Jarvinen 1995). However, resistance also varies widely in
non-diabetic subjects, some of whom are as insulin resistant as diabetic subjects
(Hollenbeck and Reaven 1987), suggesting that this defect alone cannot account for
diabetes.
The relative importance of insulin resistance or B-cell dysfunction in type 2 diabetes and
whether one defect appears before the other in the natural history of the disease is
uncertain and much disputed. Some studies indicate that insulin resistance appears before
impaired insulin secretion (Bennett 1990); it is thought that the resultant hyperglycaemia
stimulates insulin secretion, leading to hyperinsulinaemia so as to compensate and resist
blood glucose increases. Because of 13-cell defects, maximal insulin secretory capacity is
eventually reached; beyond that point (which corresponds to impaired glucose tolerance),
insulin secretion declines and overt diabetes results (Figure 2.1) (Polonski et al 1996).
2.1.2 Diabetes mellitus and arterial disease
Cardiovascular disease is the most important cause of mortality and morbidity in patients
with diabetes. Numerous prospective, population-based studies indicate that mortality
from coronary artery disease is two to four times higher in subjects with type 2 diabetes
than in comparable non-diabetic populations (Kannel and McGee 1979, Heyden et al
27
1980, Jarrett and Shipley 1985, Pyorala et al 1987, Liao et al 1993, Sprafka et al 1993).
The increased risk of disease associated with diabetes appears to be greater for women
than for men (Kannel and McGee 1979, Heyden et al 1980, Pyorala et al 1987, Liao et al
1993, Sprafka et al 1993). Cardiovascular mortality is less prominent in younger subjects
with type 1 diabetes, but is still higher than in non-diabetic young adults (Barrett-Connor
and Orchard 1985, Manske et al 1992). In addition, asymptomatic subjects with impaired
glucose tolerance or borderline fasting hyperglycaemia are found to have an increased risk of
coronaiy artery disease (Fuller et al 1979, Barrett-Connor et al 1984, Mykkanen et al 1992).
Peripheral arterial disease is also a well-recognized complication of diabetes mellitus.
Tables 2.1 and 2.2 summarize population studies performed since 1970 which have
measured the prevalence or incidence respectively of peripheral arterial disease in a
predominantly type 2 diabetic population and a comparable non-diabetic population. The
frequency of peripheral arterial disease was approximately 2.5 to 4 times higher in
diabetic men and 3 to 6 times higher in diabetic women than in their non-diabetic
counterparts, a difference which persisted after adjustment for variations in the age
structure of the compared populations (Siitonen et al 1986, Walters et al 1992). A higher
prevalence of peripheral arterial disease was found in previously undiagnosed diabetics
(identified by screening the general population using a glucose tolerance test), in newly-
presenting diabetics and in 'known' diabetics, already on treatment for the condition and with
a range of diabetes duration. An increased risk of disease has also been reported in
populations with type 1 diabetes (Walters et al 1992) and for more severe forms of
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peripheral arterial disease, such as lower limb amputations (Jarrett 1991).
More recently, impaired glucose tolerance has been considered to be a real risk factor for
peripheral arterial disease (Pyorala et al 1987, Fujimoto et al 1991, Fowkes et al 1992,
Uusitupa et al 1997). However, the evidence from various studies associating blood glucose
levels with peripheral arterial disease is conflicting. In non-diabetic men referred to a vascular
clinic, the degree of arterial disease at angiography was found to correlate with both fasting
blood glucose and with blood glucose two hours after an oral glucose load (Kingsbury 1966).
However, three cross-sectional studies found that the prevalence of intermittent claudication
was not related either to a high fasting blood glucose, or to post-glucose levels (Hughson et al
1978, Reunanen et al 1982, Gofin et al 1987), and one found an inverse relationship (DaSilva
et al 1979). Prospective studies have also produced conflicting results (DaSilva et al 1979,
Schroll and Munck 1981, Kannel and McGhee 1985).
The cause of the increased risk of arterial disease in diabetics is unknown, although it is
often assumed that adverse lipid and blood pressure profiles play an important role.
Thus, type 2 diabetes is associated with hypertension (which may be twice as common in
diabetes as in the non-diabetic population) and 'dyslipidaemia', consisting of low serum
high density lipoprotein cholesterol and high triglyceride levels (Janka et al 1980, Kreines
et al 1985, Breddin et al 1986, Kannel et al 1990, Uusitupa et al 1990, Mehler et al 1997,
Al Zahrani et al 1997). Other blood lipids may also be adversely affected, including total
and low density lipoprotein cholesterol (Breddin et al 1986, Kannel et al 1990, Uusitupa
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et al 1990, Maser et al 1991, Walters et al 1992). In addition, some studies indicate that
diabetic subjects tend to smoke more than non-diabetics (Paisey et al 1984, Breddin et al
1986, Uusitupa et al 1990). However, evidence to date suggests that such clustering of
risk factors is only partly responsible for the increased coronary artery disease risk in
diabetes (Fitzgerald and Jarrett 1991, Stamler et al 1993) and the extent to which they
might explain the increased risk of peripheral arterial disease is unknown.
2.2 Insulin
2.2.1 Normal physiology and action
Insulin is a small protein composed of two amino acids chains connected to each other by
disulphide bridges. It is synthesized by the B cells within the Islets of Langerhans in the
pancreas. Here, insulin preprohormone is cleaved to form proinsulin, which in turn is further
cleaved to form insulin (Steiner et al 1972). Under normal circumstances, 95% of the
hormone product is secreted into the circulation as insulin and less than 5% as unconverted
proinsulin (Bell et al 1980).
The main stimulator of insulin release from the B cells is glucose, such as that absorbed into
the blood after a high carbohydrate meal (Ashcroft et al 1978). Following secretion, insulin
circulates in the blood almost entirely in an unbound form; it has a plasma half-life averaging
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only about 6 minutes so that it is mainly cleared from the circulation within 10 to 15 minutes.
To initiate its effects in target cells, insulin first binds with a membrane receptor protein, a
glycoprotein consisting of two extracellular a subunits and two (3 subunits, which are partly
intracellular (Collier and Gordon 1991). This activates the receptor which initiates the insulin
effects. Elevated insulin levels, as in type 2 diabetes, lead to 'down-regulation' of the receptor,
where internalisation results in decreased numbers at the cell surface (Flier 1983). Except for
that portion of the insulin that combines with receptors in the target cells, the remainder is
mainly degraded in the liver and to a lesser extent the kidneys. This rapid removal from the
plasma is important to ensure rapid turn offof the control functions of insulin.
The main function of insulin is the regulation of blood glucose levels. In normal subjects,
blood glucose levels are maintained within relatively narrow limits at around 5 mmol/1 by the
balance between glucose entry into the bloodstream from the liver and from intestinal
absorption after meals, and glucose uptake into the peripheral tissues. Thus low, basal insulin
levels such as occurs between meals (Figure 2.2), suppress hepatic glucose output by
inhibiting glycogen breakdown - glycogenosis, and by inhibiting the formation of 'new'
glucose - gluconeogenesis. Higher post-prandial concentrations of insulin stimulate rapid
uptake, storage, and use of glucose by almost all tissues of the body, but especially the liver,
muscles, and adipose tissue (Kruszynska 1997).
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2.2.2 Role of insulin in arterial disease
Higher insulin levels in subjects with type 2 diabetes than in non-diabetics have been found for
at least five years after diagnosis (Niskanen et al 1990), presumably due to the underlying
insulin resistance and compensatory hyperinsulinaemia. In addition, individuals with type 1
diabetes are frequently hyperinsulinaemic due to peripheral administration of high-dose
exogenous insulin (Elliott and Viberti 1993). The possibility that such raised plasma insulin
levels might contribute to the increased risk of arterial disease in diabetes has stimulated
interest in hyperinsulinaemia as a risk factor for arterial disease in general.
There is some evidence that raised plasma insulin levels may increase the risk of coronary
artery disease. In two large prospective population-based studies, the Helsinki Policeman
Study (Pyorala et al 1979, Pyorala et al 1985) and the Paris Prospective Study (Ducimetiere et
al 1980, Fontbonne et al 1991), raised fasting and/or post-glucose insulin levels were
associated with the subsequent development of coronary artery disease in middle-aged, non-
diabetic men. However, recent analysis from a similar study in Busselton indicated that
hyperinsulinaemia did not affect coronary mortality in a cohort of non-diabetic men and
women (Welborn and Wearne 1979, Cullen et al 1983). A smaller prospective study in
Nauru suggested an association between insulin and coronary artery disease, but this was
based on the development of ischaemic electrocardiogram changes (Collins et al 1983).
More recently, three major cross-sectional studies also found raised fasting or post-
glucose insulin levels in men with coronary artery disease (Ronnemaa et al 1991, Modan
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et al 1991, Mykkanen et al 1993).
The role of plasma insulin in the development of peripheral arterial disease has received less
attention. Three early studies found some association between symptomatic peripheral arterial
disease in non-diabetics and elevated post-glucose insulin levels, although not fasting levels
(Welborn 1966, Sloan et al 1970, Sorge et al 1976). However, these were small hospital
based studies with poor matching of cases and controls and no adjustment for potentially
confounding factors. A more recent prospective study found that raised fasting insulin levels
were associated with an increased risk ofperipheral arterial disease in a population with type 2
diabetes but not in non-diabetics (Uusitupa et al 1990).
Raised insulin levels have been associated with a range of other cardiovascular risk factors,
including hypertension (Manolio et al 1990, Modan et al 1991), raised total serum cholesterol,
low density lipoprotein cholesterol and triglycerides and reduced high density lipoprotein
cholesterol (Laakso et al 1989, Manolio et al 1990) as well as android obesity (Stern and
Hafiher 1986). Reaven termed such clustering of risk factors in subjects with an increased
risk of atherosclerosis, 'Syndrome X', or insulin resistance syndrome, and further, suggested
that insulin resistance was the underlying defect responsible for the other manifestations of the
syndrome (Figure 2.3) (Reaven 1988). Other abnormalities which have been associated with
syndrome X include raised concentrations of plasminogen activator inhibitor-1 and fibrinogen,
which promote coagulation. The extent to which any association between hyperinsulinaemia
and arterial disease may be dependent on these other risk factors is unclear.
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2.3 Steroid sex hormones
2.3.1 Normal physiology
The steroid hormones, androgens (from the Greek cmdros, 'male') and oestrogens (from the
Greek oistros, 'a gadfly'), regulate the differentiation and development of male and female
reproductive organs, secondary sex characteristics, and behaviour patterns. Men and women
each produce both androgens and oestrogens, but they differ markedly in the extent of
production of each type ofhormone (Siiteri and MacDonald 1973, Wilson 1975).
2.3.1.1 Androgens
Production
The term androgen means any steroid hormone that has masculinizing effects. The structure
of testosterone, quantitatively the most important androgen, and the metabolic pathways by
which testosterone is synthesized are summarized schematically in Figure 2.4 (Eik-Nes 1975).
Pregnenolone is the major precursor of all steroid hormones and in each of the tissues that
produce hormones, it is the rate-limiting conversion of cholesterol to pregnenolone that is
regulated by various 'trophic' hormones produced by the pituitary (Eik-Nes 1975).
In men, the Leydig cells of the testes are the major source of androgens, including
testosterone, together with lesser amounts of dehydroepiandrosterone and
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androstenedione and very small amounts of dihydrotestosterone (Hammond et al 1977).
At least five different androgens are also produced in the adrenals, though the total
masculinizing activity of all of these is extremely slight (Nelson 1980).
In women, androgens are produced in the adrenals and ovaries; the major androgen is
androstenedione, which can be converted to testosterone (or oestrogen) in the ovary and
in extraglandular tissue (Nelson 1980, Lipsett 1986). About one fifteenth as much
testosterone is secreted into the plasma of the female by the ovaries as into the plasma of the
male by the testes (Lipsett 1986).
Protein binding and bioavailability
Following secretion, androgens are transported in blood bound to proteins. The two most
important transport proteins are albumin, which binds androgens non-specifically, and a
specific carrier protein known as sex hormone-binding globulin. Under ordinary
circumstances, 1% to 3% of the testosterone in the circulation is free (unbound), up to 44% is
bound to sex hormone-binding globulin (66% in women), and the remainder is bound to
albumin (Dunn et al 1981). Binding of testosterone to albumin is loose and dissociation of this
hormone fraction can occur within a capillary bed, such that nearly all albumin-bound
testosterone is available for tissue uptake (Pardridge 1986). Thus the bioavailable circulating
testosterone in normal subjects is equal to the free plus the albumin-bound hormone, which is
determined primarily by the circulating concentration of sex hormone-binding globulin
(Pardridge 1986). Testosterone circulates in the blood for about 15 to 30 minutes, by which
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time it either becomes fixed to the tissues or degraded into inactive products that are
subsequently excreted (Griffin and Wilson 1980). Much of the testosterone that becomes
fixed to the tissues is converted within the target cells to the more biologically active hormone,
dihydrotestosterone (Wilson 1975).
Testosterone levels in older men andwomen
In adult men, plasma testosterone levels are in the range 10 to 35 nmol/1. When older men are
carefully screened to exclude major health problems or medication use, some studies
demonstrate no fall in serum testosterone levels with age (Harman and Tsitouras 1980).
Others demonstrate a clear decrease in mean serum testosterone levels (Tsitouras and Hagen
1984). However, most older men still have serum testosterone levels within the range
considered to be normal for young men. Bioavailable testosterone is decreased in older men
(Nankin and Calkins 1986, Tenover et al 1987). In one large study testosterone parameters
began to change around age 40; free testosterone levels decreased by about 1.2% per year,
and sex hormone-binding globulin levels increased by about 1.2% per year, so that total
testosterone levels may not adequately reflect the true level of bioavailable testosterone in
older men (Gray et al 1991).
In women, plasma testosterone levels are generally less than 3.5 nmol/1. This level falls
postmenopausally, resulting in a wide range of values between approximately 0.05 and 1.5
nmol/1. This is because before the menopause, plasma androstenedione (the main precursor of
testosterone) is derived equally from the adrenal and ovary; after the menopause the ovarian
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contribution is minimal and plasma androstenedione levels decrease by 50% (Judd 1976).
2.3.1.2 Oestrogens
Oestrogens mainly promote proliferation and growth of specific cells in the body and are
responsible for development of most secondary sexual characteristics of the female, uterine
growth, thickening of the cervical mucosa, and development of the ductal system of the
breast. Only three oestrogens are present in significant quantities in the plasma of the human
female: p-oestradiol, oestrone and oestriol. The oestrogenic potency of oestradiol is
approximately 10 times that of oestrone and 25 times that of oestriol. Considering these
relative potencies, the total oestrogenic effect of oestradiol is usually many times that of the
other two together. For this reason, oestradiol is considered to be the major oestrogen,
though the oestrogenic effects of oestrone are far from negligible (Siiteri and Mac Donald
1973).
Production
The principal metabolic pathways by which oestrogens are synthesized, primarily in the
ovaries, are illustrated in Figure 2.5. During synthesis, progesterone and the male sex
hormone testosterone are generally synthesized first, mainly from cholesterol derived from the
blood; then, before these can leave the ovaries, almost all the testosterone and much of the
progesterone are converted into oestrogens (Gore-Langton and Armstrong 1994). In addition
to formation of oestrogens in the ovaries, oestrogens are also formed by aromatization of
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circulating androgenic precursors (in particular androstenedione secreted by the ovary and
adrenal) in a variety of extraglandular tissues, including muscle, adipose tissue, hair follicles,
liver and hypothalamus. Such peripheral aromatization is an important source of oestrogens,
accounting for 40% of all oestrogen formation in menstruating women, 100% in
postmenopausal women, and 85% in men (Baird et al 1968, Siiteri and MacDonald 1973).
The principal oestrogen secreted by the ovary is plasma oestradiol. Small amounts of
oestrone are also secreted, but most of this is formed by extraglandular conversion of
androgens, primarily in adipose tissue (Baird et al 1968). The rate of this aromatization is
influenced by age, obesity, liver function, and thyroid function (Siiteri and MacDonald 1973).
Oestriol is an oxidative product derived from both oestradiol and oestrone, the conversion
occurring mainly in the liver (Fishman et al 1962).
Protein binding and bioavailability
Like testosterone, oestradiol is transported in the blood bound to plasma proteins. However,
relatively less oestradiol is bound to sex hormone-binding globulin than is the case for
testosterone (about 20% in normal men and 37% in normal women), most of the remainder
binding loosely with plasma albumin (Dunn et al 1981, Rosner 1996). Although only 2% to
3% of oestradiol is free in the circulation, it is thought that part or all of the large albumin-
bound fraction may be available for uptake by some tissues and therefore have biological
activity (Pardridge 1981). Oestrone binds only loosely to albumin and hardly at all to sex
hormone-binding globulin (Dunn et al 1981). The liver conjugates oestrogens and about one
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fifth of these conjugation products are excreted in the bile while most of the remainder are
excreted in the urine. Also, the liver converts the potent oestrogens, oestradiol and oestrone,
into the almost totally impotent oestrogen oestriol.
Oestrogen levels in men andpostmenopausalwomen
In men, circulating androgens can be aromatized to oestrone and oestradiol in extraglandular
tissue (Siiteri and MacDonald 1973). Aromatization takes place in many tissues, the most
significant of which is probably adipose tissue, and the overall rate of extraglandular
aromitization increases with age and body size (Siiteri and MacDonald 1973). Small amounts
ofoestradiol are also secreted directly by the testes (MacDonald et al 1979).
In women circulating oestrogens are derived from two sources premenopausally (more than
60% secreted directly by the ovaries as oestradiol, and the remainder derived from
extraglandular conversion of androgens to oestrogen). After the menopause, the ovarian
contribution is reduced, and extraglandular formation of oestrone from adrenal
androstenedione predominates (Siiteri and MacDonald 1973, Carr and MacDonald 1983).
Thus, removal of the ovaries in postmenopausal women does not result in a further decline of
oestrogen or androstenedione (Judd 1976). Because adipose tissue is a major site of
extraglandular oestrogen production, oestrogen production is greater in obese than in thin
postmenopausal women, and total oestrogen production in the massively obese may be as
great or greater than in premenopausal women (Hemsell et al 1974, Edman and MacDonald
1978). Overall, there is considerable variation in estrone values postmenopausally (from
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around 35 to 350 pmol/1); oestradiol levels tend to be much lower, with a substantial
proportion of elderly women having a level below the usual limit ofdetection (Yen 1977).
2.3.1.3 Sex hormone-binding globulin
Sex hormone-binding globulin, also known as testosterone-estradiol binding globulin and sex
steroid binding protein, is a circulating glycoprotein with a molecular weight of around
86,000. It is thought to be synthesized in the liver. In the circulation its biological function is
the transport of steroid sex hormones. Each molecule has a single steroid-binding site (Rosner
and Smith 1975, Cheng et al 1983) with a high binding affinity for testosterone and oestradiol.
The circulating concentration of sex hormone-binding globulin is the major determinant of the
relative amounts of testosterone (and probably oestradiol) that are non-protein-bound or
bound to albumin. Thus, the ratio between serum total testosterone and sex hormone-binding
globulin (commonly expressed as the 'Free Androgen Index') is directly equivalent to the
circulating concentration of free testosterone (Nanjee and Wheeler 1985).
The production of sex hormone-binding gobulin appears to be increased by oestrogens and
thyroid hormones, but decreased by androgens. Thus, circulating levels are increased during
pregnancy, after the administration of synthetic oestrogens, in hyperthyroid patients, or after
treatment with thyroid hormones (Rosner 1990). Conversely, slightly lower plasma
concentrations in men than in women are considered to be a result of an androgen-induced
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decrease in synthesis which occurs during puberty in boys (Blank et al 1978). In addition,
insulin has been found to decrease sex hormone-binding globulin levels in men (Strain et al
1994, Pasquali et al 1995) and low levels of the globulin predict development of type 2
diabetes mellitus in men (Haflher et al 1996).
2.3.2 Role of steroid sex hormones in arterial disease
Interest in steroid sex hormones as possible risk factors for atherosclerotic disease arose from
a number of observations, including the higher incidence of atherosclerotic conditions in men
than in women and changes in coronary risk associated with the use of exogenous oestrogens.




There is considerable 'indirect' evidence for an association between blood levels of oestrogens
in women and risk of coronary artery disease. Surgical menopause in younger women
increased coronary risk (Kalin and Zumoff 1990) and both naturally and surgically
postmenopausal women had a greater risk of aortic atherosclerosis than age-matched
premenopausal women (Witteman et al 1989). Cohort studies failed to show a consistently
lower rate of coronary artery disease in premenopausal women compared to postmenopausal
41
women of a similar age, but this may have been influenced by difficulties with precise age-
matching (Gordon et al 1978, Colditz et al 1987).
Coronary risk is also affected by the use of exogenous oestrogens as components of the oral
contraceptive pill or hormone replacement therapy. In general, studies conducted when doses
ofoestrogen and progestogens in oral contraceptives were higher than they are now, indicated
that users had an increased risk of vascular disease and myocardial infarction compared to
non-users (Eaker et al 1993). More recent studies have suggested that low dose oral
contraceptives reduce the risk of cardiovascular disease attributable to oral contraceptives and
the newest preparations may even be protective (Eaker et al 1993). Interestingly, the
increased risk of cardiovascular disease associated with older contraceptives ended with their
discontinuation (Stampfer et al 1990) and it is possible that the immediate cause of coronary
morbidity was more related to thrombosis than to atherogenesis.
The major epidemiological studies investigating oestrogen replacement therapy have been
based upon unopposed conjugated equine oestrogen therapy, a 'natural' type of oestrogen
which is considerably less potent than the lowest dose of synthetic oestrogen used in the oral
contraceptive pill. In the vast majority of prospective studies, exogenous oestrogen use was
found to reduce the incidence of coronary heart disease in postmenopausal women; a meta¬
analysis of the better, adequately controlled studies demonstrated a 50% risk reduction
(Stampfer and Colditz 1990). Although these studies were not randomised trials and could
potentially have been affected by selection bias, in many studies the risk factor profiles ofusers
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and non-users were similar and in others they varied fairly equally between increased and
decreased risk (Stampfer and Colditz 1990).
In addition to a potential, directly anti-atherogenic effect on blood vessel walls (Stevenson et
al 1994), oestrogens may influence circulating levels of a number of other cardiovascular risk
factors. Thus, in the majority of studies, post-menopausal women had higher total serum
cholesterol, low density lipoprotein cholesterol, fibrinogen, and plasminogen activator
inhibitor levels, and lower high density lipoprotein cholesterol levels than age-matched,
premenopausal women (Matthews et al 1989, Scarabin et al 1993, Stevenson et al 1993).
Exogenous oestrogen administration reversed these changes (Matthews et al 1989, Folsom et
al 1991, Manolio et al 1993, Nabulsi et al 1993) and blood pressure (Lobo 1990) and fasting
plasma insulin levels (Manolio et al 1993, Nabulsi et al 1993) were also reduced. Thus the
advantageous effect of exogenous oestrogen on risk factor profiles provides a plausible
mechanism for their cardioprotective effect in postmenopausal women.
Despite the fairly strong epidemiological evidence linking exogenous oestrogens to reduced
coronary risk in postmenopausal women, the role of endogenous oestrogens in atherogenesis
remains undetermined. In particular, both the formulation and concentration of the oral
contraceptive pill and hormone replacement therapy are often incomparable to those of
endogenous hormones. However, the cardioprotective effect of exogenous oestrogens in
postmenopausal women (suggesting that the rate of development or progression of
atherosclerosis may accelerate following oestrogen loss at the time of menopause) means that
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we might expect endogenous oestrogen levels to be reduced in postmenopausal women with
atherosclerotic disease. Only a single study has investigated the relationship between
endogenous oestrogen levels and coronary artery disease in women; mean plasma oestrone
levels did not differ significantly between postmenopausal women with and without coronary
artery disease at angiography (Cauley et al 1994). However, it was not possible to measure
oestradiol in this study and both the cases and control subjects presented with angina.
Men
Evidence surrounding a role for steroid sex hormones in male cardiovascular disease is
confused. The administration of low dose exogenous oestrogens to male myocardial
infarction survivors or those with carcinoma of the prostate had no effect on subsequent
measures of cardiovascular disease (Stamler et al 1960, Oliver and Boyd 1961, Hanash et al
1970, The Coronary Drug Project Research Group 1973) or actually increased cardiovascular
mortality (The Veterans Administration Cooperative Urological Research Group 1967,
Blackard et al 1970, Henriksson et al 1987). This was despite an apparent increase in serum
high density lipoprotein cholesterol and reduction in low density lipoprotein cholesterol levels
(Russ et al 1955, Oliver and Boyd 1956). Raised endogenous oestradiol concentrations found
following myocardial infarction, generally returned to normal after a year (Kalin and Zumoflf
1990) and prospective studies failed to demonstrate a relationship between oestradiol levels
and the subsequent development of coronary artery disease (Cauley et al 1987, Barrett-
Connor and Khaw 1988, Phillips et al 1988, Eldrup et al 1989) or the extent of atherosclerosis
at angiography (Okun et al 1985, Small et al 1985).
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2.3.2.2 Androgens
Often linked to the supposition that oestrogens are cardioprotective is the hypothesis that
testicular androgens are pro-atherogenic. Support for this hypothesis came from the
observation of increased coronary risk in women with chronic anovulation, a condition
associated with hypertestosteronaemia (LaVecchia et al 1987). However, in men, higher
endogenous plasma testosterone concentrations were associated with an apparent
improvement in the male risk factor profile.
Women
Whether or not the wide range of values for testosterone found in postmenopausal women
affects their risk of atherosclerotic disease is unknown. In a limited number of studies, low
high density lipoprotein cholesterol was associated with free testosterone levels (Haffher et al
1989) and the hyperandrogenicity of polycystic ovary disease (Wild et al 1985, Wild and
Bartholomew 1988). Plasma insulin and blood glucose were positively related to free
testosterone concentrations (Haffher et al 1988, Preziosi et al 1993) but no direct relationship
was found between androgens and a variety of haemostatic factors, including plasma
fibrinogen (Blomback et al 1992). Despite possible associations between testosterone and
other cardiovascular risk factors, a single case control study found no difference in
testosterone levels between women with angiographically-proven coronary artery disease and
controls (Hauner et al 1994)
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Men
In men, endogenous testosterone levels have been frequently associated with raised high
density lipoprotein cholesterol levels (Heller et al 1981, Khaw and Barrett-Connor 1991,
Phillips et al 1994) and reduced plasminogen activator inhibitor, plasma fibrinogen and insulin
levels (Bonithon Kopp et al 1988, Yang et al 1993, Glueck et al 1993, Phillips et al 1994),
indicating an improvement in risk factor profiles. However, those cross-sectional studies
which found any variation in testosterone levels with coronary artery disease, demonstrated a
reduced level of testosterone in subjects following a myocardial infarction or with
angiographically-proven coronary artery disease (Barth et al 1983, Mendoza et al 1983,
Phillips et al 1994) and prospective studies have failed to show any relationship between
serum testosterone and the subsequent development of coronary artery disease (Cauley et al
1987, Barrett-Connor and Khaw 1988, Phillips et al 1988).
It is possible that an association between cardiovascular disease and steroid sex hormones
in the limited number of studies available has been obscured by failing to take into
account the entire hormonal 'milieu' and by not measuring free hormone levels
(potentially especially important for testosterone). Moreover, the role of steroid sex
hormones as risk factors for forms of cardiovascular disease other than coronary artery
disease has not been investigated.
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Edinburgh Artery Study: Relationship between diabetes and
cardiovascular risk factors in the development of peripheral
arterial disease
This chapter gives the methods of the Edinburgh Artery Study which are relevant to the
work presented in this thesis. It also describes how data from the baseline survey was
analysed to investigate the relationship between diabetes, cardiovascular risk factors and
peripheral arterial disease. The methods of the case control study, based on subjects
attending the 5-year follow-up phase of the Edinburgh Artery Study, and used to
investigate the role of plasma insulin and steroid sex hormones in peripheral arterial
disease, are given in chapter 4.
3.1 Study design and population
The Edinburgh Artery Study was established in 1988 as a cross-sectional survey
designed to measure the prevalence of peripheral arterial disease and its risk factors in a
representative sample of men and women from the general population. The target
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population was Edinburgh residents aged 55-74 years. Participants were selected at
random (in sex-specific, 5-year age bands) from the age sex registers of 11 general
practices serving a range of socio-economic and geographic areas throughout the city. The
aim was to include equal numbers of subjects from each 5-year age band and equal
numbers of men and women. The sample size of 1500 participants was estimated on the
basis of the number required to conduct a subsequent follow-up study with adequate power
to detect differences in the incidence of cardiovascular events according to baseline
characteristics. Subjects judged by the general practitioner to be unfit to participate (for
example due to mental illness or terminal illness) were replaced by other randomly selected
subjects (n=353; 13%).
Subjects were invited to attend a university clinic to complete a questionnaire and have a
comprehensive medical examination. In an effort to maximise participation in the study,
invitation letters were signed by the subject's general practitioner as well as the study
director and were sent out after publicity in the local media. In addition, provision was
made for home visits for subjects who would find it difficult to attend the clinics, and
travelling expenses to and from the clinic were offered. Those whose invitation letters
were returned by the post office were replaced by other randomly selected subjects (n=162;
6%). Once an affirmative reply was received, each subject was sent an appointment date, a
map, and details about the examination. Those who did not respond at all were sent a
second invitation letter. Affirmative responders who did not attend their appointment were
offered a second appointment date, usually by telephone. Ethical approval was granted
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for the study by Lothian Health Board Ethics Committee and informed consent was
obtained from each subject.
To enable comparison of study participants and non-participants, some 20% of subjects in
each practice who did not respond or attend were randomly selected for follow-up. Each
was sent a letter enclosing a short questionnaire. Subjects not returning the questionnaire
were telephoned or visited at home on up to three occasions at different times of the day
and evening.
3.2 Clinical examination
Clinical examinations were held on weekday mornings from August 1987 to September
1988 at a specially set-up research clinic. Occasional out-of-hour sessions were
arranged as required. Subjects were asked to fast overnight prior to attending for
examination (from 11pm the previous evening), but were told that this did not apply if
they were diabetic. They were also asked to refrain from smoking for two hours prior to
the examination. Each subject underwent a clinical examination performed by one of
two teams (each comprising a nurse and a technician). A self-administered
questionnaire (Appendix I) was completed which included the World Health
Organisation (WHO) intermittent claudication and angina questionnaires (Rose 1962). It
also contained standard questions on social class, cardiovascular history (including recall
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of a doctor's diagnosis of angina, myocardial infarction or intermittent claudication) and
a detailed section on smoking habit. Social class coding (OPCS 1980) included the use
of spouse's occupation for female married subjects. Retired subjects and those currently
unemployed were coded according to longest occupation.
Following ten minutes' rest in the supine position, systolic and diastolic (Phase V) blood
pressures were taken in the right arm using a Hawksley random zero
sphygmomanometer. Ankle systolic blood pressures were taken in both legs using the
random zero sphygmomanometer and a Sonicaid Doppler probe. Blood flow was
detected where possible in the posterior tibial artery. The ankle brachial pressure index
(ABPI) was calculated as ankle divided by brachial systolic pressure and the lesser ABPI
in the two legs was used since disease often occurs unilaterally. In the reactive
hyperaemia test which followed, ankle systolic pressure was measured 15 seconds after
the release of a cuff occluding arterial flow just above the knee for four minutes at about
50 mmHg above systolic pressure. The timing was standardised using an electronic
timer.
During the clinical examination, 20 mL of fasting blood was taken for measurement of
(among other factors) serum total cholesterol, high density lipoprotein cholesterol and
triglycerides, serum thiocyanate and plasma glucose. Following venepuncture, subjects
consumed 75g glucose in the form of 335mL Solripe Gluctoza Health Drink (Strathmore
Mineral Water Co). A second blood specimen was taken 2 hours after the oral glucose
load. Subjects who, because of diabetes, attended for examination unfasted, did not
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undergo the glucose tolerance test. Assays for serum lipids, thiocyanate and plasma
glucose were performed in the laboratory on a Cobas Bio analyzer, Roche Products,
using standard kits. The quality of the laboratory measures were checked by means of
blind duplicate samples taken intermittently throughout the course of data collection.
A 12-lead electrocardiogram (ECG) was taken using a Hewlett Packard 'Pagewriter'
electrocardiograph and coded independently by two specially trained researchers using
the Minnesota code (Prineas et al 1982). In the event of disparity, the ECG was coded
again by a third person. If the third code did not agree with either of the first two, the
ECG was read by a consultant cardiologist and a final code agreed following discussion
between the coders.
Standing height (without shoes) was measured to the nearest 5 mm using a free standing
metal ruler on a heavy base. Weight without shoes and outer clothing was measured to
the nearest lOOg on digital scales (Soehnle).
Before conducting the main study, a pilot study of all clinical and laboratory procedures
was carried out on 50 volunteers from the general public. The quality of the clinical
measurements was checked before and during the study by repeat measurements taken
intermittently by the study co-ordinator. Individual observer measurements were
assessed for drift and variability studies of measurements carried out previously
indicated that the level of variability was adequate for epidemiological purposes
(Fowkes et al 1988, Fowkes et al 1992).
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3.3 Data analysis
3.3.1 Classification of peripheral arterial disease
To enable comparison of subjects with and without peripheral arterial disease, the
following criteria were used to separate subjects into 2 groups;
(i) Disease group - These were subjects with either major symptomatic peripheral
arterial disease, defined as a positive WHO intermittent claudication questionnaire
(grades 1, 2 and 'probable' - calf pain but one WHO criteria not fulfilled) or major
asymptomatic disease. Major asymptomatic disease was defined as one of the
following;
• an ankle brachial pressure index of 0.9 or less and a drop in ankle systolic blood
pressure during the reactive hyperaemia test ofmore than 20%
• an ankle brachial pressure index of 0.7 or less
• a hyperaemic drop ofmore than 3 5%
(ii) Normal group - These were subjects with none of the above criteria plus an ankle
brachial pressure index greater than 0.9 and a hyperaemic pressure reduction of less
than 20%.
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For each subject the lower of the two estimates of the ABPI in the left or right leg was used
because disease often occurs unilaterally, and similarly, the greater reactive hyperaemia
pressure drop ofeither leg was taken.
3.3.2 Classification of diabetes/impaired glucose tolerance
Subjects were separated into those with diabetes, impaired glucose tolerance or normal
glucose tolerance using the responses to questions on diabetes in the self-administered
medical questionnaire (questions 9 and 10, Appendix I), and the results of the oral
glucose tolerance test. In question 9 of the questionnaire, subjects were asked whether
they had ever been told by a doctor that they had diabetes (sugar disease). In question
10, they were asked whether they were on any regular medical treatment from a doctor,
including (amongst other common medications) insulin injections and tablets for
diabetes. Space was also provided for subjects to list any other treatments not
previously specified. A fasting plasma glucose and a plasma glucose measurement 2
hours after a standard oral glucose tolerance test were also available for the majority of
subjects, but not on those who, because of diabetes, did not fast overnight or undergo the
test.
Subjects were classified as suffering from diabetes mellitus if:
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(i) they had been told by a doctor that they suffered from diabetes (answered 'yes' in
question 9) and were receiving either insulin or oral therapy (answered 'yes' in
question 10 or wrote the name of medication used in diabetes), or
(ii) because of a doctor diagnosis of diabetes (answered 'yes' in question 9), they did
not undergo the oral glucose tolerance test ('missing' entered on database) - these
subjects were classified as diabetic irrespective of whether or not they were on
insulin or oral therapy, or
(iii) the plasma glucose concentration in the fasting blood sample was >7.8 mmol/1
and/or the 2-hour blood sample was >11.1 mmol/1.
Impaired glucose tolerance was diagnosed if the plasma glucose concentration was
between 7.8 and 11.1 mmol/1 in the 2-hour blood sample. The glucose levels used to
define diabetes and impaired glucose tolerance were consistent with the WHO criteria
for diagnosis of type 2 diabetes and impaired glucose tolerance (WHO 1980).
A positive response to the diabetes question in question 9 alone (i.e. without evidence of
insulin or oral therapy or a missing oral glucose tolerance test result) was not considered
sufficient evidence of diabetes. This effectively excluded those few subjects who
claimed a doctor's diagnosis of diabetes but denied taking any diabetic medication and
subsequently underwent a normal oral glucose tolerance test.
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3.3.3 Statistical analysis
Information collected from the self-administered smoking questionnaire (Appendix I)
was used to classify subjects according to smoking status (current smokers, ex-smokers
and never smokers). The current smoking histories were considered sufficiently valid,
since stated consumption correlated with mean serum thiocyanate levels (Fowkes et al
1992). Lifetime cigarette smoking was calculated in pack-years (years of smoking
multiplied by the average number of packs smoked per day). Lifelong non-smokers
received a value of zero, and the square root of pack-years was used to reduce the
distortion to the normal distribution resulting from these extreme values.
Other variables, including systolic and diastolic brachial blood pressure, total serum
cholesterol, serum high density lipoprotein (HDL) cholesterol and serum triglycerides
were available directly from values recorded in the research clinic and the laboratory
respectively. Serum low density lipoprotein (LDL) cholesterol was calculated using the
formula, LDL cholesterol = total cholesterol - HDL cholesterol - triglycerides/5
(Friedewald et al 1972), and weight and height measurements were used to calculate
body mass index (BMI), according to the formula, BMI = weight (kg)/height (m2).
Data were analysed on the Edinburgh University mainframe computer (UNIX system)
using the SPSS and SAS (Version 6.11) software packages. Variables were checked for
normality of distribution and transformed if found to be skewed. Tests for differences in
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the age-adjusted mean levels of the risk factors between disease groups were conducted
using t-tests.
Logistic regression using the statistical package Proc GENMOD (SAS 1993) was used to
calculate the odds ratios of having peripheral arterial disease for a person who had
diabetes/impaired glucose tolerance compared to the risk of peripheral arterial disease for a
person in the normal glucose tolerance group. Age and sex adjustments were made and





Case control study: Plasma insulin and steroid sex hormones
as risk factors for peripheral arterial disease
This chapter presents the methods of the case control study, designed to investigate the
relationship between endocrine risk factors (plasma insulin and steroid sex hormones)
and peripheral arterial disease in male and female cases and controls from the general
population.
4.1 Study design and population
All subjects for this case control study were selected from the Edinburgh Artery Study
database. Using this database meant that subjects with and without disease were
readily identified, but were otherwise randomly selected members of the general
population. Cases and controls were selected from subjects attending for clinical
examination five years after the initial study examination, and who had not
subsequently been notified as dead (through flagging of notes at the UK National
Health Service Central Registry or notification from general practitioners or
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relatives). Ethical approval was granted for the study by the Lothian Health Board
Ethics ofMedical Research Sub-Committee for Medicine/Clinical Oncology.
4.2 Sample size
The sample size had to be adequate to detect significant differences between the cases
and controls in the main variables of interest. Since data was lacking on possible
differences in steroid sex hormone levels between subjects with and without peripheral
arterial disease, the sample size was based on predicted differences in plasma insulin
levels.
In his study on men with and without peripheral arterial disease, Sloan et al (1970)
found a difference in mean plasma insulin levels of 37.1 mU/1 between cases and
controls, one hour after a standard oral glucose tolerance test. This difference was
significant at the 0.1% level. A difference of 1.3 mU/1 in fasting levels was not
significant.
In a large population-based study, Pyorola et al (1985), found the following values for
serum insulin amongst 982 men aged 35 to 64 years of age;
Population mean Standard Deviation
Fasting plasma insulin (mU/1) 7.6 4.7
One-hour plasma insulin (mU/1) 62.4 43.9
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The sample size calculation was based on the following formula:
number of subjects in each group, n = 2a2 x f
(M-2-M-l) 2
where (H2-M-i) is the difference in mean plasma insulin to be detected
a is the standard deviation of plasma insulin
f is a constant, depending on the power and significance level required
This constant (f), is equivalent to the term (u + v)2
where o is the one-sided percentage point of the normal distribution
corresponding to 100% - the power, e.g. if power = 90%, (100% -
power) = 10% and u = 1.28 (o = 1.64 when power = 95%)
v is the percentage point of the normal distribution corresponding to the
required (two-sided) significance level, e.g. if significance level = 5%, v
= 1.96
With a significance level of 5%, f is equal to 10.5 (power = 90%) or 13 (power = 95%).
Using the standard deviation in one-hour plasma insulin reported by Pyorola et al
(1985), it was estimated that 36 subjects would be required in each group (cases and
controls) to detect a difference of 37.1 mU/1 or greater in one-hour plasma insulin levels
in the present study (power 95%, significance level 5%).
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In order to allow for multivariate analysis, it was proposed to increase this number to
45. To investigate the relationship between plasma insulin and disease in both sexes, 45
male cases and 45 female cases, together with equal numbers of age and sex matched
controls would be required, giving a final sample size of 90 cases and 90 controls.
4.3 Selection of cases and controls
4.3.1 Definition of cases and controls
In selecting cases from subjects attending the 5-year follow-up examination of the
Edinburgh Artery Study population, subjects were defined as a case if they had either;
(i) a history of intermittent claudication according to the WHO intermittent
claudication questionnaire, plus an ABPI <0.9 in at least one limb, or
(ii) asymptomatic peripheral arterial disease indicated by an ABPI <0.85 in
at least one limb.
Completion of the WHO intermittent claudication questionaire and measurement of the
ankle brachial pressure index in both ankles were the two methods used to assess lower
limb arterial disease at the Edinburgh Artery Study five-year follow-up examination.
Measurement of the ankle brachial pressure index was performed using the same
technique as at baseline. The reactive hyperaemia test which was performed at
baseline was not repeated at the five-year follow-up examination, predominantly due
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to poor subject compliance (many subjects complained ofmild discomfort during the
course of this test, and the investigators did not want to jeopardise the continuing
participation of these subjects in the study).
In selecting controls from the same population, a subject was defined as a control if
they had no evidence of cardiovascular disease, as indicated by all of the following;
(i) no history of intermittent claudication according to the WHO
intermittent claudication questionnaire
(ii) an ankle brachial pressure index of 1.0 or greater in both legs
(iii) no history of angina, myocardial infarction or stroke according to the
WHO chest pain questionnaire and/or a doctor's diagnosis
(iv) no evidence ofmyocardial infarction or ischaemia on electrocardiogram
(v) no history of arterial surgery
Evidence of cardiovascular disease was obtained from data collected at baseline, at the
five-year follow-up examination and during the intervening five year follow-up period.
To obtain details of non-fatal events during follow-up (including myocardial
infarction, angina pectoris, stroke and intermittent claudication), information was
sought from general practitioners, hospitals and the Information and Services
Division of the Scottish Office Home and Health Department. Subjects were also
sent an annual questionnaire which included validated questions on cardiovascular
history, intermittent claudication (Rose 1962) and angina (Rose 1962). All
cardiovascular events and deaths were further investigated using hospital or general
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practitioner records. At the follow-up examination, subjects completed a further
self-administered medical questionnaire. In addition, a 12-lead electrocardiogram was
taken and coded as at baseline (Minnesota coding).
4.3.2 Exclusion criteria
Subjects were excluded from both the case and control groups if they had any of the
following;
(i) known diabetes mellitus or newly-diagnosed diabetes according to a fasting
plasma glucose >7.8 mmol/1, or
(ii) use of drugs affecting carbohydrate metabolism (achieved by scrutinising the
list ofmedication taken by eligible cases and controls), or
(iii) women using postmenopausal hormone replacement therapy.
Subjects with diabetes were defined as those taking medication used in the treatment of
diabetes (insulin or oral hypoglycaemics), or who had a fasting blood glucose reading
of 7.8 mmol/1 or greater at the baseline Edinburgh Artery Study examination. Two
subjects were excluded subsequently on the basis of their oral glucose tolerance test
performed for the purpose of this study.
Women taking hormone replacement therapy included those who listed hormone
replacement therapy as one of their 'regular medications' on the Edinburgh Artery
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Study medical questionnaire. However, since some women may not have regarded
hormone replacement therapy as a medication (and therefore failed to list it), all
women who were otherwise eligible for the study were asked directly whether or not
they were currently taking hormone replacement therapy. This was done both in the
clinic invitation letter (Appendix II) and in person at the clinic (Appendix III).
4.3.3 Matching procedure
Controls were matched to the cases by sex and 5-year age band using the list of
eligible cases and controls obtained from the Edinburgh Artery Study database. This
list was arranged by sex and 5-year age band (using subject's date of birth), but within
each band subjects were listed in random order. Subjects were invited sequentially at a
rate of 18 per week to attend one of three morning research clinics, until the required
number had been seen. Once a case had agreed to attend, a control was selected from
the corresponding sex and 5-year age band. If the control declined the invitation, an
alternative random control was substituted from within the same age and sex band as
the originally selected control.
4.4 Sample recruitment
All selected cases and controls were sent a letter inviting them to attend for
examination (Appendix II). The letter thanked subjects for their recent participation in
the Edinburgh Artery Study, explained the purpose of the present study, and outlined
70
what would be required if they agreed to participate. In particular, it was emphasised
that subjects would have to fast for the 12 hours prior to attending for examination. To
avoid having to re-contact all the subjects again, and so help to maximise response,
each subject was provided with a specific appointment in this initial invitation letter.
A telephone number was provided so that the subject could contact the investigator to
discuss the study further before deciding whether or not to participate. A map was
enclosed, since the clinic was located at a site not previously used in the Edinburgh
Artery Study.
Subjects were asked to indicate on a reply slip whether they were able to attend for the
specified appointment, whether they would require a different appointment date or
whether they were unwilling to participate in the study. Those who refused to
participate were not contacted again. Subjects requesting an alternative appointment
were contacted by telephone to arrange a suitable date. A second letter confirming the
change in appointment was sent to these subjects.
Non-responders to the invitation letter were contacted by telephone, and, if possible
persuaded to attend. Those agreeing to attend were sent a letter confirming the agreed
appointment. The few subjects who accepted the invitation and then failed to keep
their appointment were also contacted by telephone; an alternative appointment was
arranged and confirmed by letter.
In all instances where a second letter to either change or confirm an appointment was
sent, this contained information stressing the importance of fasting overnight prior to
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the examination. This was to remind subjects of the need to fast without having to
refer back to their original invitation letter and so minimise the number of subjects who
attended without fasting.
4.5 Clinical examination
Clinic procedure: Six subjects were invited to each of three weekly clinics. These
were arranged for first thing in the morning because of the requirement to attend after
an overnight fast. Usually 4 or 5 subjects agreed to participate per clinic; these went
through each stage of the examination simultaneously. As soon as a subject arrived at
the clinic, the investigator confirmed that they had fasted overnight (if they had not
fasted, an alternative date for the examination was given and the subject sent home).
Subjects were also asked whether or not they were diabetic; this was necessary to
exclude subjects who had been diagnosed as diabetic very recently and had therefore
not yet registered as such on the Edinburgh Artery Study database. Female subjects
were also asked to confirm that they were not currently taking hormone replacement
therapy. The responses to these questions were noted on the data collection form
(Appendix III).
Informed consent: Subjects still found to be eligible for the study had the purpose and
format of the study explained to them and they were asked to sign a specially designed
consent form (Appendix IV). The consent form was co-signed by the investigator and
dated.
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Fasting venepuncture: Prior to venepuncture, the investigator checked that the subject
was not 'high risk' in terms of possible hepatitis or human immunodeficiency virus
(Appendix V). A 30 ml venous blood sample was then taken with the subject in a
recumbent position. Any practical problems with the venepuncture (such as very slow
blood flow into the syringe) were noted on the venepuncture form, together with the
amount of blood taken. This was done in order to identify potential reasons for any
samples found subsequently to be grossly abnormal or missing. The blood sample was
divided into four pre-labelled collecting tubes as follows;
• 2.5 ml in a fluoride oxalate tube for measurement of blood glucose
• 10 ml in a lithium heparin tube for measurement of plasma insulin
• 10 ml in a plain tube for measurement of total serum cholesterol, high density
lipoprotein cholesterol and triglycerides
• 8 ml in a second lithium heparin tube for measurement of total plasma testosterone,
sex hormone-binding globulin, oestrone and oestradiol
Apart from the glucose sample, more blood than was required for the stated assays was
collected in each tube. This meant that there would be one serum sample and two
plasma samples per patient available for freezing and storage, allowing measurement
of other potential risk factors at a later date.
Oral glucose tolerance test fOGTT): Following venepuncture, all cases and controls
underwent a standard 75g oral glucose tolerance test. This was performed in
ambulatory conditions and without dietary preparation using 389 ml of Lucozade
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Sparkling Glucose Drink (equivalent to the glucose load of 75g recommended by the
World Health Organisation for the OGTT in adults). A further 10 ml venous blood
sample for plasma insulin and blood glucose determination was taken 60 minutes after
glucose administration. The sample was divided between a 2.5 ml fluoride oxalate tube
(for blood glucose measurement) and a 10ml lithium heparin tube (for plasma insulin
measurement).
Waist hip ratio measurement: During the hour between glucose administration and
post-glucose venepuncture, each subject underwent measurement of their waist and hip
circumferences. These were measured to the nearest centimetre with the subject
standing and breathing normally. Hip measurements were made at the level of the iliac
crest and all measurements were made by a single observer. The waist hip ratio was
calculated as the simple ratio ofwaist to hip circumference.
Data on smoking history, blood pressure, height and weight was taken from the
Edinburgh Artery Study 5-year follow-up examination, where these factors were
recorded by the same methods as in the cross-sectional survey. This included
completion of a self-administered questionnaire with validated questions on smoking,
measurement of right brachial systolic and diastolic blood pressures after 5 minutes




Plasma insulin: The fasting and post-glucose blood samples for measurement of
plasma insulin were centrifuged at 4°C and 3000 r.p.m for 20 minutes within 15
minutes of collection. 2 mis of the supernatant plasma was pipetted into labelled
microtubes and immediately frozen at -40°C. Samples were stored at -40°C for a
maximum of six months before being delivered in batches to the Metabolic Unit,
Clinical Biochemistry Department, Western General Hospital, Edinburgh for analysis.
Any remaining plasma was pipetted into labelled microtubes and frozen at -40°C for
storage.
Blood glucose: The fasting and post-glucose blood samples for measurement of blood
glucose were centrifuged at 4°C and 3000 r.p.m for 20 minutes. The resultant
supernatant (approximately 1.5 ml) was pipetted into labelled microtubes and
immediately frozen at -40°C. Samples were stored at -40°C before being delivered in
batches to the Metabolic Unit at the Western General Hospital, together with the
samples for plasma insulin measurement.
Total plasma testosterone, sex hormone-binding globulin, oestrone and oestradiol: The
8 ml blood sample for measurement of steroid sex hormones was centrifuged at 4°C
and 3000 r.p.m for 20 minutes, usually within 15 minutes of collection. 2 mis of the
supernatant plasma was pipetted into a labelled microtube and immediately frozen at
-40°C. The samples were stored at -40°C for a maximum of six months before being
delivered to the Reproductive Medicine Centre, University of Edinburgh for analysis.
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Any remaining plasma was pipetted into a labelled microtube and frozen at -40°C for
storage.
Serum cholesterol, high density lipoprotein cholesterol and triglycerides: The 10 ml
fasting blood sample for measurement of serum lipids was left to stand for
approximately one hour until clotting had taken place. The sample was then
centrifuged at 4°C and 3000 r.p.m. for 20 minutes. 2 mis of the supernatant serum was
pipetted into a labelled microtube and frozen at -40°C until delivery to the Clinical
Biochemistry Department, Western General Hospital, Edinburgh for analysis. The
remaining supernatant was pipetted into a labelled microtube and frozen at -40°C for
storage.
4.7 Quality control
To check the quality of laboratory assays, duplicate samples were taken periodically
throughout the course of the study. This was done on subjects where the amount of
plasma or serum obtained was sufficient to produce two samples rather than the usual
one. In each case, the second sample was assigned a 'dummy' subject number. Only
the investigator was aware of which subject this number referred to. A total of 10
samples were duplicated in this way for each of the factors measured. Each laboratory




Plasma insulin concentration was measured using a microparticle enzyme immunoassay
on an EMx analyser (Abbott Laboratories Limited, Maidenhead, UK). The results of
this assay were reported in the conventional units of mU/1 (these units are equivalent to
those of pU/ml reported in some previous studies). The assay measurement range was
1-300 mU/1, with a sensitivity of 1 mU/1. Reproducibility of the method was assessed
in the laboratory using 3 quality control specimens. Intra- and inter-assay coefficients
of variation at an insulin concentration of 8.3 mU/1 were 4.0% and 4.5% respectively.
The EMx assay showed no cross-reactivity with pro-insulin (<0.005%), potentially
giving lower values than observed with other less specific immunoassays, and no
detectable cross-reactivity with C-peptide or glucagon. Although cross-reactivity with
bovine and porcine insulins has been observed with the IMx insulin assay, this was not
a problem in the present study since none of the subjects were on insulin therapy.
Insulin resistance was calculated as an index according to the equation, insulin
resistance = (fasting glucose x fasting insulin)/22.5 (Matthews et al 1985).
Blood glucose concentration was measured by a timed end-point enzymatic method
employing hexokinase and glucose-6-phosphate dehydrogenase using a Beckman
Synchron CX5 multichannel analyser (Beckman Instruments (UK) Ltd, High
Wycombe, Bucks, UK). The assay analytical range was 0.3-38.8 mmol/1, with a
sensitivity of 0.3 mmol/1. The inter-assay coefficient of variation was 0.8%. This is
one of the most specific methods for measurement of glucose.
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Plasma steroid sex hormones: Oestradiol was measured by radioimmunoassay using
sheep anti-oestradiol antibody. Oestrone was measured by ELISA using rabbit anti-
estrone-3-glucuronide-BSA antibody. Sex hormone-binding globulin and total
testosterone were measured by radioimmunoassay using commercial kits (Orion
Diagnostica and Medgenix respectively). All samples were assayed in duplicate and
the sample was assayed again if the values for the individual duplicates differed by
more than 5%. Inter- and intra-assay coefficients of variation were < 9.2% for
estradiol, < 9.9% for estrone, < 9.3% for sex hormone-binding globulin and < 11.7%
for total testosterone. For subjects whose hormone levels were found to be below the
level of sensitivity of the total testosterone assay (0.18 nmol/1) and the estradiol assay
(30 pmol/1), these values were used in the analysis. Free testosterone was calculated
using the Free Androgen Index according to the equation, free testosterone (pmol/1) =
[1000 x total testosterone (nmol/1)] / sex hormone binding globulin (nmol/1) (Nanjee
and Wheeler 1985).
Total serum cholesterol was measured by an enzymatically-linked reaction using
cholesterol ester hydrolase, cholesterol oxidase and peroxidase using a E750C dry
chemistry analyser (Ortho Clinical Diagnostics, Hemel Hempstead, UK). The
analytical range of this assay was 1.29-8.40 mmol/1; above 8.4 mmol/1, samples were
re-run on dilution, so there was no upper limit. Within-batch precision was between
0.92% and 1.17% and between-batch precision was between 1.4% and 2.6% (recorded
at mean concentrations of 2.74, 5.46 and 6.83 mmol/1).
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Serum triglycerides were measured by an enzymatic method using linked reactions and
lipase, glycerol kinase, glycerophosphate oxidase and peroxidase using a E750 C dry
chemical analyser as for total cholesterol. The analytical range of this assay was 0.11-
5.90 mmol/1; for values above this, samples were re-analysed on dilution. Within-
batch precision was between 0.88% and 1.32% and between-batch precision was
between 1.6% and 1.9% (measured at mean concentrations of 0.99, 2.62 and 4.99
mmol/1).
Serum high density lipoprotein (HDL) cholesterol was measured on a Cobas Mira Plus
analyser (Roche Diagnostics Ltd, Welwyn Garden City, UK). All other cholesterol-
containing lipoproteins were precipitated by MgCL/Phosphotungstic acid leaving HDL
cholesterol in solution. After centrifuging at 6000 rpm for 5 minutes, cholesterol was
then measured in the supernatant enzymatically using cholesterol esterase, cholesterol
oxidase and peroxidase. The analytical range of this assay was 0.2-5.0 mmol/1.
Between-batch precision was 4.6% and 3.4% (measured at mean concentrations of
0.73 and 1.99 mmol/1 respectively).
Low density lipoprotein (LDL1 cholesterol was calculated using the formula, LDL




Mean levels of risk factors were compared in study cases and controls and the
significance of differences were assessed by t-test, using the statistical package SPSS-
X. For haematologic factors with skewed distributions, levels were log transformed
before statistical analysis. Mean levels were then anti-logged to give the more readily
understandable geometric mean in the original units (confidence intervals were also
transformed back to arithmetic units). Cigarette smoking was calculated in pack-years
(years of smoking multiplied by the average number of packs smoked per day) as a
measure of lifetime smoking. Lifelong non-smokers received a value of zero, and the
square root of pack-years was used to reduce the distortion to the normal distribution
resulting from these extreme values.
Spearman's rank correlation coefficients were calculated to examine associations
between one-hour insulin levels and steroid sex hormones and the other cardiovascular
risk factors. These were calculated separately for cases and controls because they
represented two distinct groups. Multiple logistic regression was used to investigate
the independence of the relationship between risk factors and disease after controlling
for age and other cardiovascular risk factors. The odds of peripheral arterial disease
associated with a one log unit increase in one-hour insulin concentration was estimated
from the logistic regression coefficients obtained by the statistical package BMDP, and
expressed as an odds ratio. The odds of disease for a one unit increase in each of the
steroid sex hormone was also calculated for men and women separately. A one unit
increase on a log scale was used for sex hormone-binding globulin and serum oestrone,
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due to their skewed distributions. For the other hormones, the unit increase was one
standard deviation.
To investigate the relationship between smoking status and plasma insulin levels,
geometric means and transformed confidence intervals of one-hour insulin were
calculated for never-smokers and ever-smokers (current and ex-smokers). Multiple
linear regression was performed (with smoking as the independent variable and one-
hour insulin as the dependent variable) to determine the independence of the
relationship after controlling for the other cardiovascular risk factors. The following
independent variables had forced entry into the final model: presence or absence of




Edinburgh Artery Study: Relationship between diabetes and
cardiovascular risk factors in the development of peripheral
arterial disease
This chapter describes the results of analysis on the Edinburgh Artery Study cross-
sectional data to investigate the relationship between diabetes, cardiovascular risk
factors and peripheral arterial disease.
5.1 Characteristics of study population
5.1.1 Characteristics of responders and non-responders
During recruitment for the Edinburgh Artery Study, invitations were sent to 2709
subjects of whom 1592 (809 men and 783 women) ultimately participated in the study,
a crude response rate of 59%. Follow-up of the random sample of non-responders
showed that 19% had moved and 3% were dead or in hospital. Extrapolation of these
results to the whole sample suggested that the response rate of those receiving an
invitation was 65%.
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Previous analysis undertaken by the study director indicated that the responders were
reasonably typical of the target population (Fowkes et al 1991). Thus the crude
response rate did not differ substantially by age or sex, although there was slight
under-representation of women aged 70-74 years and males aged 55-59 years who
comprised 21.3% and 22.5% (instead of 25.0%) of women and men respectively.
The social class distribution of responders was similar to that of Edinburgh adult
residents in the 1981 census except that the responders contained fewer subjects from
social classes IV and V (13% compared to 19%). The crude response rate varied
between the ten general practices, from 47% to 71%, with the lower response rates
occurring in practices serving deprived areas, thus also suggesting a slight under-
representation of lower social class.
5.1.2 Characteristics of subjects with diabetes or impaired glucose
tolerance
The diabetic status of all subjects attending the Edinburgh Artery Study is given in
Table 5.1. Two hundred and eighty eight (288) subjects (18.7%) had diabetes (n = 91)
or impaired glucose tolerance (n = 197) compared with 1253 subjects with normal
glucose tolerance (51 subjects could not be classified due to missing data). Of the 91
subjects with diabetes, 8 (8.8%) were insulin treated, 18 (19.8%) were on oral
treatments, and 17 (18.7%) did not admit to taking any treatment other than diet
modification: the remainder were previously undiagnosed diabetics who were detected
using the oral glucose tolerance test (52.7%, n=48).
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5.1.3 Characteristics of subjects with peripheral arterial disease
The characteristics of subjects with peripheral arterial disease are given in Table 5.2.
Of the 1541 subjects who could be classified by diabetic status, a total of 171
(11.1%) had peripheral arterial disease according to the study criteria. Of these, 69
(40.4%) had symptomatic disease (a positive WHO intermittent claudication
questionnaire) and 102 (59.6%) had major asymptomatic disease. Fifty one (29.8%)
were classified as asymptomatic disease according to an ankle brachial pressure
index of 0.9 or less and a drop in ankle systolic blood pressure during the reactive
hyperaemia test of more than 20%. A further 35 (20.5%) had asymptomatic disease
with an ankle brachial pressure index of 0.7 or less alone and 16 (9.4%) had a
hyperaemic drop ofmore than 35% alone.
A total of 1051 subjects were entered into the 'healthy group'. These were subjects with
none of the criteria for the 'disease group' plus an ankle brachial pressure index greater
than 0.9 and a hyperaemic pressure reduction of less than 20%.
5.2 Univariate analysis
5.2.1 Prevalence of peripheral arterial disease according to diabetic
status
A total of 1222 subjects could be classified according to diabetic status and had either
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symptomatic or major asymptomatic peripheral arterial disease (n=171) or were
included in the 'healthy' group (n=1051). Sixty seven (67) of these subjects had
diabetes, 151 had impaired glucose tolerance (IGT) and 1004 subjects had normal
glucose tolerance.
Figure 5.1a gives the prevalence of peripheral arterial disease (symptomatic and major
asymptomatic disease) by diabetic status. Peripheral arterial disease was more common
in subjects with diabetes (22.4%, n=15) and with impaired glucose tolerance (19.9%,
n=30) than in those with normal glucose tolerance (12.5%, n=126, p<0.05). This
difference persisted, although to a slightly lesser extent, after age-adjustment (Figure
5.1b). The prevalence of disease was not significantly different between subjects with
diabetes and those with impaired glucose tolerance (22.4% vs 19.9%, p=0.7), and these
groups were combined to increase the power of the study. Just over a half of the total
prevalence of peripheral arterial disease in subjects with diabetes or impaired glucose
tolerance (20.6%, n=45) was due to asymptomatic disease (11.5%, n=25). In the group
with normal glucose tolerance, slightly more of the total prevalence of peripheral
arterial disease was due to asymptomatic disease (7.7%, n=78 compared with 4.8%,
n=48 for symptomatic disease).
5.2.2 Risk factor characteristics of 'disease group' compared with 'healthy
group' in diabetic/IGT study population
Within the diabetic/impaired glucose tolerant study population, mean levels of risk
factors were compared between subjects with peripheral arterial disease (disease group)
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and those without disease (healthy group). There was no significant difference in the
sex distribution between the two groups (43% of the disease group and 58% of the
healthy group were men, p>0.1). However, subjects with peripheral arterial disease
were older (mean age 68.8 ±0.8 years) than those in the healthy group (mean age 65.1
±0.4 years, p<0.001). Mean levels of the other risk factors were therefore presented
(and analysed statistically) following adjustment for age (Table 5.3).
More subjects with peripheral arterial disease were current or ex-smokers (74.1%) than
in the healthy group (48.1%, p<0.05) and lifetime smoking (measured as square root
pack-years to normalise the skewed distribution of pack-years) was significantly higher
in the disease group (mean 4.21 ±0.49 vs 2.38 ±0.23, p<0.001).
Systolic blood pressure, diastolic blood pressure and body mass index were all normally
distributed within the study population and so did not require transformation prior to
analysis. Age adjusted mean systolic blood pressure was significantly higher in the
disease group (161.8 ±3.7mmHg) than in the healthy group (150.4 ±1.8 mmHg,
p<0.01). However, there was no significant difference between the two groups in mean
diastolic blood pressure, or in mean body mass index (p>0.1).
All of the serum lipids were found to be normally distributed in the study population
except for serum tryglycerides which was positively skewed. Values for serum
triglycerides were therefore log transformed before statistical analysis and geometric
means presented. Mean levels of total serum cholesterol and serum low density
lipoprotein cholesterol appeared slightly higher in the disease group than in the healthy
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group (mean LDL cholesterol 5.61 ±0.20 mmol/1 vs 5.25 ±0.10 mmol/1), but these
differences were not statistically significant (p=0.12 for LDL cholesterol and p=0.15 for
total cholesterol). The difference in mean serum high density lipoprotein cholesterol
was also non-significant (1.29 ±0.06 mmol/1 in disease group vs 1.38 ±0.03 mmol/1 in
healthy group, p=0.19). However, mean serum triglycerides were significantly higher
in the disease group (0.69 ±0.08 mmol/1) than in the healthy group (0.46 ±0.04 mmol/1,
p<0.01)
5.2.3 Risk factor characteristics of 'disease group' compared with 'healthy
group' in normal glucose tolerant study population
Levels of risk factors were then compared between the disease group and the healthy
group in subjects with normal glucose tolerance. Again, there was no significant
difference in the sex distribution between the two groups, but subjects with peripheral
arterial disease were found to be older (mean age 66.9 ±0.5 years) than those in the
healthy group (mean age 63.9 ±0.2 years, p<0.001).
Mean levels of the other risk factors following age-adjustment are given in Table 5.4.
More subjects with peripheral arterial disease were current or ex-smokers (83.5%) than
in the healthy group (61.6%, p<0.01), and lifetime smoking (square root pack-years),
was significantly higher in the disease group (mean 4.67 ±0.25 vs 2.81 ±0.09, p<0.001).
As in the diabetic/IGT study population, age adjusted mean systolic blood pressure was
significantly higher in the disease group (147.8 ±1.9 mmHg) than in the healthy group
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(138.7 ±0.7 mmHg ,p<0.001), but there was no significant difference between the two
groups in mean diastolic blood pressure, or in mean body mass index (p>0.1).
Subjects with peripheral arterial disease had significantly higher mean levels of total
serum cholesterol and serum low density lipoprotein cholesterol compared with those
without disease (mean LDL cholesterol 5.62 ±0.11 mmol/1 vs 5.14 ±0.04 mmol/1,
p<0.001). They also had lower mean serum high density lipoprotein cholesterol (1.38
±0.04 mmol/1 vs 1.47 ±0.01 mmol/1, p<0.05). As in the diabetic/IGT study population,
mean serum triglycerides were significantly higher in the disease group (0.46 ±0.04
mmol/1) than in the healthy group (0.27 ±0.02 mmol/1, p<0.001)
5.2.4 Risk factor characteristics of subjects with diabetes or IGT
compared with normal glucose tolerant subjects
Mean risk factor levels were then compared between subjects with diabetes or impaired
glucose tolerance and those with normal glucose tolerance. This was done separately
for subjects with and without peripheral arterial disease since the presence of peripheral
arterial disease could confound any relationship between diabetes/IGT and risk factor
levels. In both subjects with and without peripheral arterial disease, the diabetic/IGT
populations were older (p<0.05) than the normal glucose tolerant subjects, so mean
levels of the other cardiovascular risk factors were age-adjusted.
In subjects with peripheral arterial disease (Table 5.5), the diabetic/IGT population had
higher mean levels of systolic blood pressure (161.8 ±3.7 mmHg vs 147.8 ±1.9 mmHg,
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p<0.01) and serum triglycerides (0.69 ±0.08 mmol/1 vs 0.46 ±0.04 mmol/1, p<0.05),
compared with the normal glucose tolerant population. These risk factors were also
raised in the diabetic/IGT population in subjects without peripheral arterial disease
(Table 5.6). In addition, in subjects without peripheral arterial disease, those with
diabetes or impaired glucose tolerance had raised mean diastolic blood pressure (78.9
±0.9 mmHg vs 76.1 ±0.4 mmHg, p<0.01) and body mass index (26.8 ±0.3 kg/m2 vs
25.0 ±0.1 kg/m2, p<0.001) and reduced mean serum high density lipoprotein
cholesterol (1.38 ±0.03 mmol/1 vs 1.47 ±0.01 mmol/1, p<0.01). However, subjects with
diabetes or impaired glucose tolerance smoked less than normal glucose tolerant
subjects; only 48.1% were current or ex smokers compared with 61.6% of subjects with
normal glucose tolerance (p<0.001).
5.3 Multivariate analysis
Multiple logistic regression was used to examine the relationship between
diabetes/impaired glucose tolerance and risk of peripheral arterial disease, before and
after adjustment for the other cardiovascular risk factors. The presence of diabetes or
impaired glucose tolerance was associated with a significant increase in the risk of
peripheral arterial disease (odds ratio for peripheral arterial disease in the diabetic/IGT
group compared with the normal glucose tolerant group was 1.64; 95% CI 1.17, 2.31
p<0.01). After adjusting for age and sex, subjects with diabetes or impaired glucose
tolerance still had a higher risk of disease (odds ratio 1.45; 95% CI 1.03, 2.04, p<0.05).
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The results of further adjustment for each of the cardiovascular risk factors in turn is
shown in Table 5.7. Adjustment for smoking increased the risk of disease in subjects
with diabetes or impaired glucose tolerance slightly (odds ratio 1.65; 95% CI 1.16,
2.34). This was not surprising given that smoking was a significant risk factor for
peripheral arterial disease and that levels of smoking were lower in the diabetic/IGT
population.
Adjustment for diastolic blood pressure and body mass index had little effect on the risk
of disease. However, following adjustment for systolic blood pressure, subjects with
diabetes or impaired glucose tolerance no longer had a significantly higher risk of
peripheral arterial disease than those with normal glucose tolerance (odds ratio 1.22,
95% CI 0.85, 1.73, p=0.3)
Adjustment for total serum cholesterol and serum low density lipoprotein cholesterol,
also had little effect on the risk of disease. However, following adjustment for serum
triglycerides, the odds ratio fell to a non-significant value of 1.26 (95% CI 0.89, 1.79,
p=0.2). After adjusting for high density lipoprotein cholesterol, subjects with diabetes
or impaired glucose tolerance still had higher levels of peripheral arterial disease, but
the odds ratio was of borderline significance (odds ratio 1.37; 95% CI 0.97, 1.94,
p=0.08).
Simultaneous adjustment for both systolic blood pressure and serum triglycerides
reduced the risk of disease among subjects with diabetics or impaired glucose tolerance
to 1.11 (95% CI 0.78, 1.58, p=0.6).
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In summary, in subjects with diabetes or IGT, mean levels of smoking, systolic blood
pressure and serum triglycerides were significantly higher in subjects with peripheral
arterial disease than in those without disease (p<0.05). In general, levels of
cardiovascular risk factors were higher in subjects with diabetes or IGT compared with
normal glucose tolerant subjects, including systolic blood pressure and serum
triglycerides (but not smoking). In multivariate analysis, subjects with diabetes or IGT
no longer had a significantly higher risk of peripheral arterial disease after adjusting
separately for systolic blood pressure (odds ratio 1.22, 95% CI 0.85, 1.73) and serum
triglycerides (odds ratio 1.26, 95% CI 0.89, 1.79). Simultaneous adjustment for both
systolic blood pressure and serum triglycerides reduced the risk further to 1.11 (95% CI
0.78, 1.58).
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Table 5.1. Classification of all subjects attending Edinburgh Artery Study
according to diabetic status












Impaired glucose tolerance 197 12.8
Normal glucose tolerance 1253 81.3
TOTAL 1541 100
(51 subjects un-classified due to missing data)
OGTT, oral glucose tolerance test
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Table 5.2. Classification of subjects by measures of peripheral arterial disease (in
those 1541 subjects who could be classified according to diabetic status)
Study Group n %
Peripheral arterial disease
Symptomatic disease
Intermittent claudication 69 40.4
Maior asymptomatic disease
ABPI <0.9 and Hyperaemia > 20% 51 29.8
ABPI < 0.7 alone 35 20.5




(51 subjects with missing data on diabetic status and
319 subjects with 'minor' asymptomatic PAD omitted)
Intermittent claudication Grades 1 (n=23), 2 (n=31) and probable (n=15)
Hyperaemia - hyperaemic reduction in ankle pressure after occlusion
ABPI - ankle brachial pressure index
'Healthy' - none of the criteria for symptomatic or major asymptomatic
peripheral arterial disease, plus an ABPI >0.9 and a hyperaemic pressure
reduction <20%
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Figure 5.1a Prevalence of peripheral arterial disease, categorised according to major
asymptomatic disease and intermittent claudication in subjects with
diabetes, impaired glucose tolerance (IGT) and normal glucose tolerance
(NGT)
IGT (n=151) NGT (n=1004)Diabetes (n=67)
Difference in prevalence from NGT group: * p=;0.05, t psO.01
Figure 5.1b Age-adjusted prevalence of peripheral arterial disease in subjects with
diabetes, impaired glucose tolerance (IGT) and normal glucose tolerance
(NGT)
NGT (n=1004)
Difference in prevalence from NGT group: * ps0.05, t p=0.07
Diabetes (n=67) IGT (n=151)
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Table 5.3 Age, sex and age-adjusted mean levels of risk factors in subjects with
diabetes or impaired glucose tolerance, with and without peripheral arterial disease






Age, years 68.8 (0.8) 65.1 (0.4) <0.001











Systolic blood pressure, mmHg

























NS, not significant (p>0.05); SE, standard error; PAD, peripheral arterial disease
LDL, low density lipoprotein; HDL, high density lipoprotein
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Table 5.4 Age, sex and age-adjusted mean levels of risk factors in normal glucose
tolerant subjects, with and without peripheral arterial disease






Age, years 66.9 (0.5) 63.9(0.2) <0.001











Systolic blood pressure, mmHg

























NS, not significant (p>0.05); SE, standard error; PAD, peripheral arterial disease
LDL, low density lipoprotein; HDL, high density lipoprotein
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Table 5.5 Age, sex and age-adjusted mean levels of risk factors in diabetic/impaired
glucose tolerant and normal glucose tolerant subjects with peripheral arterial disease






Age, years 68.8 (0.8) 66.9(0.5) <0.05











Systolic blood pressure, mmHg

























NS, not significant (p>0.05); SE, standard error; NGT, normal glucose tolerance
LDL, low density lipoprotein; HDL, high density lipoprotein
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Table 5.6. Age, sex and age-adjusted mean levels of risk factors in diabetic/impaired
glucose tolerant and normal glucose tolerant subjects without peripheral arterial
disease






Age, years 65.1 (0.4)
Sex. % male 58.4
Smoking
% current/ex smokers 48.1
V pack-years 2.38 (0.23)
Blood pressure
Systolic blood pressure, mmHg 150.4 (1.8)
Diastolic blood pressure, mmHg 78.9 (0.9)
Body Mass Index, kg/m2 26.8 (0.3)
Lipids
Total cholesterol, mmol/1 6.99 (0.11)
LDL cholesterol, mmol/1 5.25(0.10)
HDL cholesterol, mmol/1 1.38 (0.03)




















NS, not significant (p>0.05); SE, standard error; NGT, normal glucose tolerance
LDL, low density lipoprotein; HDL, high density lipoprotein
98
Table 5.7. Odds of peripheral arterial disease according to diabetic status (diabetes/IGT
versus normal glucose tolerance), before and after adjustment for each risk factor
Riskfactors adjustedfor (in Odds 95% Confidence p-value
addition to age and sexj Ratio Interval
- 1.64 (1.17, 2.31) <0.01
Sex, age 1.45 (1.03, 2.04) <0.05
Smoking status
Current/ex/never 1.65 (1.16, 2.34) <0.01
Blood pressure
Systolic blood pressure, mmHg


























Systolic BP and triglyceridesf 1.11 (0.78, 1.58) 0.6
*smoking status (current, ex, never) used as categorical variable
^simultaneous adjustment for systolic blood pressure and triglycerides (log)




Case control study: Plasma insulin and steroid sex hormones
as risk factors for peripheral arterial disease
This chapter describes the findings of the case control study. It is divided into three
sections; (i) general characteristics of the study population, (ii) plasma insulin levels in
cases and controls, and (iii) plasma steroid sex hormone levels in male and female cases
and controls.
6.1 Characteristics of study population
6.1.1 Characteristics of responders and non-responders
Subjects for the case control study were selected from the 1156 subjects attending the
Edinburgh Artery Study 5-year follow-up examination. By this stage, 203 of the
original 1592 subjects participating in the baseline cross-sectional survey had died, 131
completed a questionnaire but did not attend for examination and the remainder could
not be contacted at home or were unwilling or unable, due to illness, to continue with
the study. The response rate for clinic attendance amongst those still living was
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82.3% and examination of the characteristics of attenders compared with the total
study population eligible to attend for examination showed no significant difference
in terms of age, sex or social class distribution (Table 6.1).
Among the 1156 subjects who attended for follow-up, a total of 128 cases and 290
controls were initially identified as eligible for the case control study. The percentage of
eligible subjects varied according to 5-year age band (Table 6.2); in general, more cases
and fewer controls were eligible from successive age bands (reflecting the increasing
prevalence of arterial disease with age).
All fifty four (54) male cases who were identified as eligible for the study were invited
for examination. However, of these, two were found to have died and one had been
diagnosed as diabetic since the Edinburgh Artery Study five-year follow-up
examination, and were therefore ineligible. Of the remaining 51 cases, 40 attended
(response rate 78%). Reasons for non-attendance were refusal (n=9), inability to
contact subject by letter or telephone (n=l) and illness (n=l).
Sixty seven (67) of 74 female cases who were identified as eligible for the study were
invited for examination. The eligible cases who were not invited were all in the oldest
(75-80 year) age group; the number of cases who could be invited from this age group
was limited by the number of controls available in the corresponding age band (only 19
eligible controls compared with 27 eligible cases). Of the 67 cases invited, one was
subsequently found to have had a stroke since the five-year follow-up examination, and
was therefore ineligible. Of the remaining 66 cases, 43 attended (response rate 65%).
Reasons for non-attendance were refusal (n=18) and inability to contact subject by letter
or telephone (n=5).
A total of 149 subjects were identified who met the criteria for a male control, ofwhich
56 were invited for examination. However, three subjects were subsequently found to
be ineligible because of a recent stroke (n=2) or use of steroid medication (n=l). Of the
remaining 53 invited controls, 41 attended (response rate 77%). Reasons for non-
attendance were refusal (n=8), inability to contact subject (n=3) and illness (n=l).
A total of 141 subjects were identified who met the criteria for a female control, of
which 59 were invited for examination. However, one subject was subsequently found
to be ineligible because they were using hormone replacement therapy. Of the
remaining 58 invited controls, 47 attended (response rate 81%). Reasons for non-
attendance were refusal (n=9), inability to contact subject (n=l) and illness (n=l).
Although a control subject was only invited once a case had agreed to attend, more
controls than cases ultimately attended for examination (3 men and 4 women). This
was because, on several occasions, the case withdrew from the study or was found to be
ineligible after their matched control had been invited. However, even with these
controls included, there was no significant difference in the age or sex distributions of
the case and control groups, and so all subjects were retained for the purposes of the
analysis.
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The final study population consisted of 83 cases and 88 controls. The response rates for
cases and controls are given by sex and 5-year age-band in Table 6.3. In general,
response rates were higher in the younger age groups, especially in women. However,
there was no significant difference in the age, sex or social class distribution between
case responders and the total sample of cases eligible for inclusion in the study. There
was also no significant difference between these groups in mean ankle brachial pressure
index, nor in the prevalence of intermittent claudication (Table 6.4).
6.1.2 Disease characteristics of cases
The disease characteristics of the selected cases are given in Table 6.5. Subjects were
defined as a case if they had either a history of intermittent claudication plus an ABPI
<0.9, or an ABPI <0.85 alone. Of the 83 cases, 26 (31.3%) suffered from intermittent
claudication and had an ankle brachial pressure (ABPI) of 0.9 or less; the remainder
were asymptomatic, with an ABPI of 0.85 or less. A similar percentage of male and
female cases were symptomatic (30.0% and 32.6% respectively).
As expected, mean ankle brachial pressure index was substantially lower in cases (0.71)
than in controls (1.12; p<0.001). A similar difference in mean ABPI between cases and
controls was found for both men (0.70 vs 1.14; p<0.001) and women (0.72 vs 1.10;
p<0.001).
Twenty cases (24.1%) also had evidence of angina and a smaller percentage had
evidence of previous myocardial infarction (16.9%) or stroke (3.6%). The controls had
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no evidence of intermittent claudication, angina, myocardial infarction or stroke,
indicating that they had been correctly selected according to the control criteria.
6.1.3 Comparability of cases and controls
As expected from the matching, age and sex distributions were almost identical in cases
and controls (Table 6.6). Forty eight percent of cases were men compared with 47% of
controls. There was no significant difference in mean age between cases (71.6 years)
and controls (70.9 years) in the total study sample, nor between male cases and controls
(71.6 vs 71.4 years) or female cases and controls (71.3 vs 70.5 years).
Increasing number of cases were recruited from successive age bands between the ages
of 60 and 74 years. This was not surprising given the increase in prevalence of
peripheral arterial disease with age. However, fewer subjects were recruited from the
oldest (75 to 80 year) age band. This appeared to be a combination of the lower number
of subjects in this age band attending the Edinburgh Artery Study 5-year follow-up
examination plus a lower response rate in older groups (see Tables 6.2 and 6.3). As
matching was done by age bands, the percentage of the sample from each of the four
age bands was no different between cases and controls.
Mean levels of a number of risk factors were compared between cases and controls,
both in the total study sample and after the sample was split by sex. This included the
'established' cardiovascular risk factors (cigarette smoking, hypertension and
hyperlipidaemia) as well as blood glucose and measures of obesity (body mass index
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and waist hip ratio). These latter factors were included because of their recognised
associations with plasma insulin and oestrogen levels respectively. The results are
summarised in Table 6.7 (both sexes combined), Table 6.8 (males) and Table 6.9
(females); the main findings are described below.
Mean lifetime smoking, measured in square root pack-years to normalise the skewed
distribution of pack-years within the study population, was significantly higher in cases
(3.08; 95% CI 2.38, 3.78) than in controls (1.81; 95% CI 1.27, 2.34, p<0.01). When the
population was split by sex, higher levels of smoking were found in both male and
female cases compared with controls, although the differences were less significant.
Systolic and diastolic blood pressure measurements were found to be normally
distributed within the study population and so did not require transformation prior to
analysis. Mean systolic blood pressure was significantly higher in cases (154.8 mmHg;
95% CI 149.3, 160.3) than in controls (143.6 mmHg; 95% CI 138.7, 148.5; p<0.01).
Mean diastolic pressure was also higher in cases (83.6 mmHg; 95% CI 81.1, 86.2)
compared with controls (80.6 mmHg; 95% CI 78.3, 82.9) but this difference was less
marked and significant at the 10% level only (p=0.07). When the distribution of blood
pressure was examined in the two sexes separately, the higher mean levels of systolic
pressure in cases was confined almost exclusively to men (155.5 mmHg vs 138.7
mmHg; p<0.01); there was no significant difference in mean systolic pressure between
female cases and controls (154.2 mmHg vs 147.8 mmHg, p>0.1).
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Semm levels of total cholesterol, low density lipoprotein cholesterol, high density
lipoprotein cholesterol and triglycerides were found to be normally distributed except
for serum tryglycerides which was positively skewed (necessitating log transformation
prior to analysis). There was no significant difference between total cases and controls
in mean levels of total cholesterol (6.52 mmol/1 vs 6.57 mmol/1, p>0.1) or low density
lipoprotein cholesterol (4.58 mmol/1 vs 4.63 mmol/1, p>0.1). Similar levels of these
variables were also found in male and female cases and controls when the sample was
split by sex.
Mean high density lipoprotein cholesterol was slightly lower in cases (1.20 mmol/1;
95% CI 1.12, 1.27) than in controls (1.29 mmol/1; 95% CI 1.22, 1.36), although this
difference was only significant at the 10% level (p=0.07). This was predominantly due
to lower levels in female cases than controls (1.31 mmol/1 vs 1.44 mmol/1, p=0.06);
there was no significant difference between male cases and controls (1.07 mmol/1 vs
1.12 mmol/1, p>0.1).
The greatest difference in serum lipid levels between cases and controls was found for
serum triglycerides. In the total study sample, mean levels were considerably higher in
cases (1.52 mmol/1; 95% CI 1.39, 1.67) than in controls (1.34 mmol/1; 95% CI 1.23,
1.45 p<0.05). This was predominantly due to higher levels in male cases than controls
(1.53 mmol/1 vs 1.28 mmol/1, p=0.07); there was no significant difference between
female cases and controls (1.50 mmol/1 vs 1.39 mmol/1, p>0.1).
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Distributions of fasting blood glucose and one-hour blood glucose (blood glucose one
hour after an oral glucose load) were positively skewed, necessitating log
transformation prior to analysis. There was no significant difference in mean fasting
glucose between cases and controls in the total study sample (5.5 mmol/1 vs 5.6 mmol/1,
p>0.1), nor when the sample was split by sex. Mean one-hour glucose was higher in
total cases (8.9 mmol/1; 95% CI 8.4, 9.6) than in controls (8.1 mmol/1; 95% CI 7.6, 8.6,
p<0.05), but there was no significant difference between cases and controls when mean
levels were compared separately in men (9.0 mmol/1 vs 8.3 mmol/1, p>0.1) and in
women (8.8 mmol/1 vs 7.9 mmol/1, p>0.1).
Body mass index was normally distributed and so did not require transformation prior
to analysis. In the total study sample, there was no significant difference in mean body
mass index between cases and controls (26.3 kg/m2 vs 25.9 kg/m2, p>0.1). However,
when the sample was split by sex, male cases had a slightly higher mean body mass
index than controls (26.5 kg/m2 vs 25.2 kg/m2, p=0.06). No such difference was found
amongst female subjects.
Waist hip ratio (the ratio of waist circumference to hip circumference) was also
normally distributed. In the total study sample, the difference in mean waist hip ratio
between cases (0.90; 95% CI 0.88, 0.92) and controls (0.88; 95% CI 0.86,0.90) did not
quite reach the 10% significance level (p=0.12). However, mean waist hip ratio was
found to be significantly higher in male cases than controls (0.92 vs 0.89, p<0.05).
Female cases and controls had a similar mean waist hip ratio (0.88 vs 0.87, p>0.1).
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In summary: In the total study population, cases smoked more than controls and had
higher mean systolic blood pressure, serum triglycerides and one-hour blood glucose.
Cases also had slightly higher mean diastolic blood pressure and slightly lower mean
high density lipoprotein cholesterol. When the total study population was split by
sex, male cases had higher mean systolic blood pressure and waist hip ratio than
male controls. They also had slightly higher lifetime smoking, mean serum
triglycerides and mean body mass index. In the female study population, cases




Mean levels of fasting plasma insulin, plasma insulin one hour after the oral glucose
load (one-hour insulin) and insulin resistance in cases and controls are given in Table
6.10. For all of these variables, the levels were log transformed because of skewed
distributions (Figures 6.1 to 6.3). Geometric means and transformed confidence
intervals have therefore been presented.
There was no significant difference in mean fasting insulin between cases and controls,
either in the total study population (6.4 mU/1 vs 6.1 mU/1, p>0.1) or when the sample
was split by sex (men 6.9 mU/1 vs 5.8 mU/1, p>0.1; women 5.9 mU/1 vs 6.3 mU/1,
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p>0.1). However, mean insulin, one hour after the oral glucose load, was significantly
higher in total cases (73.6 mU/1; 95% CI 65.0, 83.3) than in controls (59.8 mU/1; 95%CI
53.2, 67.3, p<0.05). When one-hour insulin levels were compared between cases and
controls in men and women separately, male cases had slightly higher mean levels than
male controls (81.7 mU/1 vs 65.0 mU/1; p=0.06). However, the difference between
female cases and controls did not quite reach the 10% significance level (66.6 mU/1 vs
55.6 mU/1; p=0.11). Mean insulin resistance was not significantly different between
total cases and controls (1.55 vs 1.49, p>0.1), nor between male or female cases and
controls.
Correlations between one-hour plasma insulin and the other cardiovascular risk factors
are given for cases and controls separately in Table 6.11. The most marked
correlations, present in both the case and control groups, were found between one-hour
insulin and smoking (r = 0.26, p<0.05 in cases; r = 0.27, p<0.05 in controls), serum high
density lipoprotein cholesterol (r = -0.28, p<0.01 in cases; r = -0.22, p<0.05 in controls),
serum triglycerides (r = 0.18, p<0.1 in cases; r = 0.28, p<0.01 in controls), fasting blood
glucose (r = 0.21, p<0.1 in cases; r = 0.36, p<0.001 in controls) and one-hour blood
glucose (r = 0.34, p<0.01 in cases; r = 0.49, p<0.001 in controls). In the control group,
one-hour insulin also correlated with diastolic blood pressure (r = 0.39, p<0.001), serum
low density lipoprotein cholesterol (r = 0.24, p<0.05) and weakly with total serum




The results of multiple logistic regression, used to examine the association between
one-hour plasma insulin concentration and risk of peripheral arterial disease, before and
after adjustment for the other cardiovascular risk factors, are shown in Table 6.12.
Higher one-hour insulin levels were associated with a significant increase in the risk of
peripheral arterial disease (odds ratio of disease for a one log unit increase in one hour
insulin concentration, adjusted for age and sex was 1.96; 95% CI, 1.11, 3.44; p<0.05).
The strength of the association between disease and one hour insulin was not
significantly different between men (odds ratio 2.24; 95% CI, 1.00, 5.06) and women
(odds ratio 1.82; 95% CI, 0.78, 4.30: p-value for difference between odds ratios >0.1).
Because of this finding, and to prevent loss of power due to small numbers, further
multivariate adjustment was performed only with the two sexes combined.
Adjustment for the effects of systolic and diastolic blood pressure (with the sexes
combined) did not greatly alter the association between disease and one-hour insulin
concentration. Thus the odds ratio changed only marginally from 1.96 (95% CI 1.11,
3.44) to 2.04 (95% CI 1.11, 3.74), the 95% confidence intervals of these two ratios
overlapped almost entirely and the effect of insulin on disease remained significant
(adjusted odds ratio 2.04, p<0.05).
Further adjustment for the effects of plasma low density lipoprotein cholesterol, high
density lipoprotein cholesterol and triglycerides slightly weakened the relationship
between insulin and disease (odds ratio fell from 2.04; 95%CI 1.11, 3.74, to 1.86; 95%
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CI 0.99, 3.48). However, the 95% confidence intervals of these two ratios overlapped
considerably and the effect of insulin on disease remained significant at the 10% level
(multi-adjusted odds ratio 1.86, p<0.1).
The addition of smoking to the multivariate model had the greatest effect on the
relationship between insulin and disease. Adjustment for the effects of blood pressure,
serum lipids and smoking resulted in a reduction in the odds ratio to 1.64 (95% CI 0.83,
3.23). Although this was not a large drop from the previously adjusted ratio of 1.86
(and there was still considerable overlap in the 95% confidence intervals), the ratio
became non-significant (p=0.17).
Despite the high level of correlation between one-hour glucose and insulin levels,
addition of one-hour glucose to the multivariate models in Table 6.13 made very little
difference to the odds ratios for one-hour insulin and disease. After adjustment for age,
sex, blood pressure and one-hour blood glucose, higher one-hour insulin levels
remained associated with a significant increase in the risk of peripheral arterial disease
(odds ratio 1.96; 95% CI, 1.00, 3.82; p<0.05). Following further adjustment for serum
lipids, the odds ratio fell to 1.86 (95% CI 0.94, 3.66), but remained significant at the
10% level (p=0.08). Conversely, one-hour glucose was not associated with an
increased risk of peripheral arterial disease after adjustment for age, sex and one-hour
insulin (odds ratio 1.60; 95% CI, 0.52,4.93; p>0.1).
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6.2.3 Insulin, smoking and disease
The weakening of the relationship between one-hour insulin and peripheral arterial
disease when smoking was added to the multivariate model suggested that raised
plasma insulin levels might be an intermediary factor in the influence of smoking on the
development of disease. To explore this possibility further, mean one-hour insulin was
compared between ever-smokers (current and ex-smokers) and never-smokers in both
cases and controls (Figure 6.4). Mean one-hour insulin was significantly higher in ever-
smokers than in never-smokers in both cases (81.9 mU/1; 95%CI 67.2, 99.9 vs 61.6
mU/1; 95%CI 53.8, 71.1, p<=0.03) and controls (70.0 mU/1; 95%CI 58.7, 83.5 vs
49.4 mU/1; 95%CI 41.6, 58.5, p<0.01). This finding was consistent with the
significant correlation between pack-years and one-hour insulin in cases (r = 0.26,
p<0.05) and controls (r = 0.27, p<0.05).
Multivariate linear regression analysis was used to examine the independence of the
relationship between one-hour plasma insulin levels and smoking status, after
controlling for the other cardiovascular risk factors. There was a significant association
between smoking (ever- versus never-smoker) and one-hour insulin after adjustment for
the possible confounding factors of age, sex and peripheral arterial disease (B
coefficient 0.26, SE 0.09; p<0.01). The association between smoking and one-hour
insulin did not alter greatly after additional adjustment for the other cardiovascular risk
factors, including systolic and diastolic blood pressure, low density lipoprotein and high
density lipoprotein cholesterol and triglycerides (B coefficient 0.22, SE 0.09; p<0.05).
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To determine whether raised insulin levels in smokers could help to explain the effects
of smoking on the development of peripheral arterial disease, multiple logistic
regression was used to calculate the odds of disease for a one Vpack-year increase in
smoking and then to adjust this for one-hour insulin levels. Despite the association
between smoking and insulin, the relationship between peripheral arterial disease and
smoking (age and sex adjusted odds ratio of disease for a one Vpack-year increase in
smoking 1.19; 95% CI, 1.05, 1.35; p<0.01) was only very slightly weakened after this
adjustment (odds ratio 1.16; 95% CI, 1.02, 1.32; p<0.05). Further adjustment for serum
high density lipoprotein cholesterol and triglyceride levels, which were correlated with
smoking habit in subjects with peripheral arterial disease (Spearman's rank correlation
coefficients; high density lipoprotein cholesterol r = -0.32, p<0.05, triglycerides r =
0.24, p<0.05) also had little effect on the association between smoking and disease
(odds ratio 1.15; 95% CI 1.01, 1.31; p<0.05).
In summary: Compared with controls, cases had higher mean plasma insulin levels
one hour after the oral glucose load (73.6 mU/1 vs 59.8 mU/1; p<0.05), but not fasting
levels (6.4 mU/1 vs 6.1 mU/1; p>0.1). The relationship between one-hour plasma
insulin and disease was independent of blood pressure (odds ratio 2.04; 95% CI
1.11,3.74; p<0.05) and partially independent of serum low and high density
lipoprotein cholesterol and triglycerides (odds ratio 1.86; 95% CI 0.99, 3.48; p<0.1).
However, when smoking was added to the multivariate model, the relationship
between insulin and disease diminished (odds ratio 1.64; 95% CI 0.84,3.23; p>0.1),
consistent with raised mean insulin levels in smokers.
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6.3 Steroid sex hormones
6.3.1 Univariate analysis
Mean levels of steroid sex hormones were compared between cases and controls.
For plasma sex hormone-binding globulin and plasma oestrone, levels were log
transformed in both men and women because of skewed distributions. Geometric
means and transformed confidence intervals were given for these variables. All of the
other variables were normally distributed in both sexes. All analyses were performed
in men and women separately because of their unique sex hormone profiles.
Mean levels of steroid sex hormones in male cases and controls are given in Table 6.13.
There was no significant difference between cases and controls in mean levels of total
plasma testosterone (13.6 nmol/1 vs 14.9 nmol/1, p=0.3), plasma sex hormone-binding
globulin (34.6 nmol/1 vs 39.5 nmol/1, p=0.12) or free plasma testosterone (403.4 pmol/1
vs 379.2 pmol/1, p=0.5). Neither was there any significant difference in mean plasma
oestradiol (97.9 pmol/1 in cases compared with 106.1 pmol/1 in controls, p-0.2). Mean
levels of plasma oestrone were slightly higher in cases (101.9 pmol/1; 95% CI 94.8,
109.5) than controls (92.1 pmol/1, 95% CI 84.2, 100.8) but this difference was only
significant at the 10% level (p=0.09).
Mean levels of steroid sex hormones in female cases and controls are given in Table
6.14. There was no significant difference between cases and controls in mean levels of
total plasma testosterone (0.62 nmol/1 vs 0.72 nmol/1, p=0.3), plasma sex hormone-
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binding globulin (45.0 nmol/1 vs 49.0 nmol/1, p=0.5), or free plasma testosterone (15.3
pmol/1 vs 16.0 pmol/1, p=0.8). Neither was there any significant difference in mean
plasma oestrone (81.26 pmol/1 in cases compared with 82.96 pmol/1 in controls, p=0.7)
or plasma oestradiol (47.02 pmol/1 in cases compared with 49.72 pmol/1 in controls,
p=0.4).
The prevalence of thyroid disease, which can affect sex hormone-binding globulin
concentrations, was low. Five female cases, two female controls and no male subjects
were taking thyroxine (which can increase levels of the globulin) and no subjects of
either sex were being treated for hypothyroidism. When female subjects taking
thyroxine were excluded from the analysis, there remained no significant difference in
mean plasma sex hormone-binding globulin between cases and controls (44.6 nmol/1 vs
48.6 nmol/1, p=0.5).
Spearman's rank correlation coefficients were calculated to examine associations
between steroid sex hormones and the other cardiovascular risk factors in male cases
and controls (Tables 6.15 and 6.16) and in female cases and controls (Tables 6.17 and
6.18). In male cases, plasma sex hormone-binding globulin correlated significantly
with serum high density lipoprotein cholesterol (r = 0.39, p<0.05) and negatively with
serum triglycerides (r = -0.34, p<0.05), body mass index (r = -0.40, p<0.05) and waist
hip ratio (r = -0.48, p<0.01), but these correlations were not evident in male controls.
Total plasma testosterone also correlated with body mass index (r = -0.39, p<0.05) and
waist hip ratio (r = -0.31, p<0.05) and free plasma testosterone with waist hip ratio (r =
0.33, p<0.05) in male cases but not in controls. The only other significant association in
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men was a negative correlation between free plasma testosterone and diastolic blood
pressure in cases (r = -0.36, p<0.05).
In women, sex hormone-binding globulin correlated in controls with diastolic blood
pressure (r = -0.44, p<0.01), in cases with serum high density lipoprotein cholesterol (r
= 0.38, p<0.01) and in both groups with serum triglycerides (r = -0.35, p<0.05 in cases,
r = -0.47, p<0.001 in controls) and body mass index (r = -0.44, p<0.01 in cases, r = -
0.46, p<0.001 in controls). Free plasma testosterone correlated in cases with lifetime
smoking (r = 0.38, p<0.05), in both groups with diastolic blood pressure (r = 0.31,
p<0.05 in cases, r = 0.29, p<0.05 in controls) and in controls with total serum
cholesterol (r = 0.45, p<0.01), serum low density lipoprotein cholesterol (r = 0.42,
p<0.01) and serum triglycerides (r = 0.45, p<0.01). Total plasma testosterone correlated
in cases with lifetime smoking (r = 0.42, p<0.01) and in controls with total serum
cholesterol (r = 0.38, p<0.01) and serum low density lipoprotein cholesterol (r = 0.36,
p<0.05).
6.3.2 Multivariate analysis
Multiple logistic regression was used to examine the association between steroid sex
hormones and risk of disease after adjustment for the other cardiovascular risk factors.
The odds of disease was adjusted first for body mass index because of the close
relationship between obesity and sex hormones, in particular plasma oestrogens.
Adjustment was then made for the other selected risk factors linked with an increased
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risk of cardiovascular disease (systolic blood pressure, smoking, serum low density and
high density lipoprotein cholesterol and serum triglycerides).
In men, none of the sex hormones was associated with an increased or decreased risk of
peripheral arterial disease after multivariate adjustment for age and body mass index
(Table 6.19). This included plasma oestrone, for which the unadjusted mean levels had
been marginally higher in cases than in controls (odds ratio associated with a one log
unit increase in oestrone 3.36; 95% CI 0.55, 20.6, p=0.2). For the other hormones, odds
ratios ranged from 0.43 (95% CI 0.12, 1.55) for plasma sex hormone-binding globulin
to 1.21 (95% CI 0.74, 1.99) for free plasma testosterone. Further adjustment for
systolic blood pressure, smoking, serum low density cholesterol, serum high density
lipoprotein cholesterol and serum triglycerides did not alter the odds ratios greatly
(range from 0.50; 95% CI 0.10, 2.60 for plasma sex hormone-binding globulin to 1.10;
95% CI 0.61, 1.99 for free plasma testosterone). Replacement ofbody mass index with
waist hip ratio (as a measure of regional obesity) in the multivariate model had no
substantial impact on these results.
In women, findings were similar. None ofthe sex hormones was associated with risk of
peripheral arterial disease after multivariate adjustment for age and body mass index
(Table 6.20). Odds ratios ranged from 0.59 (95% CI 0.23, 1.49) for plasma sex
hormone-binding globulin to 1.98 (95% CI 0.63, 2.51) for free plasma testosterone.
Further adjustment for systolic blood pressure, smoking, serum low density lipoprotein
cholesterol, serum high density lipoprotein cholesterol and serum triglycerides did not
alter the odds ratios greatly (range from 0.70; 95% CI 0.41, 1.17 for total plasma
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testosterone to 0.79; 95% CI 0.47, 1.32 for plasma oestradiol). Again, replacement of
body mass index with waist hip ratio in the multivariate model had no substantial
impact on the results.
In summary: Mean plasma oestrone levels were slightly higher in male cases than
controls (101.9 pmol/1 vs 92.1 pmol/1; p=0.09), but this association lost significance
after multivariate adjustment for age and body mass index. Mean levels ofplasma total
and free testosterone, oestradiol, and sex hormone-binding globulin were not
significantly different in cases compared with controls in either sex (p>0.1).
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Table 6.1. Age, sex and social class distribution in subjects who attended the
Edinburgh Artery Study 5-year follow-up examination and in the total study
population eligible to attend





Males 49.5 (572) 48.4 (672)
Age
Mean years (SE) 69.7 (0.2) 69.8 (0.2)
60-64 years 25.4 (294) 24.9 (346)
65-69 years 27.6(319) 26.8 (372)
70-74 years 25.8 (298) 26.4 (367)
75-79 years 21.2(245) 21.9 (304)
Social class
I 11.9 (138) 10.9 (151)
II 34.3 (396) 32.3 (449)
IIIN 25.9 (299) 28.1 (390)
IIIM 17.4(201) 16.3 (226)
IV 7.4 (86) 8.8 (122)
V 2.8 (32) 3.1 (43)
All differences between attenders and total eligible sample non-significant (p>0.1)
SE, standard error
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Table6.2.Percentageofsubj ctsattendingthEdinburghArt rySf l ow-upexaminationwh eiti llyidentifiedasel gibleforparticipationithcason rolstudy,by5-y argendx Ageband 60-64years(n=294) 65-69years(n=319) 70-74years(n=298) 75-80years(n=245) Allages(n=1156)Eligiblesu jects\%(n) TotalMenWomen CasesontrolsCaseontrolsCaseontrols 5.1(15) 7.2(23) 14.8( 4) 17.1(42) 11.1( 28)32.0(94) 28.8(92) 19.1(57) 17.6(43) 25.1(290)6.3(8) 4.2(7) 14.8(23) 12.9(16) 9.4(5 )33.1(42) 31.9(53) 19.4(30) 19.4(2 ) 26.0(149)
4.2(7)
10.5(16) 16.8(24) 22.3( 7) 12.7(74)
31.7(53) 25.5(39) 21.0(30) 15.7(19) 24.1(141)
^Includessubj ctsidentifiedael gibleonthEdinburghArt ryStd abasedsu s quentlyf ndo ineligiblewhenth yattend dforexamination(n=4cases,o rols) 120







Ageband 60-64years 65-69years 70-74years 75-80years
86.7(13/15) 73.9(17/23) 75.0(30/44) 65.7(23/35)
92.9(13/14) 90.5(19/21) 77.5(31/40) 69.4(25/36)
87.5( /8) 71.4(5/7) 81.0(17/21) 73.3(11/15)
87.5( /8) 100(5/5) 73.9(17/23) 70.6(12/17)
85.7(6/ ) 75.0(12/16) 56.5(13/23) 60.0(12/20)








*Excludesthoses bjectsinvit dforexaminationansubs quentlyf tbin ligibl(n=4ca s,controls) 121
Table 6.4. Age, sex, social class distribution and peripheral arterial disease in
case responders and total eligible case population





Males 48.2 (40) 41.1 (51)
Age
Mean years (SE) 71.6(0.6) 72.4 (0.5)
60-64 years 15.7(13) 12.1 (15)
65-69 years 20.5 (17) 18.5 (23)
70-74 years 36.1 (30) 35.5 (44)
75-79 years 27.8 (23) 33.9 (42)
Social class
I 9.6 (8) 8.1 (10)
II 45.8 (38) 40.3 (50)
IIIN 22.9(19) 23.4 (29)
IIIM 13.3 (11) 17.7 (22)
IV 3.6 (3) 4.8 (6)
V 4.8 (4) 5.6 (7)
Intermittent claudication
Grade 1 8.4 (7) 8.1 (10)
Grade 2 10.8 (9) 10.5 (13)
Probable 12.0(10) 12.9(16)
Total 31.3 (26) 31.5 (39)
ABPI
Mean (SE) 0.71 (0.02) 0.72 (0.01)
All differences between responders and total eligible population
non-significant (p>0.1)
ABPI, ankle brachial pressure index; SE, standard error
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Table 6.5. Disease characteristics of cases of peripheral arterial disease and controls




Grade 1 8.4 (7) 0
Grade 2 10.8 (9) 0
Probable 12.0 (10) 0
Total 31.3(26) 0
ABPI, mean (SE) 0.71 (0.02) 1.12 (0.01)
Coronary artery disease
Angina 24.1 (20) 0
Myocardial infarction 16.9 (14) 0
Stroke 3.6 (3) 0
Men
Peripheral arterial disease
Intermittent claudication 30.0 (12) 0
ABPI, mean (SE) 0.70(0.02) 1.14(0.02)
Coronary artery disease
Angina 27.5 (11) 0
Myocardial infarction 20.0 (8) 0
Women
Peripheral arterial disease
Intermittent claudication 32.6 (14) 0
ABPI, mean (SE) 0.72(0.02) 1.10(0.02)
Coronary artery disease
Angina 20.9 (9) 0
Myocardial infarction 14.0 (6) 0
ABPI ankle brachial pressure index; SE, standard error
All differences in mean ABPI between cases and controls, p<0.001
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Table6.6.Agndsexcharact risticsofc sep ripheralridiseasendco ols Percentage(ormean), TotalMalesFemales CasesontrolsCaseontrolsCaseontrols (n=83)8(n=40)( 1)(n=43)( 7) Sex Males48.2(40)6.6(41)---- Age Meanyears(SE)71.6(0.6)0.9( 571.( 84( 82)71.3(0 80 57) 60-64years15.7(13)4.8(17.5(7)14.0(6)2.8(6)65-69years21.7(18). ( 92.5(5230.(13)29.4 70-74years36.1(30)5 242.5(17)(2 .912)9 8( 4 75-80years28.9(24)527.5(11)9.3( 27.91 ).7( Alldifferencesbetwe ncasa dontrolsn - ignificant(p>0.1) SE,standarderror 124
Table6.7.Meancardiovascularr skf ctorsinesfperipherala t ri ldis a edc t ols Mean(95%confidenceinterval) RiskfactorCases(n=83)
Controls(n=88)
p-value
Smoking Vpackyears Bloodpressure Systolicblo dpressure(mmHg) Diastolicblo dpressure(mmHg) Serumlipids Totalcholesterol(mmol/1) LDLcholesterol(mmol/1) HDLcholesterol(mmol/1) Triglycerides(mmol/l/ Bloodglucose Fastingglucose(mm l/l/ One-hourgluc se(mmol/l/ Obesity Bodymassindex(kg/m2) Waisthipr tio
3.08(2.38,.7 )
154.8(1 9.3,60. ) 83.6(81.1,86.2) 6.52(6.28,.76) 4.58(4.36,80) 1.20(1.12,. 7) 1.52(1.39,67) 5.5 8.9(5.4,5.7) (8.4,9.6) 26.3(25.5,27.1) 0.90(0.88,2)
1.81(1 27,2.34) 143.6(1 8.7,8.5) 80.6(78.3,82.9) 6.57(6.33,.81) 4.63(4.42,84) 1.29(1.22,36) 1.34(1.23,45) 5.6 8.1(5.5,5.7) (7.6,8. ) 25.9(2 .2,26.6) 0.88(0.86,90)
<0.01 <0.01 <0.1 NS NS <0.1 <0.05 NS <0.05 NS NS
^ geometricmeanoflo gedvari bleantransform dconfide eint val NSnotsignificant,p>0.1;LDL,lowde sitylipoprotein;Hh hde s tlipo tei
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Table6.8.Meancardiovascularri kfactorsimalecas sfpe ipheralrt ri ldiseasendco trols Mean(95%confidenceinterval) RiskfactorCases(n=40)Controls(=41)p-value Smoking Vpackyears4.12(3. 3,5.11)2.85( .91,3.79)<0 1 Bloodpressure Systolicblo dpressure(mmHg)155.5(146.5,164.4)138.7(132.0,1 5.4)< 05Diastolicblo dpressure(mmHg)83.9(79.4,87.9)78.2(73.9,82.5)NS Serumlipids Totalcholesterol(mmol/1)6.23(5.91,6.55)6.21(5.88,6.54)NSLDLcholesterol(mmol/1)4.38(4.07,4.68)4. 8(4 7,4.79)NSHDLcholesterol(mmol/1)1.07(0.97,1.17)1. 2(1 03,1.21)NSTriglycerides(mmol/1)^.53(1.32,1.78)1.28(1.13,1.45)<0 1 Bloodglucose Fastingglucose(mmol/l/*5.65(5.48,5.83)5.(5.45,5.71)NSOne-hourglucose(mmol/l/8.96(8.12,9.88)8.27(7.58,9.01)NS Obesity Bodymassindex(kg/m2)26.5(25.4,27.6)25.2(24.3,26.0)<0.1Waisth pratio0.92(0. 0,0.94)0.8(0. 7,0.91)<0.05
f geometricmeanfloggedvariablentransformedco fid ncei ervalNSnotsignificant,p>0.1;LDLlowdensitylipopro ein;HDL,highde sityli oprotein
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Table6.9.Meancardiovascularskfa t rsinfem lec esfperiph ralteridiseasendco t ols Mean(95%confidenceinterval) RiskfactorCases(n=43)Co t ols=47)p-va ue Smoking Vpackyears2.14(1 24,3.04).03(0.51,1.55)< .0 Bloodpressure Systolicblo dpressure(mmHg)154.2(147.4,161.0)47.8(1 1.0,154.7)NS Diastolicblo dpressure(mmHg)83.3(81.9,84.7)2.7(81.7,83.1)NS Lipids Totalcholesterol(mmo /1)6.81(6 46,7. 6).88(6 57,7.19)NS LDLcholesterol(mmol/1)4.77(4 45,5.08).77(4.49,5.05)NS HDLcholesterol(mmol/1)1.31(1 22, .40).44(1 5,1.53)<0. Triglycerides(mmol/l/1.50(1 33,1.71). 9(1 26,1.43)NS Bloodglucose Fastingglucose(mmol/l/5.36(5 19,5.54).57(5 8,5.73)NS Onehourglucose(mmol/l/8.84(8 08,9.68)7.93(7.16,8.78)NS Obesity Bodymassindex(kg/m2)26.1(24.9,27.4)6.5(25.4,27.6)NS Waisthipr tio0.88(0 85,0.90). 7(0 5,0.90)NS
' geometricmeanflo g dvari bleantransform dco fidenceinterval NSnotsignificant,p>0.1;LDL,lowde sitylipopro ein;HDL,highde s tylipopr
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Table6.10.Meanlevelsofplasmainsu inandi lir sistanceca esofperipheraleri ldis sedco t o s(byx) Mean,95%confidenceint rval CasesControls
p-value




Men Fastinginsuli(mU/1) One-hourinsulin(mU/1) Insulinresista ce
6.85(5.77,8.14). 6(5 01, .62)NS 81.74(66.79,100.02)5.03(55.05,76.82)< .1 1.72(1 43, .07).43(1 24,1.65)NS






f geometricmeanflo g dvari bleantr nsform dco fidenceint rval
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Figure6.1requencydistrib tiooffast ginsul n 30 25 20 Number °f15subjects 10 5 0 2345678910123456789 Fastinginsul ,mll/l(midpoint) 129
Figure6.2req encydistrib tioofne-hourinsul n 130
Figure6.3requencydistrib tioofins l nr sistance 0.50751 02.23.50754 05 2 Insulinresistance(midpoint) 131
Table 6.11. Spearman's rank correlation coefficients of one-hour plasma insulin levels







Systolic blood pressure, mmHg
































*p<0.1, **p<0.05, ***p<0.01, ****p<0.001
132




















*inadditiontogendsex * oddsratiof roneu tincre salogsc lene-houinsuli Variablesincludedmo l:systolicndd a t licbloopres ur( lpr r ),serumlowde itylip pr teina dhighde y lipoproteincholest rol(LDLandHcholes l)andpack-y arssme suroflifetimsm king(smoki g) CI,confidenceinterval 133
Figure6.4Geometricmean(transformed95%confide einte vals) ofne-hourinsulinlev lsnev r smokersandver- smokers,acc rdingtdi eastatus 100 90 80 70
Meanone60 hourinsulin50 (mU/l)5°







Table6.13.Meanlevelsofst roidxhormonesinalec saontrols Mean(95%confidenceinter al) Cases(n—40)ontrols= 1)p-va ue Plasmatestosterone Total,nmol/113.6(12.0,15.3)4.9(13.3, 6.5)NS Freetestosterone,pmol/1403.4(354.6,452.2)79.2(336.4, 2.0)NS PlasmaSHBGfnmol/134.6(30.4,39.3)9 5(35.6,43.8)0 12 Plasmaoestrogens Oestrone1,pm l/1101.9(94.8,109.5)2.(84.2,100.8)0 Oestradiol,pmol/197.9(88.6,107.3)10 .(97.3,1 4.9)NS geometriceanofl ggedvari ble SHBG,sexhormone-bindingglobulin;NSn tsignificant(p>0.1)
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Table6.14.Meanlevelsofst roidxhormon sinf lecasano trols Mean(95%confide ceint rval) Cases(n=43)
Controls(=47)
p-value
Plasmatestosterone Total,nmol/1 Free,pmol/1 PlasmaSHBGf.nmol/1 Plasmaoestrogens Oestrone1,pm l/1 Oestradiol,pmol/1
0.62(0 50,0.73) 15.3(11.24,19.35) 45.0(38.2,53.1) 81.26(73.96,89.27) 47.02(42.76,51.29)
0.72(0 58,0.86)NS 16.0(12.4,19.5)NS 49.0(42.4,56.7)NS 82.96(77.92,88.33)NS 49.72(45.44,54.00)NS
geometricanofl ggedvariable SHBG,sexhormone-bindingglobulin;NS,notsignificant(p>0.1)
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* p<0.05,* 1;SHBGsexhormone-bindingglobulin,LDLlowde s tylip prote ;DLhighdens tyli t i 137















































* p<0.05,* p<0.01;LDLlowdensityli oprotein;HDL,highdensitylipoprote n
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Table6.17.Spearman'srankcorre tioncoefficie tsfplasmatestost ronedxhormon -bindingg obulinwi hc rd va cularr k factorsinemalecasesando t ols Totaltestosterone,nmo /lFreetestost rone,pmol/lSHBGnm l/l RiskfactorCasesontrolsaseCont olsaseControls Smoking Packyears Bloodpressure Systolicblo dpressure,mmHg Diastolicblo dpressure,mmHg Lipids Totalcholesterol,mmol/1 LDLcholesterol,mmol/1 HDLcholesterol,mmol/1 Triglycerides,mmol/1 Obesity Bodymassindex,kg/m2 Waisthipr tio0.42" -0.010.38' 0.120.150.26 0.150.060.31' 0.150.38"0.15 0.120.36*0.12 0.230.02-0.09 0.010.250.23 0.15-0.110.18 0.08-0.040.10
0.09-0.16- .15 0.19-0.24-0.07 0.29* -0.22-0.44" 0.45" -0.05-0.21 0.42" -0.06- .1 -0.100.38" .22 0.45" -0.35* -0.47*** 0.13-0.44" -0.46*** -0.01- .12-0.07
* p<0.05,* . 1;SHBGsexhormone-bindingglobulin,LDLl wde s tyli prote ;DLhighdens tyli te 139
















































* p<0.05,* . 1;LDLlowdensityipoprotein;Hhighs tylipo in
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Table 6.19. Multivariate logistic regression of steroid sex hormones on peripheral
arterial disease in men
Hormone (SD or log unit)
factors adjustedfor Odds ratio (95% CI)' p-value
Total testosterone (5.22 nmol/1)
age, BMI 0.84 (0.52,1.36) NS
multiple 0.75 (0.41,1.38) NS
Free testosterone (148 pmol/1)
age, BMI 1.21 (0.74,1.99) NS
multiple 1.10 (0.61,1.99) NS
SHBG (log unit)
age, BMI 0.43 (0.12,1.55) NS
multiple 0.50 (0.10,2.60) NS
Oestrone (log unit)
age, BMI 3.36 (0.55,20.6) NS
multiple 2.13 (0.21,21.2) NS
Oestradiol (29.54 pmol/1)
age, BMI 0.74 (0.46,1.19) NS
multiple 0.67 (0.36,1.26) NS
NS, not significant (p>0.1); SD, standard deviation; CI, confidence interval; BMI,
body mass index
Multiple adjustment for age, body mass index, systolic blood pressure, cigarette
smoking (pack-years), serum low density lipoprotein cholesterol, high density
lipoprotein cholesterol and triglycerides
f odds ratio for a one standard deviation increase (or a one unit increase on a log
scale) in steroid sex hormone
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Table 6.20. Multivariate logistic regression of steroid sex hormones on peripheral
arterial disease in women
Hormone (SD or log unit)
factors adjustedfor Odds ratio (95% CI)f p-value

























NS, not significant (p>0.1), SD, standard deviation; CI, confidence interval; BMI,
body mass index
Multiple adjustment for body mass index, systolic blood pressure, cigarette smoking,
serum low density lipoprotein cholesterol, high density lipoprotein cholesterol and
triglycerides
f odds ratio for a one standard deviation increase (or a one unit increase on a log




Glucose intolerance, steroid sex hormones and
peripheral arterial disease
In this discussion chapter, methodological issues surrounding the analysis of the
cross-sectional data in the Edinburgh Artery Study and the design of the case control
study are considered first. The results of each study are then discussed in turn, with
respect to the objectives presented in chapter 1.
7.1 Methodological considerations
7.1.1 Classification of peripheral arterial disease
In the Edinburgh Artery Study cross-sectional survey, responses to the World Health
Organisation intermittent claudication questionnaire alone were used to identify
subjects with symptomatic peripheral arterial disease. This is the most widely accepted
method of detecting symptomatic peripheral arterial disease in epidemiological studies.
Unfortunately, cases of intermittent claudication identified solely by the WHO
questionnaire have been shown to include about one quarter of false positives when
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compared to a clinician's diagnosis of claudication (Richard et al 1972). It is therefore
likely that some of the subjects included in the disease group were biologically normal.
One method of improving diagnostic specificity would have been to combine
responses to the questionnaire with another marker of disease (for example, a low
ankle brachial pressure index, as in the case control study), but this would have
reduced overall sensitivity and so reduced the power of the study. Also, previous
analysis had shown no difference in baseline risk factor profiles between subjects with
WHO intermittent claudication alone and those with both claudication and a low ankle
brachial pressure index (FGR Fowkes, personal communication).
To identify subjects with major asymptomatic peripheral arterial disease, a
combination of the ankle brachial pressure index (ABPI) and reactive hyperaemia test
was used. The ABPI is normally distributed within the general population, and it is
generally accepted that as the ABPI falls, so the severity of the peripheral arterial
disease increases. A cut-off point of 0.7 in ABPI was chosen as a single indicator of
disease because, although arbitrary, results from clinical studies would suggest that few
normal individuals have such a low level (Bernstein and Fronek 1982) and in the
Edinburgh Artery Study population, subjects with such levels were well down in the
normal distribution. However, false negative ABPI readings may result from rigid
tibial arteries which prevent easy compression by the cuff (for example in association
with calcification and severe diabetes), resulting in the use of cuff pressures which are
higher than the actual intra-arterial pressure. Since abnormalities may be detected in
such individuals when a stress is applied, the reactive hyperaemia test was used in
conjunction with the ABPI to categorise subjects with asymptomatic disease when the
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ABPI was between 0.9 and 0.7, thus improving diagnostic sensitivity. A drop in ankle
systolic pressure of greater than 20% after occlusion was used since this would appear,
in the clinical setting at least, to be valid in identifying patients with peripheral arterial
disease (Baker 1978, Bernstein and Fronek 1982, Fowkes 1988a). When the result of
the reactive hyperaemia test was used as an indicator of major asymptomatic disease
disease on its own, a more severe cut-off point of 35% or greater was chosen. This
categorisation of asymptomatic peripheral arterial disease has been used previously in
the Edinburgh Artery Study, at which time validation of disease status was checked
using duplex scanning. This confirmed, in a subsample of cases, the presence of
significant atherosclerosis in those classified as asymptomatic disease but not in those
classified as 'healthy' (Fowkes et al 1991).
In the case control study, subjects with symptomatic disease were also identified using
the WHO intermittent claudication questionnaire. However, in order to minimise the
number of false positives included in the case group, subjects with positive WHO
intermittent claudication were included in the study only if they also had an ankle
brachial pressure index of 0.9 or less in one leg. To identify cases with
asymptomatic disease, an ankle brachial pressure index of 0.85 or less was taken as a
single indicator of disease (since the reactive hyperaemia test was not repeated at the
Edinburgh Artery Study five-year follow-up examination, this test could not be used
to categorise subjects as in the cross-sectional study). A cut-off point of 0.85 in
ABPI was chosen because this was the lowest possible level at which an adequate
number of subjects could be identified for the study. The specificity of the ABPI in
terms of detecting asymptomatic disease in subjects from the general population is
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unknown. However, it is thought likely that (at least in subjects with relatively severe
disease) this would be close to 100%, as reported for an ABPI <0.9 in the detection of
angiogram-positive disease in hospital patients (Fowkes 1988a). Since specificity is
likely to increase even further at lower levels of the index, the number of false
positives included in the present study was therefore likely to be small.
To identify control subjects, an ABPI of 1.0 or greater in both legs was taken to
indicate the absence of (asymptomatic) peripheral arterial disease. Since a cut-off
value of less than 0.9 has been shown to have a sensitivity around 95%, and since this
is likely to increase at higher cut-off values, the risk of including subjects with
peripheral arterial disease in the control group (false negatives) was also small.
The most probable effect of including biologically normal subjects in the 'disease' or
'case' group and/or subjects with disease in the 'healthy' or control group would be
to diminish associations between disease and risk factors. As such, this would not
detract from any positive findings in the study.
7.1.2 Representativeness of study populations
The Edinburgh Artery Study population participating in the original cross-sectional
survey was an age and sex-stratified, random sample of the general population of
Edinburgh. Subjects were chosen from general practices serving the wide range of
socio-economic and geographic areas present throughout the city of Edinburgh and
the final social class structure of the study population was similar to that of the city
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as a whole. Follow-up of a sample of non-responders indicated that there was no
substantial bias in terms of age and sex between subjects agreeing to participate and
those in the total selected population.
Comparison of age, sex and social class distributions indicated that subjects
attending the 5-year follow-up examination (from which subjects for the case control
study were selected) remained representative of the original study population. Cases
agreeing to participate in the case control study were also similar to the total
population of eligible cases identified, both in terms of age, sex and social class
distribution and in terms of markers of peripheral arterial disease. In conclusion,
both subjects participating in the cross-sectional study and cases participating in the
case control study appeared to be representative of all persons, and all persons with
disease respectively, in the general population. The results of both studies can
therefore be extrapolated to the population in general with some confidence.
7.1.3 Bias
Bias is the systematic error in design or analysis of a study that results in incorrect
estimates of risk factor association with disease. Case control studies are particularly
susceptible to bias, although it can also affect the validity of results from other study
types, including cross-sectional surveys. Bias can arise from differential reporting or
recording of exposure information between study groups based on their disease status
(observation bias) or, in case control studies, from the differential selection of cases
or controls into the study on the basis of their exposure status (selection bias).
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Selection bias is a particular problem when cases and controls are selected from two
different populations. This invariably occurs in hospital-based case control studies,
where persons with disease who have been treated at a particular hospital during a
specified period are identified and matched with patients from another section of the
hospital, relatives or the general population. In this situation, bias can arise from
whatever factors lead an affected individual to utilise a particular health care facility.
An advantage of the present population-based case control study was the ability to
identify cases and controls from the same general population using subjects
participating in the Edinburgh Artery Study, thus reducing the risk of selection bias.
Since, in addition, response rates amongst cases and controls were similar and the
exposure status of the subjects (their plasma insulin and sex hormone levels) was
unknown at the time of selection, it is unlikely that selection bias had a major impact
on the final results.
Observation bias occurs when there is differential reporting of exposure information
between study groups based on their status as diseased or healthy. However, in the
present studies, the majority of'exposure' factors were haematological and personnel
performing the assays for these factors were blinded to the subjects' disease status.
Thus, blood samples were identified only by means of the subject study number, and
laboratory personnel did not have access to the database which assigned disease
status to each study number. In the case control study, batches of samples sent to
participating laboratories contained samples from both cases and controls, and so any
systematic variations in measurement or reporting of assay results over time should
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have affected cases and controls equally. In addition, quality control procedures
suggested that inter-batch variation was low.
It is possible that observation bias could have affected two of the other variables
measured, namely smoking (reporting and/or interviewer bias) and waist hip ratio
(measurement bias). Smoking status was based on the results of a smoking
questionnaire. Interviewer bias (where the investigator may record smoking status
more favourably for healthy subjects than for diseased subjects) was minimised by
applying a self-administered questionnaire which clinic personnel only discussed
occasionally with participants if there were difficulties. Although it is possible that
subjects with peripheral arterial disease may have felt more guilty about smoking
because of previous medical advice and may have underestimated their smoking
compared with others (reporting bias), a good correlation between smoking levels
and serum thiocyanate levels suggested that the smoking histories were probably
reasonably accurate.
Waist hip ratio was measured by a single investigator (the author), to whom the
disease status of the individual was potentially known. In an attempt to minimise
measurement bias, waist and hip circumferences were measured according to a set
protocol for every subject. Also, most clinics were attended by a combination of
cases and controls, and on the day of the clinic, no documentation specifically
identifying subjects as a case or a control was readily accessible. The author
therefore did not automatically know the disease status of the individual, although
this was sometimes apparent in general conversation.
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7.2 Diabetes, cardiovascular risk factors and peripheral
arterial disease
7.2.1 Prevalence of peripheral arterial disease in diabetes and impaired
glucose tolerance
The prevalence of peripheral arterial disease in the Edinburgh Artery Study was 22.4%
in diabetic subjects and 19.9% in subjects with impaired glucose tolerance. Differences
in disease prevalence between the present and previous studies will reflect variations in
definitions of peripheral arterial disease and diabetes (or impaired glucose tolerance), as
well as different characteristics of the populations surveyed, such as age, sex and race.
The present study included subjects with major asymptomatic peripheral arterial disease
as well as subjects with intermittent claudication. It is not surprising, therefore, that the
prevalence of peripheral arterial diseases was considerably higher than the 2% to 8%
previously reported for intermittent claudication alone in diabetic populations (Nilsson
et al 1967, Janka et al 1980, West et al 1983, Uusitupa et al 1990, Mohan et al 1996).
A more comparable study is a large-scale survey in England in which peripheral arterial
disease was diagnosed according to an ankle brachial pressure index of 0.9 or less
(Walters et al 1992). In general, the population characteristics of this study were also
similar to the present study, in that disease was measured in a random sample of male
and female type 2 diabetics from the general population, with a mean age of 67.7 years.
The prevalence of peripheral arterial disease was found to be similar to that in the
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Edinburgh Artery Study at 23.5%. These results suggest that peripheral arterial disease
may affect between 1 in 4 and 1 in 5 type 2 diabetics in the United Kingdom.
As expected, the prevalence of peripheral arterial disease in subjects with diabetes or
impaired glucose tolerance (20.6%) was greater than in those with normal glucose
tolerance (12.5%). However, the degree of increased risk of peripheral arterial disease
associated with diabetes or impaired glucose tolerance (1.45 times higher risk after age
and sex adjustment), was rather less than the 2.5 to 6 times higher risks of disease
previously reported in diabetic subjects (see Table 2.1). It is likely that this reflects two
factors. Firstly, the inclusion of subjects with impaired glucose tolerance who had a
slightly lower prevalence of peripheral arterial disease than frankly diabetic subjects.
Secondly, a slightly higher than normal prevalence of peripheral arterial disease in the
non-diabetic population, possibly due to a particularly poor risk factor profile in
Scotland in terms of hypercholesterolaemia and cigarette smoking.
7.2.2 Risk factors for peripheral arterial disease in subjects with diabetes
or impaired glucose tolerance
Consistent with the results of several previous studies (Schroll and Munck 1981,
Kannel and McGhee 1985, Leng and Fowkes 1993), higher levels of cigarette smoking,
systolic blood pressure, serum triglycerides, serum total cholesterol and serum low
density lipoprotein cholesterol, and lower levels of serum high density lipoprotein
cholesterol were found to be risk factors for peripheral arterial disease in normal
glucose tolerant subjects. A similar array of factors appeared to increase the risk of
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peripheral arterial disease in subjects with diabetes or impaired glucose tolerance, with
levels of systolic blood pressure, plasma triglycerides and cigarette smoking particularly
high in subjects with peripheral arterial disease compared with the 'healthy' group.
Most (Janka et al 1980, Paisey et al 1984, Kreines et al 1985, Kannel et al 1990,
Uusitupa et al 1990, Mehler et al 1997, Al Zahrani et al 1997) but not all (West et al
1983, Walters et al 1992,) previous studies have also found a relationship between
hypertension, hypertriglyceridaemia and smoking and the risk of peripheral arterial
disease in diabetic subjects. Two studies found an association between hypertension
and a low ankle brachial pressure index in diabetic subjects (Mehler et al 1997, Al
Zahrani et al 1997), whilst in the University Group Diabetes program, baseline serum
triglyceride was significantly related to the risk of intermittent claudication in men
(Kreines et al 1985). In Finland, baseline systolic blood pressure, serum triglycerides
and, in men, smoking were related to the five-year incidence of WHO intermittent
claudication in newly-diagnosed type 2 diabetics (Uusitupa et al 1990). An association
between both hypertension and hypertriglyceridaemia and the subsequent development
of intermittent claudication in men and women with diabetes was also reported in the
Framingham study (Kannel et al 1990). In a clinic-based sample of type 2 diabetic
subjects, logistic regression also revealed a relationship between peripheral arterial
disease and smoking (Paisey et al 1984).
In the present study, differences in serum total, low density and high density lipoprotein
cholesterol between subjects with and without peripheral arterial disease did not reach
statistical significance, possibly due to relatively small subject numbers. However,
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other studies have shown associations between manifestations of peripheral arterial
disease and raised serum total cholesterol and low density lipoprotein cholesterol and
with reduced serum high density lipoprotein cholesterol in diabetic subjects (Kannel et
al 1990, Uusitupa et al 1990, Maser et al 1991, Walters et al 1992).
Taken together, these results suggest that the same risk factors which are important in
the development of peripheral arterial disease in normal glucose tolerant subjects are
also important in diabetic subjects, with systolic blood pressure, serum triglycerides and
cigarette smoking potentially having a particularly important role in diabetes.
7.2.3 Contribution of cardiovascular risk factors to the risk of peripheral
arterial disease in diabetes
As expected (Laakso and Lehto 1998), subjects with diabetes or impaired glucose
tolerance had a more detrimental cardiovascular risk factor profile compared with
normal glucose tolerant subjects. In particular, systolic blood pressure and serum
triglycerides were higher in glucose intolerant subjects, whether or not they also had
peripheral arterial disease. The only exception was cigarette smoking; more subjects
with diabetes or impaired glucose tolerance were never smokers and they had lower
mean lifetime smoking. The Framingham study also found increased levels of cigarette
smoking in male non-diabetic subjects compared with the male diabetic group, although
women with diabetes tended to smoke more than those without diabetes (Kannel et al
1990).
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Multivariate analysis indicated that raised serum triglycerides and elevated systolic
blood pressure in subjects with diabetes or impaired glucose tolerance could explain, at
least statistically, a major portion of the increased risk of peripheral arterial disease in
these subjects. Adjustment for all of the other risk factors individually resulted in, if
anything, only a slight reduction in the impact of diabetes on the likelihood of having
peripheral arterial disease, while cigarette smoking increased the odds of diabetes or
impaired glucose tolerance as a risk factor for disease (due to the higher percentage of
never smokers in the diabetic/glucose intolerant group). In the only other previous
study to attempt similar multivariate adjustment, the relative risk of peripheral arterial
disease associated with baseline diabetic status was substantially reduced, but remained
significantly elevated, after adjustment for age, serum cholesterol, smoking, systolic
blood pressure and left ventricular hypertrophy. However, serum triglyceride levels
were not included in this model (Kannel et al 1990).
There are several possible explanations for the results presented here. Firstly, since this
was a cross-sectional study, the temporal relationship between altered risk factor levels
and the development of peripheral arterial disease cannot be established and it is
possible that raised systolic blood pressure and serum triglycerides were secondary to
the disease. This possibility must be considered since previous prospective studies have
failed to show a consistent relationship between elevated systolic blood pressure and the
development of peripheral arterial disease, and, although most have found a univariate
association between raised triglyceride levels and disease, this may be explained by a
high correlation between triglyceride levels and cholesterol lipoproteins. A second
explanation may be that some underlying phenomenon, such as insulin resistance
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syndrome (Reaven 1988), was responsible for both the elevation in systolic blood
pressure and serum triglycerides, and the higher prevalence of peripheral arterial
disease. However, there may also be a direct causal relationship between raised systolic
blood pressure and serum triglycerides and the development of peripheral arterial
disease, in which case better control of these risk factors in diabetics should lead to a
reduced incidence of disease; this can only be proven in future clinical trials.
Finally, this study considered only a limited number of those risk factors which could
potentially contribute to the increased risk of peripheral arterial disease in diabetes.
Although the odds ratio for peripheral arterial disease associated with diabetes became
non-significant after adjustment for systolic blood pressure and serum triglycerides, the
power of the study was limited by relatively small numbers of subjects, especially in the
group with both diabetes or impaired glucose tolerance atid peripheral arterial disease
(the statistical significance of the odds ratio was affected by wide confidence intervals,
and the absolute value of the ratio remained greater than 1.0). It is likely that factors
other than systolic blood pressure and serum triglycerides contribute to the increased
risk of peripheral arterial disease in subjects with diabetes. Indeed, the final risk of
peripheral arterial disease in diabetes is likely to result from the net effect of a wide
range of different risk factors. For example, diabetics are known to have pro-
thrombotic states compared with non-diabetics; the additional influence of such factors
on the increased risk of peripheral arterial disease in diabetes merits further
investigation.
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7.3 Hyperinsulinaemia and arterial disease
7.3.1 Univariate association between hyperinsulinaemia and peripheral
arterial disease
In the case control study, plasma insulin levels one hour after an oral glucose load
were significantly higher in subjects with symptomatic or severe asymptomatic
peripheral arterial disease compared with 'healthy controls'. This is consistent with
findings for coronary artery disease, where several large prospective studies found
that raised plasma insulin levels were associated with an increased risk of disease in
men (Pyorala et al 1985, Fontbonne et al 1991, Yarnell et al 1994, Despres et al 1996).
It also confirms the findings of early studies on peripheral arterial disease, in which
non-diabetic men with intermittent claudication had raised post-glucose plasma
insulin levels compared with controls (Welborn 1966, Sloan et al 1970, Sorge et al
1976). In addition, associations between fasting plasma insulin levels and peripheral
arterial disease, including the development of intermittent claudication, have been
reported in diabetic subjects (Standi and Janka 1985, Uusitupa et al 1990). Since the
insulin immunoassay in the present study did not cross-react with pro-insulin (as may
have been the case in earlier studies), this study confirms that the active insulin
metabolite is associated with disease.
Recently, the results of further studies on plasma insulin and peripheral arterial
disease have been published, with generally inconsistent results (Table 7.1). In the
Hoorn Study, neither fasting nor 2-hour post-glucose plasma insulin was associated
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with the presence of peripheral arterial disease, as indicated by abnormal Doppler
wave forms, an ABPI less than 0.9 or a history of prior vascular surgery (Beks et al
1995). However, the random population sample used in this study was stratified by
glucose tolerance, such that it included a high proportion of subjects with diabetes
and impaired glucose tolerance as well as normal glucose tolerant subjects; it is
possible that other factors associated with each of these groups confounded any
relationship between plasma insulin and disease. Three further studies considered
predominantly asymptomatic disease in non-diabetic subjects (Laakso et al 1991,
Jacob et al 1995, Kekalainen et al 1996). No association was found between fasting
or post-glucose insulin levels and the presence of femoral atherosclerosis at
ultrasound examination (Laakso et al 1991, Kekalaien et al 1996), but non-diabetic
patients with a low ankle brachial pressure index were found to have elevated insulin
levels (Jacob et al 1995). In diabetic subjects, increased intima media thickness and
arterial disease of the carotid and femoral arteries were associated with lower
concentrations of fasting serum insulin (Elkeles et al 1996). The reasons for these
apparently conflicting results are unclear, but may reflect differences in the methods
used to detect peripheral arterial disease and the degree to which the compared, non-
diseased study population was free from atherosclerotic disease.
Most previous studies on the relationship between plasma insulin and peripheral arterial
disease have included only men, raising the question of whether insulin is also
associated with risk of arterial disease in women. This is particularly interesting since
diabetes is a two to three fold stronger risk factor for coronary artery disease in women
than in men (Barrett-Connor et al 1991), and the same appears to be true for peripheral
157
arterial disease (Reunanen et al 1982, Uusitupa et al 1990). Of the three original large-
scale prospective studies on coronary artery disease, the Helsinki Policeman Study
(Pyorala et al 1979, Pyorala et al 1985), the Paris Prospective Study (Ducimetiere et al
1980, Fontbonne et al 1991) and the Busselton Study (Welborn and Wearne 1979,
Cullen et al 1983), only one included women. In the Helsinki Policeman Study
(Pyorala et al 1985) and the Paris Prospective Study (Fontbonne et al 1991) raised
fasting and/or post-glucose insulin levels were associated with the subsequent
development of coronary artery disease in middle-aged men. Women were included in
the Busselton Study, but the most recent analysis from this study indicated that
hyperinsulinaemia did not affect coronary mortality in either sex (Cullen et al 1983).
More recent prospective studies have also demonstrated an association between
coronary artery disease and hyperinsulinaemia, but again these were confined to men
(Yarnell et al 1994, Despres et al 1996). Of only three cross-sectional studies to
included both sexes, two found fasting (Ronnemaa et al 1991) or post-glucose
(Mykkanen et al 1993) insulin levels to be indicators of coronary artery disease in both
sexes. The third showed an excess coronary risk associated with hyperinsulinaemia in
men only (Modan et al 1991).
Although women have been included more often in recent studies on peripheral arterial
disease, results have not generally been reported separately for the two sexes. In the
present study, mean post-glucose insulin levels were higher in both male and female
cases than in sex-matched controls, although the difference in women did not quite
reach statistical significance. However, there was no significant difference in the
strength of the association between insulin and disease in men compared with women.
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The most likely explanation for these results is that post-glucose insulin is associated
with peripheral arterial disease in both sexes, and that lack of a significant difference in
insulin levels between female cases and controls reflected a small sample size.
7.3.2 Multivariate association between hyperinsulinaemia and peripheral
arterial disease
The present study considered a wide range of potentially confounding risk factors,
including blood pressure, serum triglycerides, low density lipoprotein cholesterol and
high density lipoprotein cholesterol. Detrimental levels of these risk factors are found
to cluster in subjects with hyperinsulinaemia, possibly as part of the metabolic
syndrome, syndrome X (Reaven 1988, Stout 1990), and an adverse effect of plasma
insulin on such risk factors may explain some of the effect of insulin on disease.
However, the present study showed, for the first time, that the association between
insulin and peripheral arterial disease in non-diabetic subjects was independent of blood
pressure and only partially dependent on serum triglycerides, serum low density
lipoprotein cholesterol and serum high density lipoprotein cholesterol. The same
independent relationship has been observed recently between insulin and coronary
artery disease (Despres et al 1996) and between hyperinsulinaemia and the incidence of
intermittent claudication in diabetic subjects (Uusitupa et al 1990).
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7.3.3 Biological explanation for association between hyperinsulinaemia
and peripheral arterial disease
There are several possible explanations for the independent association found here
between peripheral arterial disease and plasma insulin. Firstly, hyperinsulinaemia may
cause atherosclerosis of the lower limbs either directly (via a direct pro-atherogenic
effect on blood vessel walls), and/or indirectly via an adverse effect of high plasma
insulin levels on cardiovascular risk factors not considered here. Thus, under
experimental conditions, insulin stimulates proliferation and migration of arterial
smooth muscle cells. It also stimulates cholesterol synthesis and low density
lipoprotein binding in arterial smooth muscle cells and macrophages (Stout 1990).
However, in addition to its association with blood pressure and dyslipidaemia,
hyperinsulinaemia has been linked to adverse levels of other cardiovascular risk factors,
including plasminogen activator inhibitor-1 (Elliott and Viberti 1993), and this could
potentially mediate the effect of hyperinsulinaemia on arterial disease.
Secondly, some other factor, associated with hyperinsulinaemia, could be the important
aetiological factor with insulin serving simply as a 'marker' for the underlying
abnormality. A possible candidate for such an aetiological factor includes raised blood
glucose levels. However, in the present study, the association between insulin and
peripheral arterial disease remained significant after adjustment for blood glucose,
suggesting that hyperinsulinaemia has an effect on disease independent of co-existent
hyperglycaemia. Others have suggested that hyperinsulinaemia may act as a marker for
insulin resistance, with the latter determining cardiovascular risk (Laakso et al 1991);
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this theory received support when coronary artery disease was found to be directly
associated with insulin resistance in men (Bressler et al 1992). However, in the
present study, insulin resistance itself was not associated with peripheral arterial
disease.
Finally, as with any cross-sectional or case control study, the possibility that
hyperinsulinaemia was a secondary manifestation of existing vascular disease must be
considered (Godsland and Stevenson 1995). Generalised atherosclerosis and reduced
vasodilatory capacity in subjects with peripheral arterial disease may be associated with
reduced glucose uptake into skeletal muscle and compensatory hyperinsulinaemia
(Laakso et al 1990, Baron 1994). In addition, endothelial dysfunction caused by
atherosclerosis may affect transport of insulin across capillary membranes (Godsland
and Stevenson 1995), leading to elevated post-glucose insulin levels in the presence of
normal fasting levels, as in the present study. A prospective cohort study will be
required to ensure hyperinsulinaemia precedes the development of peripheral arterial
disease.
7.3.4 Smoking, insulin and peripheral arterial disease
An association between smoking, a particularly strong risk factor for peripheral arterial
disease (Powell 1991), and post-glucose insulin levels was also demonstrated.
Furthermore, this association explained at least some of the effect of insulin on disease.
Smoking has not traditionally been associated with hyperinsulinaemia and/or syndrome
X, although a recent report found higher insulin levels and greater insulin resistance
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associated with hypertriglyceridaemia and reduced high density lipoprotein cholesterol
levels in 20 smokers than in 20 non-smokers (Facchini et al 1992). Fasting insulin
levels were also raised in smokers and ex-smokers compared with non-smokers in 616
non-diabetic men from the general population (Ronnemaa et al 1996). This relationship
was independent of other factors potentially affecting insulin sensitivity. It has been
hypothesised that insulin resistance, hyperinsulinaemia and dyslipidaemia in cigarette
smokers might be one mechanism by which smoking increases the risk of
atherosclerotic disease (Facchini et al 1992). Although the present study confirmed a
relationship between smoking and insulin levels and further, showed that this
relationship was independent of other cardiovascular risk factors, neither insulin levels
alone, nor in combination with high density lipoprotein cholesterol and triglyceride
levels, accounted for the effect of smoking on disease.
7.4 Endogenous steroid sex hormones and peripheral arterial
disease
The present case control study was the first epidemiological investigation into the
relationship between endogenous steroid sex hormones and the risk of peripheral
arterial disease. A wide range of sex hormones, as well as sex hormone-binding
globulin was measured, using plasma which had been stored for only a limited time
and subjects from the general population rather than hospitals. Despite this, there was
no evidence to support the suggestion that plasma testosterone (total or free), sex
hormone-binding globulin, oestradiol or oestrone were risk factors for peripheral
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arterial disease in either men or women. The most important risk factors were systolic
blood pressure, cigarette smoking, serum triglycerides, body mass index and waist hip
ratio in men and smoking and reduced serum high density lipoprotein cholesterol in
women.
7.4.1 Men
Several case control studies of endogenous hormones in men with coronary artery
disease found higher oestrogen levels and lower testosterone levels in survivors of
myocardial infarction compared with controls (Kalin and Zurnoff 1990). Although in
the present study plasma oestrone levels were slightly higher in male cases than in
male controls, this relationship was only weakly significant and became non¬
significant after adjustment for age and body mass index. Obesity has been associated
with altered sex hormone levels (in particular oestrogens) in previous studies, although
these factors did not correlate in the present study, possibly due to the small number of
obese subjects in the study sample. Obesity is also a potential risk factor for
cardiovascular disease, and was therefore an important confounding factor. Neither
mean plasma oestradiol nor total plasma testosterone levels were significantly different
in men with peripheral arterial disease compared with controls. These results are
consistent with those of prospective studies, in which none of the three sex hormones,
oestradiol (Cauley et al 1987, Phillips et al 1988, Barrett-Connor and Khaw 1988,
Eldrup et al 1989, Yarnell et al 1993), oestrone (Cauley et al 1987, Barrett-Connor and
Khaw 1988, Eldrup et al 1989), or total testostosterone (Cauley et al 1987, Phillips et
al 1988, Barrett-Connor and Khaw 1988, Yarnell et al 1993) predicted subsequent
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myocardial infarction. It is likely that the altered hormone levels found in myocardial
infarction survivors were a consequence of myocardial infarction, rather than a
precursor. In our population, only 20% of male cases and 14% of female cases had a
history of myocardial infarction and none of these events occurred within the year
prior to hormone measurement.
More than 90% of total plasma testosterone circulates bound to proteins,
predominantly sex hormone-binding globulin, and it is possible that only the free
(bioavailable) testosterone fraction is important in determining cardiovascular risk.
However, neither in the present study, nor in prospective studies of coronary artery
disease, was free plasma testosterone associated with the presence or development of
atherosclerotic disease (Cauley et al 1987, Barrett-Connor and Khaw 1988). More
recently, it has been suggested that sex hormone-binding globulin itselfmight be a risk
factor for cardiovascular disease, largely because of observed correlations between sex
hormone-binding globulin and cardiovascular risk factors such as high density
lipoprotein cholesterol and insulin (Pugeat et al 1995). However, the present study
found no significant difference in the levels of sex hormone-binding globulin between
men with and without peripheral arterial disease, consistent with previous case control
(Hamalainen et al 1987, Hautanen et al 1994) and prospective (Barrett-Connor and




Postmenopausal women taking pharmacological doses of exogenous estrogens reduce
their risk of cardiovascular disease (Stampfer and Colditz 1991). However, there was
no significant difference in endogenous oestrone or oestradiol levels between women
with and without peripheral arterial disease in the present study, suggesting that
physiological levels of estrogens may not be associated with disease.
Correspondingly, no association has been found between circulating oestrone levels
and prevalent heart disease (Cauley et al 1994), nor between oestrone or oestradiol and
the development of symptomatic cardiovascular disease (Barrett-Connor and
Goodman-Gruen 1995).
Neither testosterone (total or free), nor sex hormone-binding globulin levels differed
between women with and without peripheral arterial disease in the present study.
Previous information on endogenous testosterone levels and atherosclerotic disease in
women is scarce. Although women with testosterone excess associated with chronic
anovulation had an increased risk of myocardial infarction (La Vecchia et al 1987), in
a single prospective study, neither total nor free testosterone predicted fatal
cardiovascular disease in postmenopausal women (Barrett-Connor and Goodman-
Gruen 1995). However, low sex hormone-binding globulin levels did increase the
twelve year incidence of cardiovascular disease in postmenopausal women (Lapidus et
al 1986).
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An important consideration in any negative study is whether the study had sufficient
power to detect a significant difference. With the given sample size and at a power of
80% (a=0.05), the present study could detect a difference in each sex hormone
equivalent to approximately half a standard deviation of it's sex specific distribution
(for example, a difference in total testosterone of 2.55 nmol/1 in men and 0.27 nmol/1 in
women). It is possible that smaller differences might have been detected using larger
subject numbers, but the physiological relevance of such small differences is
questionable. It is also possible that the results could have been affected by the
sensitivity of the hormone assays; in the laboratory, 18% and 22% of women were
below the sensitivity range for oestradiol and total testosterone respectively, but no
men were below the sensitivity range of any of the sex hormones and no women were
below the sensitivity range for oestrone or sex hormone-binding globulin. Diurnal
variation in hormone levels should not have affected the results since all samples were
taken fasting at the same time in the morning.
The population studied in this investigation was relatively elderly (mean age 71 years).
The fact that exogenous estrogens reduce cardiovascular risk in postmenopausal
women suggests that exposure to sex hormones, even in later life, may be an important
factor in determining disease. However, the latency period of cardiovascular disease is
long, and it is also possible that any effects of endogenous sex hormones on disease are
more important earlier in life, during the development phase of atherosclerosis. This is
a particularly important consideration in women, since oestrogen levels fall
substantially during the menopause. Although study of premenopausal women would
be difficult due to their low risk of cardiovascular disease (necessitating prolonged
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follow up) and difficulties in determining 'average' hormone concentrations during the
menstrual cycle, such studies are necessary to demonstrate whether endogenous sex
hormones are indeed important in the subsequent development of atherosclerotic
disease.
7.5 Chapter summary
The work presented here was inspired by several observations described in the world
literature on vascular disease, in particular, the higher prevalence of peripheral arterial
disease in people with diabetes compared with non-diabetics and in men compared
with women. Also the intense worldwide interest in the interaction between hormones
and vascular disease and in the role of hyperinsulinaemia and sydrome X. The
analysis subsequently undertaken on the Edinburgh Artery Study suggests three main
findings: an important explanatory role for systolic blood pressure and serum
triglycerides in the increased prevalence of peripheral arterial disease in diabetic
subjects; a detrimental effect of hyperinsulinaemia on the development of peripheral
arterial disease in non-diabetic subjects; and a lack of effect of endogenous steroid sex
hormones on peripheral arterial disease in postmenopausal women or men.
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In this chapter, the principal conclusions of the work presented in the thesis are
summarised and recommendations for further research in this area are listed.
8.1 Conclusions
8.1.1 Diabetes and peripheral arterial disease
Subjects with diabetes or impaired glucose tolerance from the general population have a
higher prevalence of symptomatic and asymptomatic peripheral arterial disease
compared with normal glucose tolerant subjects. In people with diabetes, systolic
hypertension, hypertriglyceridaemia and cigarette smoking may be particularly
important risk factors for the development of peripheral arterial disease. Indeed, raised
levels of serum triglycerides and systolic blood pressure in subjects with diabetes or
impaired glucose tolerance may explain a major portion of their increased risk of
peripheral arterial disease compared with normal glucose tolerant subjects.
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8.1.2 Hyperinsulinaemia and peripheral arterial disease
Peripheral arterial disease is associated with raised plasma insulin levels and it is most
likely that this is the case for both men and women. The relationship between plasma
insulin and peripheral arterial disease is independent of other cardiovascular risk factors
associated with hyperinsulinaemia, including blood pressure, serum low density and
high density lipoprotein cholesterol, serum triglycerides, and blood glucose, suggesting
that insulin may have a direct effect on atherogenesis. However, smokers appear to be
hyperinsulinaemic compared with non-smokers and this may explain some of the
relationship between insulin and peripheral arterial disease. This latter finding also
raises the intriguing possibility that raised plasma insulin levels could contribute to the
detrimental effect of cigarette smoking on peripheral arterial disease.
8.1.3 Steroid sex hormones and peripheral arterial disease
Mean plasma levels of a range of steroid sex hormones, including total and free
testosterone, sex hormone-binding globulin, oestradiol and oestrone, are similar in
elderly men and postmenopausal women with and without peripheral arterial disease.
This does not support the hypothesis that endogenous sex hormone levels are
important in determining risk of atherosclerotic disease in either sex. However, neither
does it preclude a role for endogenous steroid sex hormones in the development of
atherosclerosis in younger men or premenopausal women.
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8.1.4 Aetiology of peripheral arterial disease
Research into peripheral arterial disease has increased recently. However, there is still
much to be learned about the aetiology of this condition, especially in comparison with
coronary artery disease. The findings described here provide some insight into the
importance of glucose intolerance, hyperinsulinaemia and endogenous steroid sex
hormones in the aetiology of a condition which, ultimately, is likely to result from a
web of interactions between a large number of risk factors, both genetic and
environmental. The on-going challenge is to unravel this web.
8.2 Recommendations for future research
1. A prospective cohort study is required to confirm the temporal relationship
between the risk factors identified here and the development of peripheral
arterial disease in subjects with diabetes. Unfortunately, the Edinburgh
Artery Study population, whilst being followed up prospectively, is likely to
contain too few diabetic subjects to enable such an analysis. However, the
cross-sectional data already available can be analysed to investigate the
impact of a wider range of risk factors than was included here on the higher
prevalence of peripheral arterial disease in diabetic populations. This
includes haemostatic and rheological factors such as plasma fibrinogen and
plasminogen activator inhibitor which are known to be raised in people with
diabetes.
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2. Within randomised controlled trials aimed at reducing the incidence of
macrovascular complications in general (including coronary artery disease) in
type 2 diabetes, it should be possible to investigate the effects of lowering
systolic blood pressure and serum triglycerides on the risk of peripheral
arterial disease (in particular, to determine whether strict regulation of these
factors can reduce the risk of peripheral arterial disease to levels comparable
with those of non-diabetic subjects).
3. Prospective studies are also required to establish the temporal relationship
between hyperinsulinaemia and the development of peripheral arterial
disease. Such studies should include both men and women in large enough
numbers to allow separate analysis according to sex. Careful consideration
should be given to the methods used to detect the development of peripheral
arterial disease and to the measurement of the wide range of potentially
confounding cardiovascular risk factors, particularly those linked with
syndrome X.
4. Given the preponderance of studies on plasma insulin and coronary artery
disease, further studies are required on the relationship between insulin and
other forms of arterial disease, such as cerebrovascular disease and measures
of asymptomatic disease such as intimal medial thickening.
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5. Further investigation is required into the significance of the relationship
between cigarette smoking and plasma insulin levels and, in particular,
whether raised insulin levels might mediate some of the effect of cigarette
smoking on the development of arterial disease.
6. Further prospective studies are required to investigate the impact of
endogenous steroid sex hormones on arterial disease in younger populations.
In particular, it would be important to determine whether endogenous
oestrogen levels in pre-menopausal women influence the development of
arterial disease later in life.
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Appendix I. Edinburgh Artery Study baseline questionnaire
EDINBURGH ARTERY STUDY
QUESTIONNAIRE
THE INFORMATION IN THIS QUESTIONNAIRE IS HIGHLY CONFIDENTIAL AND IS PART OF
A MEDICAL RESEARCH STUDY
The information you give in this personal health record will be treated as
strictly confidential and will be available only to your own doctor and the
study team. The results of the research will appear only in the form of
general statistics from which it will be impossible to identify you as an
individual.




If you have any difficulties in answering some questions you will have a
chance to discuss these later with a member of the study team.
THANK YOU FOR YOUR CO-OPERATION IN THIS STUDY. THE FINDINGS WILL HELP TO
IMPROVE HEALTH IN SCOTLAND.
IT IS IMPORTANT TO ANSWER ALL THE QUESTIONS CAREFULLY. PLEASE TAKE YOUR
TIME.
There is some evidence of a relationship between health and other factors
such as exercise, occupation, education, diet etc. In order to compare our
data with national figures and other research work, we are interested to
have the following details about yourself.
PERSONAL HISTORY
1. Please tick one box:
















4. What is the HIGHEST level of education you and your spouse or ex-spouse




Other professional or technical

























Please complete questions 6 and 7
spouse or ex-spouse.
6. YOURSELF
as appropriate for yourself and your
'
YOUR SPOUSE or EX-SPOUSE
(a) Please give the name of your present job and describe what you do as
fully as possible. If unemployed or retired, do not complete this
question, BUT PROCEED TO QUESTION 7.
(b) What business or industry is this in?





(d) In this job do you supervise/employ?
25 or more people □
fewer than 25 people □
no-one □
self-employed □ foreman □
manager □ other Q]
25 or more people




YOUR SPOUSE or EX-SPOUSE7. YOURSELF
(a) Please give the name of the job you have done for the longest period of
your life, and describe what you did as fully as possible. (If the
answer is the same as in Question 6 above, write SAME)
(b) What business or industry was this in?






self-employed □ foreman □
□ other nemployee 1 1
manager
(d) In this job did you supervise/employ?
25 or more people □ 25 or more people





FOR OFFICE USE ONLY
S.C.
SMOKING
Smoking has been linked with many health problems. It is important that you
answer the following section as accurately as possible. Please tick
appropriate boxes.
8{a) Do you smoke at present? Yes |~] No □
IF NO, PROCEED TO QUESTION 8(f)'
(b) What do you usually smoke now?
cigarettes Yes □ No □
pipe Yes □ No □
cigars Yes □ "No □
(c) How many do you usually smoke now?
cigarettes per day cigarettes
oz. tobacco per week oz.
cigars per week cigars
(d) For how many years during your life have you
smoked cigarettes? years
(e) How many cigarettes have you smoked on average
per day during the period you have smoked? cigarettes
NOW PROCEED TO QUESTION 8(k)
(f) Have you ever smoked regularly? Yes □ No □
IF NO, PROCEED TO QUESTION 8(k)
(g) What did you usually smoke?
cigarettes Yes □ No □
pipe Yes □ No □
cigars Yes □ No □
(h) How much did you smoke on average while you
were a smoker?
cigarettes per day cigarettes
oz. tobacco per week oz.
cigars per week cigars
(i) For how many years did you smoke cigarettes? years
(j) If you smoked cigarettes, how long is it
since you finally gave up? years months
(k) Is any other member of your household a
smoker? Yes □ No □
MEDICAL HISTORY
We should now like to ask you questions about your health, illnesses you
have had in the past, and how you are feeling now. Please tick appropriate
boxes.
9. Have you ever been told by a doctor that you have or liave had. any of
the following?
Yes Mo
Hardening of the arteries in the legs □ □
Angina □ □
Heart attack (coronary thrombosis, myocardial
□ □infarction)
High blood pressure □ □
Stroke □ □




10. .Are you on any regular medical treatment from a doctor as follows?
Yes No
Drugs to lower blood pressure □ □
Diuretics (water tablets) □ □
Insulin injections □ □
Tablets for diabetes □ □
Other treatments?
Give names if possible.
□ □
CHEST PAIN
11(a) Do you ever get pain or discomfort in your chest?
IF NO, PROCEED TO QUESTION 12
Yes □ No □
(b) Do you get this pain or discomfort when you walk uphill or hurry?
IF NO, PROCEED TO QUESTION llg
Yes □ No □
(c) Do you get it when you walk at an ordinary pace on the level?
Yes □ No □
(d) When you get any pain or discomfort in your chest what do you do?
Stop | j
Slow down □
Continue at the same pace □
(e) Does it go away when you stand still or sit down?
Yes □ No □
(f) How soon?
10 minutes or less Yes □ No □
more than 10 minutes Y'es □ No □
(g) Where do you get this pain or discomfort? Mark the place(s) with 'X'
on the diagram.
RIGHT . "y LEFT
12(a) Have you ever had a severe pain across the front of your chest lasting
for half an hour or more?
Yes □ No □
(b) What was the cause?
FOR OFFICE USE ONLY A: GRADE MI:
coxa
13(a) Do you usually cough several times first thing in the morning in the
winter? (Ignore clearing throat or single cough)
Yes □ No □
(b) Do you usually cough during the day or night in winter? (Ignore the
occasional cough)
Yes □ No □
(c) If yes to (a) or (b), do you cough on most days for at least three
months each winter?
Yes Q No □
PHLEGM (SPIT)
14(a) Do you usually bring, up any phlegm (spit) from your chest first thing
in the morning in the winter?
Y'es I I No | 1
(b) Do you usually bring up any phlegm from your chest during the day, or
at night, in the winter?
Yes □ No [[]
(c) If yes to (a) or (b) , do you bring up phlegm like this on most days
for as much as three months each year?
Yes □ No □
BREATHLESSNESS
15(a) Are you troubled by shortness of breath when hurrying on level ground
or walking up a slight hill?
IF NO, GO TO QUESTION 16
Yes □ No LJ
(b) Do you get short of breath walking with other people of your own age
on level ground?
Y'es □ No □
(c) Do you have to stop for breath when walking at your own pace on level
ground?
Yes □ No □
FOR OFFICE USE ONLY
B GRADE
WHFK7TNr.
16(a) Have you had attacks of wheezing or whistling in your chest at any
time in the last 12 months?
Yes [_J No I |
(b) Have you ever had attacks of shortness of breath with wheezing?
Yes No
(c) If yes to (b), is/was your breathing absolutely normal between
attacks?
Yes Q No Q
(d) Have you at any time in the last 12 months been woken at night by an
attack of shortness of breath?
Yes □ No □
LEG PAIN
17(a) Do you get a pain in either leg on walking?
IF NO, GO TO QUESTION 18
Yes No
(b) Does this pain ever begin when you are standing still or sitting?
Yes [^j No | |
(c) Do you get this pain in your calf (or calves)?
Yes j^j No
(d) Do you get it when you walk uphill or hurry?
Yes Q No | |
(e) Do you get it when you walk at an ordinary pace on the level?
Yes Q No [j
(f) Does the pain ever disappear while you are still walking?
Yes Q No j |
(g) What do you do if you get it when you are walking?
Stop 1 | |
Slow down 2 | i
Continue at same pace 3 | [
(h) What happens to it if you stand still?
Usually continues for more than 10 minutes 1 [ j
Usually disappears in 10 minutes or less 2
18. Have you ever had surgery on the arteries of your legs other than for
varicose veins?
Yes | | No | |
Please specify
19. Have you ever had surgery to remove
toes? Yes Q No Q~]
leg below the knee? Yes No J^j
leg above the knee? Yes j^J No Qj]
FOR OFFICE USE ONLY
I.C. GRADE
other memrkrs of your family
20. Please tick the appropriate boxes for other members of your family if
they have been diagnosed as having any of the illnesses below:
Illnesses Father Mother Any brother Any son or
or sister daughter
Angina □ □ □ □
Stroke □ □ □ □
High blood cholesterol I I I 1 I I i I
level
Diabetes (sugar disease) □ □ □ □
Hardening of the arteries
in the leg/claudication □ □ □ □
Thrombosis/embo1ism □ □ □ □
High blood pressure □ □ □ □
Heart attack □ □ □ □
If died from heart attack,
at what age?
....Yrs ....Yrs ....Yrs ....Yrs
PHYSICAL ACTIVITY
The following section gives examples of the sort of activities you might do








Walking (include to and
from work,to shops etc)
Y'oga







Cycling (include to and
























21. In a typical week during the last year, on how many occasions would
you take part FOR MORE THAN 20 MINUTES EACH TIME:
Insert'None'if appropriate
in LIGHT physical activity? in summer times
in winter times
in MODERATE physical activity? in summer times
in winter times
in STRENUOUS physical activity? in summer times
in winter times
22. In a typical week, when you were 35-45 years old, on how many
occasions would you take part, FOR MORE THAN 20 MINUTES EACH TIME:
Insert 'None' if appropriate
in LIGHT physical activity? in summer times
in winter times
in MODERATE physical activity? in summer times
in winter times
in STRENUOUS physical activity? in summer times
in winter times
Which of the following best describes your daily work or other daytime
activity at the present time?
Please tick one box only.
I am usually sitting during the i 1 eg. office workers,
day and do not walk about much | | drivers
I stand or walk about quite a
lot during the day, but do not
have to carry or lift things
very often
I usually lift or carry light
.loads and have to climb stairs
and/or hills often








Which of the following best described your daily work or other daytime
activity WHEN YOU WERE 35-45 YEARS OLD?
I usually sat during the | I eg. office workers,
day and did not walk about much | | drivers
I stood or walked about quite a
lot during the day, but did not
have to carry or lift things
very often
I usually lifted or carried light





I did heavy work and carried heavy
loads □ eg. building, mining hea\yworkers, agricultural
workers
LIFE STYLE AND ATTITUDES
25. Each of us belongs somewhere along the line between two extremes. For
example, most of us are neither the most competitive nor the least
competitive person we know. What we would like you to do is to make a
vertical line where you think you belong between these two extremes.
For example:
Always tidy I Never tidy
(a) Never late
(b) Not competitive
(c) Anticipate what ethers




(e) Can wait patiently
(f) Go "all out"
(g) Take things one at a
time
(h) Emphatic in speech
(may pound desk or chair)
(i) Have wanted good job
recognised by others
















Try to do many things
at once, think about












26. The next section contains descriptions of how you may have felt,
thought, or acted during most of your life. Below each statement there
are four words or phrases; choose the one which best describes you for
most of your life and draw a circle round it.
EXAMPLE
(а) I have enjoyed being with other people.
Nearly always ^OfterT) Seldom Never
The first example would mean that most of your life you have often
enjoyed being with other people.
(1) I would have liked to get my own back on someone.
Very often Often Seldom Never
(2) I have been content to act in a very hianble way.
Never Seldom Often Nearly always
(3) I have thought that people will tell the truth, even if it gets them
into trouble.
Nearly always Often Seldom Never
(4) I have felt as capable as other people.
Never Seldom Often Nearly always
(5) When I've wanted to have a row with someone, I have done so.
Nearly always Often Seldom Never
(б) I have preferred to take a lot of advice before doing anything.
Never Seldom Often Nearly always
(7) I have felt like telling people to go to blazes.
Nearly always Often Seldom Never
(8) When in a group I have been content to be led.
Never Seldom Often Nearly always
(9) When someone has been particularly helpful, I've wondered what real
reason lay behind it.
Nearly always Often Seldom Never
(10) I have had confidence in myself.
Never Seldom Often Nearly always
(11) When I've disliked someone, I have shown it.
Nearly always Often Seldom Never
(12) I have wanted plenty of support from people.
Never Seldom Often Nearly always
(13) I have felt the urge to smash things.
Very often Often Seldom Never
(14) I have been content to be dominated by someone else.
Never Seldom Often Nearly always
(15) I have believed that people are pretty reliable.
Nearly always Often Seldom Never
(16) I have been very unsure of myself.
Never Seldom Often Nearly always
(17) When I've been angry with someone, I've bottled it up.
Nearly always Often Seldom Never
(18) I have liked to be told what needs doing.
Never Seldom Often Nearly always
(19) I have wanted to give someone a piece of my mind.
Very often Often Seldom Never
(20) I have preferred to let people have their own way.
Never Seldom Often Nearly always
(21) I have felt that people would tell lies to get ahead.
Nearly always Often Seldom Never
(22) I have given up doing something because I thought too little of ray own
ability.
Never Seldom Often Very Often
(23) Even when crossed, I've let people get away with it.
Nearly always Often Seldom Never
(24) I have been content to lean on other people for emotional support.
Never Seldom Often Nearly always
(25) I would have liked to pick a quarrel with someone.
Very often Often Seldom Never
(26) I have been happy to play second fiddle.
Never Seldom Often Nearly always
(27) I have felt that people are out for what they can get.
Nearly always Often Seldom Never
(28) I have felt that even when difficulties were piling up I would
overcome them.
Never Seldom Often Very often
(29) When I've thought I was justified in losing my temper, I have done so
in no uncertain terms.
Very often Often Seldom Never
(30) I have preferred to find out for myself what's to be done.
Never Seldom Often Nearly always
(31) I have felt like blaming others when things have gone wrong.
Nearly always Often Seldom Never
(32) I have preferred to stay in the background.
Never Seldom Often Nearly always
(33) I have thought one can safely trust people.
Nearly always Often Seldom Never
(34) I have felt pretty useless.
Never Seldom Often Nearly always
(35) When I've felt like blaming someone to their face for something that
has gone wrong, I have done so.
Nearly always Often Seldom Never
(36) I have needed a lot of help from other people.
Never Seldom Often Very often







Thank you for attending the Edinburgh Artery Study examination last year. Following
our telephone conversation today, I am enclosing the details of a further examination
which we are currently undertaking to help us find out more about the causes of arterial
disease.
If you are willing to attend our research clinic this year, you would need to fast for
twelve hours prior to your appointment. We would then take a blood sample and give
you a drink of 'Lucozade', followed by a further blood sample after one hour.
Refreshments will be provided at the end of the examination.
I have arranged an appointment for you on [Day] [Date] at 9.15 am in
the 'Edinburgh Vein Study' rooms, Medical School Quadrangle,
Teviot Place (A map is enclosed).
I would be grateful if you could return the enclosed form, confirming whether or not
you are able to attend on this date. If you have any queries about the study, please
telephone me at the number above,
With many thanks for your continued cooperation,
Dr Jackie Price
Clinical Research Fellow
Please note: It is important that you have nothing to eat or drink (except for
water) for the twelve hours preceding your appointment, ie. after 9 pm on [Date].
Appendix II. Reply slip (women)
PLEASE COMPLETE THE FOLLOWING
SECTION A
YES NO
Do you presently take Hormone Replacement Therapy 0 LJ
IfNO, continue to section B
IfYES, it is not possible for you to be included in the present study. Please simply
return this form and ignore both the appointment and section B of this form.
(You will of course continue to be included in the Edinburgh Artery Study as
before)
SECTION B
(tick only one box here)
1) I will be attending the clinic on
[Day] [Date] at 9.15am 0
OR 2) I am unable to attend on [Date]
Please send me another appointment D
OR 3) I am NOT willing to attend for the
blood tests described above
NAME
□
THANK YOU FOR COMPLETING THIS FORM
PLEASE RETURN IT IN THE PRE-PAID ENVELOPE
Appendix II. Reply slip (men)
PLEASE COMPLETE THE FOLLOWING
(tick only one box)
1) I will be attending the clinic on
[Day] [Date] at 9.15am 0
OR 2) I am unable to attend on [Date]
Please send me another appointment 0
OR 3) I am NOT willing to attend for the
blood tests described above 0
NAME
THANK YOU FOR COMPLETING THIS FORM
PLEASE RETURN IT IN THE PRE-PAID ENVELOPE
Appendix III. Data collection form
CASE CONTROL STUDY
Data collection form
Subject Name Date Subject No.
Has subject fasted?
Is subject on HRT?
Is subject diabetic
Consent form signed?
Time ofBlood Sample 1
Time ofOGTT
Time ofBlood Sample 2
YES/NO (IfNO, new appointment date )
YES/NO
YES/NO (IfYES, treatment )
YES/NO
Waist circumference cm Hip Circumference cm









Appendix IV. Consent form
Subject No
CONSENT FORM
AETIOLOGY OF PERIPHERAL ARTERIAL DISEASE:
A CASE CONTROL STUDY
Purpose of the Study
The purpose of this study is to obtain further information on constituents of the blood
which may predispose people to developing narrowing of the arteries in the legs. It is
also intended to look at how these factors differ between men and women. The ultimate
aim is to improve disease prevention and treatment.
Research Examination
A blood sample will be taken and you will be given a sweet drink. A further blood test
will be taken after one hour. Your waist and hip circumferences will also be measured.
Consent Agreement
I understand the purpose of this research which has been fully explained to me by a
member of the research team. The study has been given ethical approval by the
Medicine/Clinical Oncology Research ethics Sub-Comittee of the Lothian Health
Board.
I give my consent to the research team carrying out the medical investigations on me as









Recorder: 1J.P. 2E.K. 3 F.S.
1. Has patient had hepatitis or jaundice suspicious ofhepatitis? YES/NO
2. Has patient had childhood jaundice? YES/NO
3. Is patient known HIV positive? YES/NO
4. Was venepuncture normal? YES/NO
5. Was venepuncture difficult/slow? YES/NO
6. Was venepuncture not possible? YES/NO
7. How much blood was obtained?
First blood test ml
Second blood test ml
8. Other comments
Published papers
1. MacGregor AS, Price JF, Hau CM, Lee AJ, Carson MN, Fowkes FGR. The role
of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial
disease: The Edinburgh Artery Study. Diabetes Care 1999;22:453-8.
Reprinted with permission from American Diabetes Association, Copyright
(1999).
2. Price JF, Lee AJ, Fowkes FGR. Hyperinsulinaemia: a risk factor for peripheral
arterial disease in the non-diabetic general population. J Cardiovasc Risk
1996;3:501-5.
Reprinted with permission from Rapid Science Publishers, Copyright (1996).
3. Price JF, Lee AJ, Fowkes FGR. Steroid sex hormones and peripheral arterial
disease in the Edinburgh Artery Study. Steroids 1997;62:789-94.
Reprintedwith permission from Elsevier Science, Copyright (1997).
Role of Systolic Blood Pressure and
Plasma Trialycerides in Diabetic
PeripherafArterial Disease
The Edinburgh Artery Study
Andrew S. MacGregor, mb, chb Amanda J. Lee, phd
Jacqueline F. Price, mb, chb Maggie N. Carson, msc
Cathryn M. Hau, msc F. Gerald R. Fowkes, phd
OBJECTIVE— To determine the risk factors for peripheral arterial disease (PAD) in a diabetic
population and to examine whether different levels of these risk factors might explain why dia¬
betic subjects have an increased risk of PAD compared with normal glucose tolerance subjects.
RESEARCH DESIGN AND METHODS— There were 1,592 men and women aged
55-74 years selected at random from the age-sex registers of 11 general practices in Edinburgh,
Scotland. Subjects underwent a comprehensive medical examination, including assessment for
PAD (intermittent claudication on World Health Organization questionnaire or major asymp¬
tomatic disease on noninvasive testing) and a glucose tolerance test.
RESULTS— Of the subjects, 288 (18.7%) were found to have diabetes or impaired glucose
tolerance (1GT). The prevalence of PAD was greater in those with diabetes/lGT (20.6%) com¬
pared with those with normal glucose tolerance (12.5%) (odds ratio [OR] 1.64, 95% CI
1.17-2.31). Among the diabetes/IGT group, mean levels of smoking, systolic blood pressure,
and triglycerides were higher in subjects with PAD than in those without PAD (P £ 0.05). Mean
levels of systolic blood pressure and plasma triglycerides were also higher in diabetic subjects
than in nondiabetic subjects with PAD (P £ 0.05). In multivariate analysis, those with dia¬
betes/IGT no longer had a significantly higher risk of PAD after adjusting separately for sys¬
tolic blood pressure (OR 1.22, 95% CI 0.85—1.73) and plasma triglycerides (OR 1.26, 95% CI
0.89-1.79). Simultaneous adjustment for both systolic blood pressure and triglycerides
reduced the risk of PAD among diabetic subjects to 1.11 (95% CI 0.78-1 58).
CONCLUSIONS— Increased mean levels of triglycerides and systolic blood pressure may
help to explain the higher prevalence of PAD in diabetic subjects compared with that in nor¬
mal glucose tolerance subjects.
Diabetes Care 22:453-458, 1999
The prevalence of cardiovascular dis¬ease has been shown to be higher inthe diabetic (both type 1 nd 2) pop
ulation than in the nondiabetic population
(1-3). Most research, however, has focused
on coronary heart disease in diabetic sub¬
jects (4-7), and there are relatively few
general population studies that have exam¬
ined the prevalence of atherosclerotic
peripheral arterial disease (PAD) according
to diabetic status. Studies looking at inter¬
mittent claudication and a range of surro¬
gate measures of PAD, including lower-limb
amputations, pulse deficits, and medial cal¬
cification, have led to the general accep¬
tance that PAD is more common in diabetic
than in nondiabetic subjects (8-15).
The cause of this higher prevalence of
PAD in diabetic subjects is unknown, but at
least some of the effect may be related to dif¬
fering levels of intermediate cardiovascular
risk factors. For example, diabetic subjecLs
have been found to have higher levels of
hypertension (5,16-18), cigarette smoking
(11,19,20), tnglycendes (5,11,20,21), cho¬
lesterol (11,20,22), and other blood lipids
(5,11,23) compared with nondiabetic sub¬
jects. Epidemiological studies have impli¬
cated many of these factors in the
development of PAD in diabetes, but such
studies have often relied on clinic-based
samples of diabetic subjects and/or ques¬
tionable measures of PAD (such as lower-
limb amputations or pulse deficits).
Information on the relationship between
putative risk factors and PAD in diabetic
subjects from the general population is.
therefore, scarce (8).
In the present report, we examined
data from the Edinburgh Artery Study, a
prospective survey of 1,592 men and
women selected from the general popula¬
tion. The aims of the study were to deter¬
mine the nsk factors for PAD in a diabetic
population and to investigate whether
raised levels of such nsk factors in diabetic
subjects might help to explain their




The Edinburgh Artery Study began in 1988
as a cross-sectional survey of 809 men and
783 women aged 55-74 years. This popu¬
lation was selected at random, in 5-vear age
bands, from 11 general practices serving a
range of socioeconomic and geographic
areas throughout the city. The response rate
was 65% (resulting in the final study pop-
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Risk factors for PAD in diabetes
ulation of 1,592), and follow-up of a sam¬
ple of nonresponders showed no substan¬
tial bias. Subjects attended a university
clinic to complete a questionnaire and have
a comprehensive medical examination.
Details of the study recruitment and exam¬
ination process have been described (24).
Ethics committee approval was given for
this study, and informed consent was
obtained from each subject.
Study measurements. Each subject com¬
pleted a questionnaire that included the
World Health Organization (WHO) inter¬
mittent claudication questionnaire (25) and
a detailed section on smoking habit. After a
10-min rest in the supine position, systolic
and diastolic (phase V) blood pressures
were taken in the right arm using a Hawk-
sley random zero sphygmomanometer. A
single reading was taken unless the
researcher expenenced difficulty, in which
case the reading was repeated until he or
she felt confident with the reading. Ankle
systolic blood pressures were taken in both
legs using the random zero sphygmo¬
manometer and a Sonicaid Doppler probe.
Blood flow was detected where possible in
the posterior tibial artery. The ankle-
brachial pressure index (ABPI) was calcu¬
lated as ankle divided by brachial systolic
pressure, and the lesser ABPI from the two
legs was used, since disease often occurs
unilaterally. In the reactive hyperemia test
that followed, ankle systolic pressure was
measured 15 s after the release of a cuff
occluding arterial flow just above the knee
for 4 mm at ~50 mmHg above systolic
pressure. The timing was standardized
using an electronic timer. This test was con¬
ducted to detect those subjects with penph-
eral anenal disease in whom the presence of
medial arterial calcification (as may occur in
diabetes) may have rendered measurement
of the ABPI an unreliable marker pf disease.
Measunng the blood pressure 15-30 s after
the cuff has been released has been shown
to be the optimum time to distinguish
between subjects with angiogram-positive
disease and control subjects; in this situa¬
tion, the test is >95% sensitive in detecting
disease (26,27).
During the clinical examination, 20 ml
of fasting blood was taken, after which sub¬
jects consumed 75 g glucose in the form of
335 ml of Solripe Gluctoza Health Drink
(Strathmore Mineral Water, Forfar, Scot¬
land, U.K.). A second blood specimen was
taken 2 h after the oral glucose load. Stand¬
ing height (without shoes) was measured to
the nearest 5 mm using a free standing
metal ruler on a heavy base. Weight with¬
out shoes and outer clothing was measured
to the nearest 100 g on digital scales
(Soehnle, Murrhardt, Germany). BMI as a
measure of obesity was calculated as weight
(in kilograms) divided by height (in
meters) squared. In the laboratory, tests for
serum total cholesterol, HDL cholesterol,
triglycerides, thiocyanate, and plasma glu¬
cose were performed on a Cobas Bio ana¬
lyzer (Roche, Welwyn Carden City, U.K.)
using standard kits. LDL cholesterol was
calculated using the formula: LDL choles¬
terol = total cholesterol — HDL cholesterol
— tnglycerides/5 (28). Quality control was
measured by means of blind duplicate sam¬
ples taken intermittently throughout the
study.
Classification of PAD
For the purposes of this study, subjects
were classified into two groups: 1) the dis¬
ease group, members of which had symp¬
tomatic PAD (determined by positive
WHO intermittent claudication question¬
naire) or major asymptomatic disease
(ABPI ^0.9 and drop in ankle systolic
blood pressure dunng reactive hyperemia
test of >20% or ABPI ^0.7 or hyperemic
drop of >35%), and 2) the normal group,
whose members met none of the above
conditions and had ABPI >0.9 and hyper¬
emic pressure reduction of <20%. This
categonzation has not been used in other
studies, but results comparing the ABPI
and reactive hyperemia test separately with
angiography would suggest that it had ade¬
quate face validity; an ABPI of <0.9 has
been shown to be up to 95% sensitive in
detecting angiogram-positive disease (26).
Also, we carried out duplex scanning on a
subsample of cases confirming the presence
of significant atherosclerotic disease. In the
present study, 10% of subjects were classi¬
fied as having PAD on the basis of an
abnormal reactive hyperemia test alone (the
remainder had intermittent claudication
and/or an ABPI <0.9).
Diagnosis of diabetes/impaired
glucose tolerance
Results of the oral glucose tolerance test
were categorized according to WHO crite¬
ria (29). Subjects were classified as suffering
from diabetes if 1) they had been told by a
doctor that they suffered from diabetes and
were receiving treatment (insulin or oral
therapy), 2) the glucose concentration in the
2-h blood sample was 2:11.1 mmol/1, or 3)
because of a doctor diagnosis of diabetes,
they did not undergo the oral glucose tolet
ance test (these subjects were classified a
diabetic irrespective of whether or not the
were on insulin or oral therapy). Impairet
glucose tolerance (IGT) was diagnosed if th
glucose concentration was between 7.8 anc
11.1 mmol/1 in the 2-h blood sample.
Data analysis
Data were analyzed on the Edinburgh Uni
versity UNIX system using the SAS soft
ware package (version 6.11). Distribution:
of the fasted and 2-h glucose samples anc
triglycerides were positively skewed, thu
logarithmic transformations were used n
all analyses. The smoking history was sut
ficiently valid because reported consump
tion correlated well with mean thiocyanau
level. Smoking status, defined as current
ex-, or never smokers, was used as a cate
gorical variable. Tests for differences in the
age-adjusted mean levels of the risk factor:
between those with and without PAD wen
conducted using t tests for both the dia
betic/IGT group and the normal glucose
tolerance group. Logistic regression using
the statistical package Proc GENMOD (30'
was used to calculate the odds ratio (OR
for having PAD in a person who had dm
betes/IGT compared with the nsk of PAD
for a person in the normal glucose toler¬
ance group. Age and sex adjustments wen-
made, and then each of the other potential
related factors was individually included ir
a multivanate model.
RESULTS— There were 288 subjects
(18.7%) who had diabetes (n = 91) or IGT
(n = 197), compared with 1,253 subjects
with normal glucose tolerance (51 subjects
could not be classified because of missing
data). Of the subjects with diabetes, 9T
were insulin treated, 20% were on ora.
treatments, and 19% did not admit to tak
ing any treatment other than diet modifi¬
cation; the remainder were previous!}
undiagnosed diabetic patients who wen
detected using the oral glucose tolerance
test. Figure 1 shows that PAD was more
common in those with diabetes (22.4%, f
< 0.05) and IGT (19.9%, P < 0.05), com
pared with those with normal glucose tol¬
erance (12.5%). The prevalence of PAD
was not significantly different (P = 0.7) ir.
the diabetes and IGT groups, and these
groups were combined to increase the
power of the study. The OR for PAD among
the diabetes/IGT group compared with tin
normal glucose tolerance group was l o-
(95% CI 1.17-2.31, P< 0.01).












Figure 1—Prevalence oj PAD, categorized according to major asymptomatic disease (■) and inter¬
mittent claudication (■) in subjects with diabetes, ICT, and normal glucose tolerance (NGT). Differ¬
ence in prevalence from NGT group: *P ^ 0.05, tP :£ 0.01.
The mean levels of risk factors in sub¬
jects with diabetes/lGT with and without
PAD are summarized in Table 1. Subjects
with PAD were older than those without
PAD (P < 0.001), so all risk factor levels
were adjusted for age. Diabetic/IGT sub¬
jects with PAD had significantly higher
mean levels of systolic blood pressure (P S
0.01) and plasma triglycendes (P S 0.01)
compared with those without PAD. In
addition, 74.1% of the diabetic group with
PAD were current or ex-smokers, com¬
pared with only 48.1% of the diabetic sub¬
jects without PAD (P ^ 0.05). The mean
levels of total and LDL cholesterol tended
to be higher, and HDL cholesterol levels
lower, in those with PAD compared with
those without PAD, but these differences
were not statistically significant (P > 0.05).
Table 2 shows that in subjects with
normal glucose tolerance, those with PAD
had significantly higher mean levels of sys¬
tolic blood pressure, tnglycendes, and total
and LDL cholesterol (P £ 0.001), and
significantly lower levels of HDL choles¬
terol (P < 0.05), compared with those
without PAD. Some 83.5% of the normal
glucose tolerance group who had PAD were
current or ex-smokers, compared with
hi.6% of the normal glucose tolerance sub¬
jects without PAD (Pj£ 0.01). There were
no statistically significant differences in sex,
BMI, or diastolic blood pressure.
Risk factor levels among the dia¬
betes/IGT group with PAD and the normal
glucose tolerance subjects with PAD were
then compared (Tables 1 and 2, column 1).
Patients in the diabetes/lGT group with
PAD were older (P ^ 0.05), with higher
mean levels of systolic blood pressure (P ^
0.01) and plasma triglycerides (P S 0.05),
than those with normal glucose tolerance
and PAD. Differences in mean levels of the
other risk factors between the two groups
did not reach statistical significance,
although the diabetes/lGT subjects with
PAD had a more adverse risk factor profile
in general than the normal glucose toler¬
ance subjects with PAD.
The unadjusted OR for diabetes/lGT as
a risk factor for PAD was 1.64 (95% CI
1.17-2.31, P < 0.01). Table 3 shows the
ORs for diabetes/IGT as a risk factor for PAD
compared with normal glucose tolerance,
after adjusting for each of the common nsk
factors in turn. After adjusting for age and
sex, diabetic subjects still had a higher nsk
of PAD (OR 1.45, 95% CI 1.03-2.04, P <
0.05). In multivanate analysis, those with
diabetes/IGT no longer had a significantly
higher risk of PAD after adjusting separately
for systolic blood pressure (OR 1.22, 95%
CI 0.85-1.73) and plasma triglycendes (OR
1.26, 95% CI 0.89-1.79). However, it
should be noted that every nsk factor, with
the exception of smoking status, individu¬
ally reduced the odds of diabetes as a nsk
factor for PAD. For example, after adjusting
for age, sex, and HDL cholesterol, diabetic
subjects still had higher levels of PAD, but it
was of borderline significance (OR 1.37.
95% CI 0.97-1.94, P = 0.08). Simultaneous
adjustment for both systolic blood pressure
and triglycendes reduced the risk of PAD
among diabetic patients to 1.11 (95% CI
0.78-1.58, P> 0.05).
CONCLUSIONS— In this popula¬
tion-based study, we have confirmed that
the prevalence of PAD in subjects with dia¬
betes or IGT is considerably greater than
that in those with normal glucose tolerance.
Table 1—Age-adjusted levels of risk factors in subjects with diabetes/IGT with and without
PAD
Diabetes/IGT
Risk factor PAD No PAD P value
n 45 173
Age tyears) 68.8 ± 0.8 65.1 ± 0.4 <0.00 i
Sex (% M) 43.1 58.4 Ns
Smoking status (% current or former) 74.1 48.1 <0.05
Systolic blood pressure (mmHg) 161.8 ± 3.7 150.4 ± 1.8 <0.01
Diastolic blood pressure (mmHg) 80.5 ± 1.9 78.9 ±0.9 Ns
BMI (kg/m2) 27.0 ± 0.7 26.8 ± 0.3 NS
Total cholesterol (mmol/1) 7.35 ± 0.22 6.99 ±0.11 Ns
LDL cholesterol (mmol/1) 5.61 ± 0.20 5.25 ± 0.10 Ns
HDL cholesterol (mmol/1) 1.29 ± 0.06 1.38 ± 0.03 Ns
Triglyceride (In mmol/1) 0.69 ± 0.08 0.46 ±0.04 <0.01
Data are means ± SEM.
-Diabetes Care, volume 22, number 3, March 1999 455
Table 2—Age-adjusted levels of risk factors in normal glucose tolerant subjects with and
without PAD
Normal glucose tolerance
Risk factor PAD No PAD P value
n 126 878
Age (years) 66.9 ± 0.5* 63.9 ±0.2 <0.001
Sex (% M) 50.4 52.7 NS
Smoking status (% current or former) 83.5 61.6 <0.01
Systolic blood pressure (mmHg) 147.8 ± 1.9t 138.7 ± 0.7 <0.001
Diastolic blood pressure (mmHg) 77.5 ± 1.1 76.1 ±0.4 NS
BMI (kg/m2) 25.2 ±0.3 25.0 ±0.1 NS
Total cholesterol (mmol/1) 7.32 ± 0.12 6.89 ± 0.04 <0.001
LDL cholesterol (mmol/1) 5.62 ±0.11 5.14 ±0.04 <0.001
HDL cholesterol (mmol/1) 1.38 ±0.04 1.47 ±0.01 <0.05
Triglyceride (In mmol/1) 0.46 ± 0.04* 0.27 ±0.02 <0.001
Data are means ± SEM. Mean levels higher in diabetic/PAD than normal glucose tolerance/PAD group:
*P < 0.05, TP < 0.01.
In our sample of Scottish men and women
aged 55-74 years, 20.6% of those with
diabetes/IGT had PAD, compared with
12.5% of those with normal glucose toler¬
ance, supporting the commonly held view
that diabetic patients are at increased risk of
developing PAD (8). The present study
included those with intermittent claudica¬
tion and major asymptomatic PAD diag¬
nosed using the WHO questionnaire, the
ABP1, and the reactive hyperemia test.
Because the WHO questionnaire has lim¬
ited sensitivity (30) and use of the ABPI as
a single measure of PAD can also be criti¬
cized (22,31), it is a major strength of this
study that three measures of PAD were
used. In addition, research has shown that
subjects with asymptomatic PAD have an
increased nsk of cardiovascular complica¬
tions, as well as claudicants (24,27), and
asymptomatic PAD is more common in
diabetic subjects (22,31).
The prevalence of PAD in diabetic sub¬
jects in previous studies vanes widely as a
result of different definitions of PAD and
glucose tolerance, as well as different char-
actensttcs of populations surveyed (includ¬
ing age and race). In general, the prevalence
of PAD among diabetic (22.4%) and 1GT
(19.9%) subjects reported in this study is
higher than has been reported previously
(11,15,18,22,32,33), probably because of
the inclusion of subjects with major asymp¬
tomatic PAD. For example, Uusitupa et al.
(11), using the WHO questionnaire,
reported prevalences of intermittent clau¬
dication among newly diagnosed type 2
diabetic patents (45-64 years of age) of
9% in men and 3% in women. In a recent
population-based study in England, the
prevalence of PAD, defined by history,
peripheral pulse deficits, and an ABPI of
<0.9, was 8.7% in insulin-dependent sub¬
jects (mean age 39.3 years) and 23.5% in
subjects with type 2 diabetes (mean age
67.7 years) (22). The authors concluded
that peripheral vascular disease was signifi¬
cantly more common in the diabetic than
in the nondiabetic subjects only when
asymptomatic cases of PAD were added to
both groups. The prevalence of PAD in the
present study was almost identical to that
found in a population-based study of 50- to
75-year-old Dutch Caucasians, which
examined crural artery obstructions in dia¬
betic and nondiabetic subjects using
Doppler waveform analysis in addition to
the ABPI (31).
Our findings of a worse cardiovascular
risk factor profile in normal glucose toler¬
ance subjects with PAD compared with
those without PAD are consistent with pre¬
vious studies (34). This included higher
levels of cigarette smoking, systolic blood
, pressure, triglycerides, total and LDL cho¬
lesterol, and lower levels of HDL choles¬
terol. We also found that among the
diabetes/IGT group a similarly adverse risk
factor profile was present in those with
PAD compared with those without PAD
This suggests that the same nsk factors that
are important in the development of PAD
in normal glucose tolerance subjects are
also important in diabetic subjects. How¬
ever, in diabetic subjects, differences in sev¬
eral of the risk factors studied did not reach
statistical significance, possibly because of
the relatively small numbers of subjects
affected.
The greatest difference in risk factor
levels between diabetic subjects with and
without PAD was found for systolic blood
pressure, tnglycendes, and cigarette smok¬
ing, suggesting that these risk factors may
be particularly important in the develop¬
ment of PAD in diabetic populations.
Hypertension and hypertriglyceridemia
have previously been found to be nsk fac¬
tors in the development of PAD in diabetic
subjects (5,11,16-18,21). Two studies
found a relationship between hyperten¬
sion and a low ABPI in diabetic subjects
(16,17), while in the University Group
Diabetes program, baseline serum triglyc¬
eride was significantly related to nsk of
intermittent claudication in men only (21).
In Finland, a study using the WHO ques¬
tionnaire as a single measure of PAD (11)
found a relationship between triglycerides
and PAD on univariate analysis. An associ¬
ation between both hypertension and
hypertriglyceridemia and risk of tntermit-
Table 3—-Odds of PAD according to diabetic status (diabetes/IGT vs. normal glucose
tolerance) before and after adjustment for each risk factor
Risk factors adjusted for OR 95% CI P value
Age and sex 1 45 1.03-2.04 <0.05
Smoking status 1.65 1.16-2.34 <0.01
Systolic blood pressure (mmHg) 1.22 0.85-1.73 0.3
Diastolic blood pressure (mmHg) 1.42 1.01-2.01 <0 05
BMI (kg/m2) 1.42 1.00-2.01 <0 05
Total cholesterol (mmol/1) 1.42 1.01-2.01 <0.0 5
LDL cholesterol (mmol/1) 1.43 1.01-2 32 <0.05
HDL cholesterol (mmol/1) 1.37 0.97-1.94 0 os
Triglyceride (In mmol/1) 126 0.89-1.79 0.2
Systolic blood pressure and triglyceride* 1 11 0.78-1.58 0 P
Smoking status (current, ex, never) was used as a categorical variable "This nsk factor involves simuli.'
neous ad|ustment for systolic blood pressure and triglycerides (log).
456 Diabetes Care, volume 22, number 3, March I4uq
tent claudication was reported by the
Framingham Study, which used its own
questionnaire to ascertain claudication (5).
In contrast, some other studies have failed
to show a statistically significant relation¬
ship between mean levels of triglycerides
and/or blood pressure and PAD in diabetic
populations (19,21,22,33). The relation¬
ship between cigarette smoking and PAD
in diabetic subjects has also been shown
previously A population-based study
found an independent association between
smoking and PAD upon multivariate
analysis when both diabetic and nondia-
betic subjects were pooled together (11).
In a clinic-based study, logistic regression
revealed a relationship between PAD and
smoking in a sample of type 2 diabetic
subjects (19).
Other studies have shown associations
between cholesterol (total, HDL, and LDL)
(5,11,22,23) and obesity (5,21) and mani¬
festations of PAD among diabetic subjects.
In our study, differences in total, LDL, and
HDL cholesterol in diabetic/IGT subjects
with PAD compared with those without
PAD did not reach statistical significance,
again possibly because of relatively small
subject numbers.
Mean levels of several of the identified
PAD risk factors were, in general, present at
a more detrimental level in diabetic subjects
than in nondiabetic subjects. For example,
in subjects with PAD, systolic blood pres¬
sure and plasma triglycerides were both
significantly higher in the diabetic subjects.
These nsk factors have previously been
implicated in the development of PAD in
diabetic subjects (5,11,16-18,21). A larger
percentage of the nondiabetic PAD group,
however, were current or ex-smokers
(84.8%) compared with the diabetic PAD
group (74.5%). The Framingham Study also
found increased levels of cigarette smoking
in male nondiabetic subjects compared with
those in the male diabetic group, although
women with diabetes tended to smoke
more than women without diabetes (5).
It is possible that some of these differ¬
ences in intermediary nsk factors may con¬
tribute to the increased prevalence of PAD
found in diabetic populations. To investi¬
gate this further, we calculated the risk of
diabetes and then adjusted this for the
other nsk factors.
Adjustment for each nsk factor exam¬
ined in the present study reduced the
impact of diabetic status on the likelihood
of having PAD apart from cigarette smoking.
This was due to the high percentage of
never smokers in the diabetic subjects with
PAD (25.9%) compared with the nondia¬
betic subjects with PAD (16.5%). Diabetic
status was no longer a significant risk factor
for PAD when adjustment was made for sys¬
tolic blood pressure and triglycendes, sug¬
gesting that these two factors might be
particularly important in helping to explain
the increased prevalence of PAD in subjects
with diabetes/IGT. The Framingham Study
examined the influence of diabetes on man¬
ifestations of cardiovascular disease and did
show a substantial reduction in the relative
risk of PAD after adjusting for risk factors
including cholesterol, smoking, and sys¬
tolic blood pressure on multivariate analy¬
sis, compared with the age-adjusted figures.
However, in this latter study the influence of
diabetes on PAD remained significant after
multivanate adjustment (5).
In conclusion, the results from this
population-based study confirm that sub¬
jects with diabetes and IGT have a higher
prevalence of PAD than those with normal
glucose tolerance. Higher mean levels of
tnglycerides and systolic blood pressure in
diabetic subjects may help to explain this
higher prevalence. If the association
between raised triglycerides and systolic
blood pressure and the development of
penpheral arterial disease in diabetic
patients is found to be causal in future
prospective studies, better control of these
risk factors in diabetic patients should lead
to a reduced incidence of PAD. Alterna¬
tively, it may be that some underlying phe¬
nomenon, such as insulin resistance
syndrome (35), is responsible for both the
elevation in systolic blood pressure and
tnglycendes and the higher prevalence of
peripheral vascular disease. Indeed, we
have shown previously that hyperinsuline-
mia is a nsk factor for PAD, independent of
blood pressure and serum lipids (36). Fur¬
ther longitudinal studies, including meas¬
urement of blood pressure, triglycendes,
and insulin resistance, will be required to
resolve these questions.
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Hyperinsulinaemia: a risk factor for peripheral arterial disease in
the non-diabetic general population
Jacqueline F. Price, Amanda J. Lee and F. Gerald R. Fowkes
Background Peripheral arterial disease is a common
complication of diabetes mellitus, and hyperinsulinaemia has
been associated with an increased incidence of intermittent
claudication in diabetic subjects. Our aim was to investigate the
relationship between hyperinsulinaemia and peripheral arterial
disease in the non-diabetic general population.
Methods Eighty-three cases with peripheral arterial disease
and 88 age- and sex-matched controls were selected from
non-diabetic participants in the Edinburgh Artery Study, a
survey of 1 592 men and women aged 55-74 years randomly
selected from the general population.
Results Mean plasma insulin, 1 h after a 75 g oral glucose
load, was higher in cases than in controls (73.6 versus 59.8
mU/l; P< 0.05). The relationship between insulin and disease
was independent of blood pressure [odds ratio (OR) 2.04; 95%
CI 1.1 1-3.74; P<0.05] and partially independent of low- and
high-density lipoprotein cholesterol and triglycerides (OR 1.86;
95% CI 0.99-3.48; P< 0.1). Mean 1 h insulin was higher in
current or ex-smokers than in those who had never smoked
(P< 0.05) and when smoking was added to the multivariate
model, the relationship between insulin and disease diminished
(OR 1.64: 95% CI 0.83-3.23; P> 0.1).
Conclusions In the non-diabetic general population, peripheral
arterial disease is associated with post-glucose
hyperinsulinaemia, independently of blood pressure, lipoproteins
and triglycerides. Some of this association may be mediated by
a relationship between hyperinsulinaemia and smoking.
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Introduction
Atherosclerotic disease of the lower limbs is a frequent and
debilitating complication of diabetes mellitus and inter¬
mittent claudication is three to six times more common in
diabetic than in non-diabetic subjects [1], In its early
stages, non-insulin-dependent diabetes is associated with
insulin resistance and compensatory hvperinsulinacmia,
and individuals with insulin-dependent diabetes are fre¬
quently hyperinsulinaemic because of peripheral adminis¬
tration of high-dose exogenous insulin [2], It has therefore
been postulated that hyperinsulinaemia is involved in the
aetiology of peripheral arterial disease.
Although hyperinsulinaemia has been associated with an
increased risk of ischaemic heart disease in four prospec¬
tive studies [3-6], the role of insulin in other forms of
atherosclerotic disease has been less well investigated. In
particular, the association between insulin and the devel¬
opment of peripheral arterial disease in the non-diabetic
general population is unknown. Two small studies indicated
that non-diabetic men with atherosclerotic disease of the
lower limbs had higher plasma insulin levels than healthy
controls [7,8], but the studies did not consider the influ¬
ence of other cardiovascular risk factors. In this respect,
hyperinsulinaemia is know n to be associated with hyper-
triglvceridaemia. low levels of high-density lipoprotein
(HDL) cholesterol, and hypertension [9], Also, smoking
might affect insulin levels [10], However, the degree to
which the association between hypcrinsulinaemia and car¬
diovascular disease is dependent on these other risk factors
is unclear.
Our aim was to determine whether hyperinsulinaemia was
associated with an increased risk of peripheral arterial dis¬
ease in non-diabetic men and women, selected at random
from the general population, and the extent to which this




All the subjects in this nested case-control study were
selected from the Edinburgh Artery Study, a prospective
survey of 809 men and 783 women aged 55-74 years,
selected at random from the general population. Details of
the study recruitment, baseline examination and follow -up
procedure have been described [11,12]. Studv participants
have now been followed-up for 5 years for cardiovascular
events using annual validated questionnaires on cardiovas¬
cular history, intermittent claudication and angina [13], and
information from general practitioners, hospitals, and the
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Information Services Division (ISD) of the Scottish Office
Home and Health Department. All cardiovascular events
were further investigated using hospital or general practi¬
tioner records. At the 5-year follow-up examination, sub¬
jects completed a self-administered questionnaire which
included validated questions on smoking, cardiovascular
events and the World Health Organisation (WHO) angina
and intermittent claudication questionnaires [13]. Right
brachial systolic and diastolic blood pressures were recorded
after 5 min rest using a random zero sphygmomanometer.
Right and left posterior tibial systolic pressures were
recorded in the supine position after 5 min rest, using a
Doppler probe (Sonicaid, Chichester, UK) and random zero
sphygmomanometer. The ankle brachial pressure index
(ABPI) was calculated for each limb by dividing the poste¬
rior tibial by the brachial pressure. A 12-lead ECG was
taken and coded independently by two observers using the
Minnesota code [14],
Cases were selected from participants attending the 5-year
follow-up examination if they had either: (i) a history of
intermittent claudication according to the WHO intermit¬
tent claudication questionnaire, plus an ABPI <0.9 in at
least one limb; or (ii) asymptomatic peripheral arterial dis¬
ease indicated bv an ABPI <0.85 in at least one limb.
Controls were selected from the remaining study population
if they had no WHO history of intermittent claudication
and an ABPI > 1.0 in both legs, no WHO or doctor recall
history of cardiovascular disease (including angina,
myocardial infarction or stroke) and no evidence of
myocardial infarction or ischaemia on ECG. The controls
were matched to the cases by sex and 5-year age band.
Subjects were excluded from both the case and control
groups for any of the following reasons: (i) known diabetes
or newly-diagnosed diabetes according to a fasting plasma
glucose > 7.8 mmnl/l [15], (ii) women using post¬
menopausal hormone-replacement therapy (to comply
with requirements for a parallel study), or (iii) use of drugs
affecting carbohydrate metabolism.
Risk factor measurement
All selected cases and controls underwent a standard 75 g
oral glucose tolerance test, performed in ambulatory con¬
ditions and without dietary preparation after a 12 h
overnight fast and after providing their informed consent.
Venous samples for plasma insulin and blood glucose
determination were taken before the test (fasting) and at
60 min after glucose administration. Samples were cen-
trifuged at —1°C within 15 min of collection and plasma
was immediately frozen and stored at —10°C. Before analy¬
sis. samples were stored at —20°C. Samples for total serum
cholesterol, HDL cholesterol and triglycerides were also
taken in the fasting state.
In the laboratory, plasma insulin concentration was mea¬
sured using a microparticle enzyme immunoassay on an
IMx analvser (Abbott Laboratories Ltd, Maidenhead, I K").
The assav measurement range was 1-300 ml '/I. with a
sensitivity of 1 mU/1. Intra- and inter-assay coefficients of
variation at an insulin concentration of 8.3 mU/1 were 4.0
and 4.5%, respectively. The IMx assay showed no cross-
reactivity with pro-insulin (< 0.005%) and no detectable
cross-reactivity with C-pcptide or glucagon. Plasma glu¬
cose concentration was measured by a timed end-point
enzymatic method employing hexokinase and glucose-6-
phosphate dehydrogenase using a Beckman Synchron
CX5 multichannel analyser (Beckman Instruments Ltd,
High Wycombe, UK). The assay analytical range was
0.3-38.8 mmol/1, sensitivity 0.3 mmol/1 and inter-assav
coefficient of variation 0.8%. Tests for total cholesterol and
triglycerides were performed on a E750C dry chemistry
analyser (Ortho Clinical Diagnostics Ltd, Hemcl
Hempstead, UK). Coefficients of variation were 1.4-2.1%
for total cholesterol and 1.6-1.9% for triglycerides. HDL
cholesterol was measured on a Cobas Mira Plus analyser
(Roche Diagnostics Ltd, Welwyn Garden City, UK)
following chemical precipitation of other cholesterol-
containing lipoproteins (coefficient of variation 3.4—1.6% ).
Low-density-lipoprotcin (LDL) cholesterol was calculated
using the formula: LDL cholesterol = total cholesterol -
HDL cholesterol - triglvcerides/5 [16],
Statistical analysis
Mean levels of risk factors were compared in study cases
and controls, and the significance of differences were
assessed by Student's t-tcst, using the statistical package
SPSS-X (SPSS Inc., Chicago, USA). For triglycerides, fast¬
ing insulin, 1 h insulin, fasting glucose, 1 h glucose and
insulin resistance, the values were log transformed because
of skewed distributions. Geometric means and transformed
confidence intervals were given for these variables.
Cigarette smoking was calculated in pack-vears (years of
smoking multiplied by the average number of packs
smoked per day) with the value zero entered for lifelong
non-smokers. Square root of pack-years was taken to
normalise the skewed distribution. Multiple logistic regres¬
sion was used to investigate the independence of the
relationship between pcist-glucose (1 h) insulin and disease
with respect to age, sex and other cardiovascular risk factors;
it was also used to test the independence of the association
between smoking and disease with respect to 1 h insulin.
Odds ratios were estimated from the logistic regression coef¬
ficients obtained from the statistical package BMDP
(BMDP Statistical Software Inc., Los Angeles, USA).
Geometric means and transformed confidence intervals of
1 h insulin were calculated for nevcr-smokers and ever-
smokers (i.e. current and ex-smokers). Multiple linear
regression analysis was used to determine the relationship
between smoking status (evcr-smoker versus ncver-
smoker) and 1 h insulin. The following independent vari¬
ables had forced entry into the final model: presence (cc = 1)
or absence (cc = 2) of peripheral arterial disease; sex (male = 1
female = 2); age (using approximate mean for study popula¬
tion); smoking (never-smokcrs = 0, over-smokers = 1). '|'|K.
final regression equation, predicted 1 h insulin = antilo"
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(4.59 - 0.18cc - O.lOsex + 0.002age + 0.26smoking), was
used to give die predicted insulin levels for male never-
smokers and ever-smokers separately.
Results
Subject characteristics
Age, sex and disease characteristics of the 83 cases (40 men
and 43 women) and 88 controls (41 men and 47 women)
are shown in Table 1. As expected from the matching, age
and sex were similar in cases and controls. Mean ABPI was
substantially lower in cases (0.7 in the cases, 1.1 in the con¬
trols; P < 0.001), 31% of whom had a history of intermittent
claudication. Some of the cases also had evidence of angina
(24%), previous myocardial infarction (16%) or previous
stroke (4%).
Univariate analysis of risk factors
Table 2 shows the mean risk factor levels in cases and con¬
trols. Cases smoked more than controls and had higher
mean blood pressure and serum triglycerides (P < 0.05).
Cases also had slightly lower HDL cholesterol (P < 0.1).
There was no significant difference in mean fasting insulin
or fasting glucose between cases and controls (P>0.1).
However, mean insulin and glucose, 1 h after the oral glu¬
cose load, were higher in cases than in controls (I h insulin.
73.6 ml.T/l in cases, 59.8 ml '/I in controls: P < 0.05; 1 h glu¬
cose, 8.9 ml;/! in cases. 8.1 mH/l in controls; /J <0.05).
When the total study population was split by sex, 1 h
insulin was significantly higher in men than in women
(men 72.8 ml /I, women 59.4 ml /I; P< 0.05). Male eases
had slightly higher 1 h insulin than male controls (male-
case 81.7 miyi, male control 65.0 ml'/I; /'<(). 1), but the
difference betw een female cases and controls did not quite
reach the 10% significance level (female case 66.6 ml /I,
female control 55.6 ml /I; P = 0.11).
Multivariate analysis of risk factors
The results of multiple logistic regression, used to exam¬
ine the association between 1 h post-glucose insulin con¬
centration and risk of disease, before and after adjustment
for the other cardiovascular risk factors, are shown in Table
3. Higher 1 h insulin levels were associated w ith a signifi¬
cant increase in the risk of peripheral arterial disease [Odds
ratio (OR) of disease for a one log unit increase in 1 h
insulin concentration, adjusted for age and sex was 1.96;
95% CI 1.11-3.44; < 0.05]. The strength of the associa¬
tion between disease and 1 h insulin was not significantly
Table i Age, sex and cardiovascular disease characteristics of
cases of peripheral arterial disease and controls
Cases (n = 83) Controls (n = 88)
Age, mean years (SEM) 71.6 (0.6) 70.9 (0.5)
Males 48 (40) 47 (41)
Intermittent claudication 31 (26) 0
Mean ABPI (SEM) 0.7 (0.02) 1.1 (0.01)
Angina 24 (20) 0
Myocardial infarction 17 (14) 0
Stroke 4 (3) 0
ABPI, ankle-brachial pressure index. P < 0.001 for difference in ABPI between
cases and controls. Values are expressed as percentage (number) unless other¬
wise stated.
Table 2 Mean cardiovascular risk factor levels in cases of
peripheral arterial disease and controls
Risk factor Cases (n = 83) Controls (n = 88) P
Systolic BP (mmHg) 154.8(149.3-160.3)143.6(138.7-148.5) <0.01
Diastolic BP (mrtiHg) 83.6(81.1-86.2) 80.6(78.3-82.9) <0.1
Smoking (/packyears) 3.08(2.38-3.78) 1.81(1.27-2.34) <0.01
LDL cholesterol (mmol/l) 4.58 (4.36-4.80) 4.63 (4.42-4.84) NS
HDL cholesterol (mmol/l) 1.20(1.12-1.27) 1.29(1.22-1.36) <0.1
Triglycerides (mmol/l)* 1.52(1.39-1.67) 1.34(1.23-1.45) <0.05
Fasting insulin (mU/l)* 6.4(5.8-7.1) 6.1(5.5-6.7) NS
1 h insulin (mU/l)* 73.6(65.0-83.3) 59.8(53.2-67.3) <0.05
Fasting glucose (mmol/l)" 5.5 (5.4-5.7) 5.6 (5.5-5.7) NS
1 h glucose (mmol/l)* 8.9(8.4-9.6) 8.1(7.6-8.6) <0.05
"Geometric mean of logged variable and transformed CI. BP, blood pressure;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; NS, not significant.
Values are expressed as means (95% CI).
Table 3 Multivariate logistic regression of 1 h plasma insulin
levels on peripheral arterial disease (all odds ratios adjusted for
age and sex)
Risk factors in model* Odds ratio (95% CI)** P
1.96 (1.1 1-3.44) <0.05
BP 2.04 (1.11-3.74) <0.05
BP, LDL, HDL, Trig 1.86 (0.99-3.48) <0.1
BP, LDL, HDL, Trig, Cigs 1.64 (0.83-3.23) 0.17
*ln addition to age and sex. "Odds ratio for a one unit increase on a log scale in
1 h post-glucose insulin. BP. systolic and diastolic blood pressure; LDL, low-
density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; Trig,
triglycerides; Cigs, cigarette smoking (packyears).
different between men (OR 2.24; 95% OI 1.00-5.06) unci
women (OR 1.82; 95% CI 0.78—4.30; P > 0.1 for difference
between OR). Adjustment for the effects of systolic and
diastolic blood pressure, with the sexes combined, did not
greatly alter the association between disease and 1 h
insulin concentration. Further adjustment for the effects of
plasma LDL cholesterol, HDL cholesterol and triglyc¬
erides slightly weakened the relationship, but the odds
ratio of 1.86 remained significant at the 10% level.
However, when the effect of smoking was added to the
model, the OR fell to 1.64 and was no longer significant.
One-hour glucose and insulin levels were highly correlated
(Spearman's rank correlation coefficient; eases 0.34.
P< 0.05; controls 0.49, P< 0.001). However, addition of 1
h glucose to the multivariate models in Table 3 made very
little difference to the OR for 1 h insulin and disease, with
1 h insulin remaining associated with disease at the 10%
level or less before adjustment for smoking (data not
shown). Conversely, 1 h glucose was not associated with an
increased risk of peripheral arterial disease after adjustment
for age, sex and 1 h insulin (OR 1.60; 95% CI 0.52-4.93;
/J>0.1).
Insulin, smoking and disease
To investigate the possible inter-relationship between
insulin levels and smoking, mean 1 h insulin wa, compared
between ever- and nevcr-smokers in both eases and
controls (big. 1). Mean 1 h insulin was significantly higher
in ever-smokers than in never-smokers in both group-,
(eases P < 0.05: controls P<0A)\). Multivariate linear
regression analysis was performed with smoking as the
independent variable and 1 h insulin as the dependent
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variable. There was a significant association between
smoking (ever- versus never-smoker) and 1 h insulin after
adjustment for age, sex and peripheral arterial disease (B
coefficient 0.26, SE 0.09; P < 0.01). This was equivalent to
a predicted increase of 16.2 mU/l of 1 h insulin for ever-
smokers compared with never-smokers, in men aged 70
years with peripheral arterial disease. The association
between smoking and 1 h insulin did not alter greatly after
additional adjustment for the other cardiovascular risk fac¬
tors, including systolic and diastolic blood pressure, LDL
and HDL cholesterol and triglycerides (B coefficient 0.22,
SE 0.09; P < 0.05).
Despite the association between smoking and insulin, the
relationship between peripheral arterial disease and smok¬
ing (age- and sex-adjusted OR of disease for a 1 Vpack-year
increase in smoking 1.19; 95% CI 1.05-1.35; P<0.01) was
only very slightly weakened after adjustment for 1 h
insulin levels (OR 1.16; 95% CI 1.02-1.32; T<0.()5).
Further adjustment for HDL cholesterol and triglyceride
levels, which were correlated with smoking habit in sub¬
jects with peripheral arterial disease (Spearman's rank cor¬
relation coefficients; HDL -0.32, P< 0.05, triglycerides
0.24, P< 0.05) also had little effect on the association
between smoking and disease (OR 1.15; 95% CI 1.01-1.31;
/' < 0.05).
Discussion
Hyperinsulinaemia and peripheral arterial disease
Post-glucose insulin levels (but not fasting levels) were
higher in non-diabetic subjects with symptomatic or severe
asymptomatic peripheral arterial disease compared with
healthy controls. This confirms the findings of earlier stud¬
ies involving relatively small numbers of non-diabetic men
with intermittent claudication [7.8]. However, unlike the
present studv. these studies did not take into account
other, potentially confounding, cardiovascular risk factors.
Raised blood pressure, triglycerides, LDL cholesterol and
reduced HDL cholesterol are found to cluster in subjects
with hyperinsulinaemia (syndrome X), and may explain at
least some of the effects of insulin on disease [9], Our
study shows, for the first time, that the association
between insulin and peripheral arterial disease is indepen¬
dent of blood pressure and only partially dependent on
serum triglycerides, LDL cholesterol and HDL choles¬
terol. The association was also independent of blood glu¬
cose. The same independent relationship has been
observed recently between insulin and coronary artery dis¬
ease [6]. In addition, hyperinsulinaemia has been found to
be related to the incidence of intermittent claudication in
diabetic subjects after similar multivariate adjustment [17],
Our results are consistent with the hypothesis that hyper¬
insulinaemia is involved in the aetiology of peripheral arte¬
rial disease and mav contribute to the higher incidence of
disease in diabetic than in non-diabetic subjects. However,
as with any cross-sectional or case-control study, the possi¬
bility that hvperinsulinaemia was a secondary manifesta-
Fig. 1
Never-smokers Ever-smokers
Geometric mean (transformed 95% CI) of 1 h insulin levels in never-
smokers and ever-smokers, according to disease status. *P< 0.05,
"P<0.01 (ever-smoker versus never-smoker).
tion of existing vascular disease must be considered [18],
Generalised atherosclerosis and reduced vasodilators
capacity in subjects with peripheral arterial disease may be
associated with reduced glucose uptake into skeletal mus¬
cle and compensatory hyperinsulinaemia [19,20). In addi¬
tion, endothelial dysfunction caused by atherosclerosis
might affect transport of insulin across capillary mem¬
branes [18], leading to elevated postglucose insulin levels
in the presence of normal fasting levels, as in the present
study. A prospective cohort study will be required to deter¬
mine whether hyperinsulinaemia precedes the develop¬
ment of peripheral arterial disease.
An advantage of this study over numerous previous studies
is that the insulin immunoassay did not cross-react with
pro-insulin, confirming that the active insulin metabolite is
associated with disease. The pathophysiological mecha¬
nism by which insulin might promote the development of
atherosclerosis is unknown. In addition to its association
with blood pressure, dyslipidaemia and possibly other car¬
diovascular risk factor such as plasminogen activator
inhibitor-1 [2], insulin might have a direct pro-atherogenie
effect on blood vessel walls [9], Alternatively, hypcrinsulin-
aemia might act as a marker for insulin resistance, with the
latter determining cardiovascular risk [21).
Insulin, disease and sex
Another advantage of the present study is the inclusion of
both men and women. There has been some debate con¬
cerning whether insulin is a risk factor for coronary artery
disease in women as well as in men, as most large-scale
prospective studies have been confined to men [3-6,22).
This question is particularly interesting since diabetes is a
two- to three-fold stronger risk factor for coronary artery
disease in women than in men [23), and the same appears
to be true for peripheral arterial disease [17,24], Mean
post-glucose insulin levels were higher in both male and
female cases than in sex-matched controls, although the
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difference in women did noc quite reach statistical signifi¬
cance. Furthermore, there was no significant difference in
the strength of the association between insulin and disease
in men compared with women. The most likely expla¬
nation of these results is that post-glucose insulin is a risk
factor for peripheral arterial disease in both sexes, and that
lack of a significant difference in insulin levels between
female cases and controls reflected a small sample size.
Smoking, insulin and disease
We also demonstrated an association between smoking (a
particularly strong risk factor for peripheral arterial disease
[25]) and post-glucose insulin levels. Furthermore, this
association explained at least some of the effects of insulin
on disease. Smoking has not traditionally been associated
with hyperinsulinaemia or syndrome X, although a recent
report found higher insulin levels and greater insulin resis¬
tance associated with hypertriglyceridaemia and reduced
HDL cholesterol levels in 20 smokers than in 20 non-
smokers [10], Fasting insulin levels were also raised in
smokers and ex-smokers compared with non-smokers in
616 non-diabetic men from the general population [26],
This relationship was independent of other factors poten¬
tially affecting insulin sensitivity. It has been hypothesised
that insulin resistance, hyperinsulinaemia and dyslipid-
aemia in cigarette smokers might be one mechanism by
which smoking increases the risk of atherosclerotic disease
[10], Although we have confirmed a relationship between
smoking and insulin levels and have further shown that
this relationship is independent of other cardiovascular risk
factors, neither insulin levels alone, nor in combination
with HDL cholesterol anil triglyceride levels, accounted
for the effect of smoking on disease.
Conclusion
Raised post-glucose insulin levels were associated with
atherosclerotic disease of the lower limbs in non-diabetic
men and women from the general population. This associ¬
ation was at least partially independent of variations in
blood pressure, lipoproteins and triglycerides and is con¬
sistent with the hypothesis that hyperinsulinaemia is
involved in the aetiology of peripheral arterial disease in
non-diabetic subjects. A positive correlation between
smoking and raised insulin levels explained at least some
of the relationship between insulin and peripheral arterial
disease and merits further investigation.
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ELSEVIER
Steroid sex hormones and peripheral
arterial disease in the Edinburgh
Artery Study
J. F. Price, A. J. Lee, and F. G. R. Fowkes
Wolfson Unit for Prevention of Peripheral Vascular Diseases, Department of Public Health
Sciences, University of Edinburgh, Edinburgh, UK
Although treatment with high dose exogenous sex hormones affects cardiovascular risk, the role ofphysiological
levels of endogenous sex hormones in the development ofatherosclerotic disease in men and women is unknown.
Forty men and 43 women with peripheral arterial disease and 88 age- and sex-matched controls were selected
from participants in the Edinburgh Artery Study, a random survey of 1592 men and women ages 55-74 years
from the general population. Compared with sex-matched controls, male cases had higher systolic blood pressure
(155.5 mmHg vs. 138.7 mmHg; p £ 0.01) and waist hip ratio (0.92 vj. 0.89; p £ 0.05) and female cases hud
higher lifetime smoking (V packyears 2.14 vs\ 1.03; p £ 0.05). Mean estrone levels were slightly higher in male
cases than controls (101.9 pmol/Liter vs. 92.1 pmol/Liter; p = 0.09), but this association lost significance after
multivariate adjustment for age and bod\ mass index. Mean levels of total and free testosterone, estradiol, and
sex hormone binding globulin were not significantly different in cases compared with controls in either sex (p >
0.1). These results, in accordance with previous prospective studies on coronary artery disease, do not support
a role for physiological levels of endogenous sex hormones in the development ofperipheral arterial disease in
men or postmenopausal women. (Steroids 62:789-794. 1997) © 1997 by Elsevier Science Inc.
Keywords: peripheral arterial disease: atherosclerosis', steroid sex hormones; estrogen: testosterone
Introduction
It is widely believed that the different hormonal milieu of
men and women may help to explain the higher incidence of
coronary artery disease in males than in females. Indeed, a
protective role for estrogens in the development of cardio¬
vascular disease has been suggested by the increased risk of
both coronary artery disease1 and atherosclerosis2 in women
following surgical menopause and by the lower risk of
cardiovascular disease in postmenopausal women taking
exogenous estrogen.' Moreover, both male and female sex
hormone levels have been correlated with a variety of
cardiovascular risk factors, including high density lipopro¬
tein and low density lipoprotein cholesterol.4 However, little
is known about the relationship between endogenous sex
hormones and risk of atherosclerosis. Most previous studies,
confined to subjects with coronary artery disease, have
measured only a limited range of sex hormones (often on
frozen blood samples after prolonged storage with possible
associated deterioration in hormone levels), neglected the
possible importance of sex hormone binding globulin
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(SHBG) and the associated bioavailability of testosterone,
or were confined to hospital populations.5
The aim of the present study was to explore the relation¬
ship between total testosterone, free testosterone, SHBG.
estrone and estradiol, and atherosclerosis by comparing
levels of these hormones in men and women with and
without atherosclerotic disease of the lower limbs, selected
at random from the general population.
Methods
All the subjects in this nested case-control study were
selected from the Edinburgh Artery Study, a prospective
survey of 809 men and 783 women ages 55-74 years,
selected at random from the general population. Details of
the study recruitment, baseline examination, and follow-up
procedure have been described.6-7 Study participants have
now been followed up for 5 years for cardiovascular events
using annual validated questionnaires on cardiovascular his¬
tory. intermittent claudication" and angina," and information
from general practitioners, hospitals, and the Information
Services Division of the Scottish Office Home and Health
Department. All cardiovascular events were further inves¬
tigated using hospital or general practitioner records.
At the 5-year follow-up examination, subjects completed




questions on smoking, cardiovascular events, and the WHO
angina and intermittent claudication questionnaires.8 Bra¬
chial systolic and diastolic blood pressures were recorded
after 5 minutes rest using a random zero sphygmomanom¬
eter. Right and left posterior tibial systolic pressures were
recorded in the supine position after 5 minutes rest, using a
Doppler probe (Sonicaid, Chichester, UK) and random zero
sphygmomanometer. The ankle brachial pressure index
(ABPI) was calculated for each limb by dividing the pos¬
terior tibial by the brachial pressure. A 12-lead ECG was
taken and coded independently by two observers using the
Minnesota code.9 Standing height (without shoes) was mea¬
sured to the nearest 5 mm using a freestanding metal ruler
and weight (without shoes and outer garments) was mea¬
sured to the nearest 100 g on digital scales.
Cases were selected from participants attending the 5-
year follow-up examination if they had either (a) a history
of intermittent claudication according to the WHO intermit¬
tent claudication questionnaire, plus an ABPI ^0.9 in at
least one limb, or (b) asymptomatic peripheral arterial dis¬
ease indicated by an ABPI ^0.85 in at least one limb. An
ABPI of less than 0.9 is known to be up to 95% sensitive
and approximately 100% specific in detecting angiogram
positive disease10 and it is related to the severity of dis¬
ease." Controls were selected from the healthy study pop¬
ulation if they had no history of intermittent claudication
and an ABPI s 1.0 in both legs, no history of cardiovascular
disease (including angina, myocardial infarction or stroke),
and no evidence of myocardial infarction or ischaemia on
ECG. The controls were matched to the cases by sex and
5-year age band. Subjects were excluded from both the case
and control groups for the following reasons: (a) known
diabetes or newly diagnosed diabetes according to a fasting
plasma glucose S:7.8 mmol/Liter or the use of drugs affect¬
ing carbohydrate metabolism (to comply with requirements
for a parallel study on insulin resistance) and (b) women
with present or prior use of postmenopausal hormone re¬
placement therapy:
Morning fasting venous blood samples were taken from
all selected cases and controls for determination of total
plasma testosterone, SHBG, estrone, and estradiol. Samples
were centrifuged at —4°C within 15 minutes of collection,
and plasma was immediately frozen and stored at — 20°C
for a maximum of six months before assay. Samples for
total serum cholesterol, high density lipoprotein (HDL)
cholesterol, and triglycerides were taken at the same time,
also in the fasting state. Waist and hip circumferences were
measured to the nearest centimeter with the subject standing
and breathing normally. Hip measurements were made at
the level of the iliac crest and all measurements were made
by a single observer. The waist hip ratio was calculated as
the simple ratio of waist to hip circumference.
In the laboratory (Reproductive Medicine Laboratory,
University of Edinburgh), estradiol was measured using an
in-house radioimmunoassay following ether extraction of
serum. Estradiol-3-CME iodohistamine was used as tracer,
and the antibody was sheep anti-estradiol (lot BW 26/9/80).
Bound and free tracer were separated using dextran-coated
charcoal. Estrone was measured using an in-house ELISA
following ether extraction of serum. The primary antibody
was rabbit anti-estrone-3-glucuronide-BSA (obtained from
the MRC/AFRC Comparative Physiology Group, Institute
of Zoology, London, UK) with estrone-3-glucuronide con¬
jugated to horseradish peroxide as tracer and o-phenylene-
diamine dihydrochloride as substrate. SHBG and total tes¬
tosterone were measured by radioimmunoassay using
commercial kits (Orion Diagnostica, Espoo, Finland and
Medgenix, Springfield, Missouri, USA, respectively). All
samples were assayed in duplicate, and the sample was
assayed again if the values for the individual duplicates
differed by more than 5%. Inter- and intra-assay coefficients
of variation were <9.2% for estradiol, <9.9% for estrone,
^9.3% for SHBG, and <11.7% for total testosterone. For
subjects whose hormone levels were found to be below the
level of sensitivity of the total testosterone assay (0.18
nmol/Liter) and the estradiol assay (30 pmol/Liter), these
values were used in the analysis. Free testosterone was
calculated using the Free Androgen Index according to the
equation free testosterone (pmol/Liter) = [1000 X total
testosterone (nmol/Liter)]/sex hormone binding globulin
(nmol/Liter).
Tests for total cholesterol and triglycerides were per¬
formed on a E750C dry chemistry analyzer (Ortho Clinical
Diagnostics, Raritan, New Jersey, USA). Coefficients of
variation were 1.4-2.1% for total cholesterol and 1.6-1.9%
for triglycerides. HDL cholesterol was measured on a Cobas
Mira Plus analyser (Roche Diagnostics Ltd) following
chemical precipitation of other cholesterol-containing li¬
poproteins (coefficient of variation 3.4-4.6%). Low density
lipoprotein (LDL) cholesterol was calculated according to
the formula of Friedewald et al.12: LDL cholesterol = total
cholesterol — HDL cholesterol — triglycerides/5.
Mean levels of risk factors were compared in study cases
and controls, and the significance of differences were as¬
sessed by r-test, using the statistical package SPSS-X. For
triglycerides, SHBG, and estrone, the levels were log trans¬
formed because of skewed distributions, and geometric
means were given for these variables. Cigarette smoking
was calculated in pack years (years of smoking multiplied
by the average number of packs smoked per day) with the
value zero entered for lifelong nonsmokers. Square root of
pack years was taken to normalize the skewed distribution.
Multiple logistic regression was used to investigate the
relationship between sex hormones and disease after con¬
trolling for age, body mass index (BMI), and other cardio¬
vascular risk factors. Odds ratios and 95% confidence in¬
tervals were estimated from the regression coefficients
obtained from the statistical package BMDP.
Results
Age and disease characteristics of the male cases (n = 40)
and controls (n — 41) and female cases (n = 43) and
controls (n — 47) are shown in Table 1. As expected from
the matching, age was similar in cases and controls. Mean
ABPI was substantially lower in both male and female
cases, over 30% of whom had a history of intermittent
claudication. Several of the cases also had evidence o!
angina or previous myocardial infarction.
Table 2 shows the mean risk factor levels in male cases
and controls. Male cases had significantly higher mean
systolic blood pressure and greater waist to hip ratios than
790 Steroids, 1997, vol. 62, December
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Table 1 Age and Disease Characteristics of Male and Female Cases of Peripheral Arterial Disease and Controls
Men Women
Cases (n = 40) Controls (n = 41) Cases (n = 43) Controls (n = 47)
Age, mean years (SE) 71.9 (0.8) 71.4 (0.82) 71.3 (0.8) 70.5 (0.7)
Intermittent claudication, % (n) 30 (12) 0 33 (14) 0
Mean ABPI (SE) 0.70 (0.02) 1.14 (0.02) 0.72 (0.02) 1.10 (0.01)
Angina, % (n) 28 (11) 0 21 (9) 0
Myocardial infarction, % (n) 20 (8) 0 14 (6) 0
ABPI, ankle brachial pressure index.
controls [p s 0.05). They also had slightly higher serum
triglyceride levels, BM1, and lifetime smoking (p < 0.1).
There was no significant difference in mean levels of total
testosterone, SHBG, free testosterone, or estradiol between
leases and controls (p > 0.1), but mean estrone was slightly
higher in the cases (101.9 pmol/Liter vs. 92.1 pmol/l, p =
,0.09).
f Table 3 gives mean levels of the same risk factors in
jfemale cases and controls. Female cases had significantly
!higher lifetime smoking than controls (p ^ 0.05) and
'slightly lower HDL cholesterol (p < 0.1). There was no
significant difference in mean levels of total testosterone,
SHBG, free testosterone, estradiol, or estrone between cases
and controls {p > 0.1).
The prevalence of thyroid disease, which can affect
SHBG concentrations, was low (data not shown). Five
female cases, two female controls, and no male subjects
were taking thyroxine (which can increase SHBG levels)
and no subjects of either sex were being treated for hypo¬
thyroidism. When female subjects taking thyroxine were
excluded from the analysis, there remained no significant
difference in SHBG levels between cases and controls
(mean SHBG 44.6 cases; 48.6 controls; p = 0.46).
The results of multiple logistic regression, used to ex¬
amine the association between steroid sex hormones and
risk of disease after adjustment for the other cardiovascular
risk factors, are shown in Table 4. None of the sex hor¬
mones was associated with an increased or decreased risk of
peripheral arterial disease, including serum estrone in men.
after multivariate adjustment for age and BMI. Further
adjustment for systolic blood pressure, smoking, LDL and
HDL cholesterol, and triglycerides had no major effect on
these results.
Discussion
To our knowledge, this is the first report of a study inves¬
tigating the relationship between endogenous sex hormones
and peripheral arterial disease. We were able to measure a
wide range of sex hormones, as well as SHBG, usin«
plasma that had been stored for only a limited time, and
subjects from the general population rather than hospitals.
We found little evidence to support the suggestion that
testosterone (total or free), SHBG, estradiol, or estrone were
risk factors for peripheral arterial disease in either sex. The
most important risk factors were systolic blood pressure,
cigarette smoking, triglycerides. BMI and waist hip ratio in
men. and smoking and reduced HDL cholesterol in women
Men
Several case-control studies of endogenous hormones in
men with coronary artery disease found higher estrogen
Table 2 Mean Risk Factor Levels in Male Cases of Peripheral Arterial Disease and Controls
Male cases (n - 40) Male controls (n - 41)
Mean 95% CI Mean 95% CI p-value
Systolic BP, mmHg 155.5 (146.5,164.4) 138.7 (132.0,145.4) 0.004
Smoking, \ packyears 4.12 (3.13,5.11) 2.85 (1.91,3.79) 0.07
Total cholesterol, mmol/Liter 6.23 (5.91,6.55) 6.21 (5.88,6.54) 0.94
LDL cholesterol, mmol/Liter 4.38 (4.07,4.68) 4.48 (4.17,4.79) 0.65
HDL cholesterol, mmol/Liter 1.07 (0.97,1.17) 1.12 (1.03,1.21) 0.47
Triglycerides, mmol/Liter* 1.53 (1.32,1.78) 1.28 (1.13,1.45) 0.07
BMI, kg/mz 26.5 (25.4,27.6) 25.2 (24.3,26.0) 0.06
WHR 0.92 (0.90,0.94) 0.89 (0.87,0.91) 0.04
Total testosterone, nmol/Liter 13.6 (12.0,15.3) 14.9 (13.3,16.5) 0.28
SHBG, nmol/Liter* 34.6 (30.4,39.3) 39.5 (35.6,43.8) 0.12
Free testosterone. pmol/Liter 403.4 (354.6,452.2) 379.2 (336.4,422.0) 0.47
Estrone. pmol/Liter* 101.9 (94.8.109.5) 92.1 (84.2,100.8) 0.09
Estradiol, pmol/Liter 97.9 (88.6,107.3) 106.1 (97.3,114.9) 0.21
•geometric mean of logged variable.
BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; BMI, body mass index; WHR, waist hip ratio; SHBG.
sex hormone binding globulin.
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Table 3 Mean Risk Factor Levels in Female Cases of Peripheral Arterial Disease and Controls
Female cases (n = 43) Female controls (n = 47)
Mean 95% CI Mean 95% CI
Systolic BP, mmHg 154.2 (147.4,161.0) 147.8 (141.0,154.7)
Smoking, V packyears 2.14 (1.24,3.04) 1.03 (0.51,1.55)
Total cholesterol, mmol/Liter 6.81 (6.46,7.16) 6.88 (6.57,7.19)
LDL cholesterol, mmol/Liter 4.77 (4.45,5.08) 4.77 (4.49,5.05)
HDL cholesterol, mmol/Liter 1.31 (1.22,1.40) 1.44 (1.35,1.53)
Triglycerides, mmol/Liter* 1.50 (1.33,1.71) 1.39 (1.26,1.43)
BMI, kg/m2 26.1 (24.9,27.4) 26.5 (25.4,27.6)
WHR 0.88 (0.85,0.90) 0.87 (0.85,0.90)
Total testosterone, nmol/Liter 0.62 (0.50,0.73) 0.72 (0.58,0.86)
SHBG, nmol/Liter* 45.0 (38.2,53.1) 49.0 (42.4,56.7)
Free testosterone, pmol/Liter 15.3 (11.24,19.35) 16.0 (12.4,19.5)
Estrone, pmol/Liter* 81.26 (73.96,89.27) 82.96 (77.92,88.33)















♦geometric mean of logged variable.
BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; BMI, body mass index; WHR, waist hip ratio; SHBG,
sex hormone binding globulin.
levels and lower testosterone levels in survivors of myocar¬
dial infarction compared with controls.5 Although we found
slightly higher levels of estrone in male cases than in male
controls, this relationship was only weakly significant and
became nonsignificant after adjustment for age and BMI.
Since obesity is associated with altered sex hormone levels
and is also a risk factor for cardiovascular disease, it is an
important confounding factor. Neither mean estradiol nor
total testosterone levels were significantly different in men
with peripheral arterial disease compared with controls.
These results are consistent with those of prospective stud¬
ies, in which none of the three sex hormones, estradiol,13-17
estrone,131617 or total testosterone13-16 predicted subsequent
myocardial infarction13-1517 or the development of symp¬
tomatic cardiovascular disease.16 It is likely that the altered
hormone levels found in myocardial infarction survivors
were a consequence of myocardial infarction, rather than a
precursor. In our population, only 20% of male cases and
14% of female cases had a history of myocardial infarction
and none of these events occurred within the year before
hormone measurement.
More than 90% of total testosterone circulates bound to
proteins, predominantly SHBG, and it is possible that only
the free (bioavailable) testosterone fraction is important in
determining cardiovascular risk. However, neither in the
present study, nor in prospective studies of coronary artery
disease, was free testosterone associated with the presence
or development of atherosclerotic disease.13-16 More re¬
cently, it has been suggested that SHBG itself might be a
risk factor for cardiovascular disease, largely because of
observed correlations between SHBG and cardiovascular
risk factors such as HDL cholesterol and insulin.1" How-
Table 4 Multivariate Logistic Regression of Steroid Sex Hormones on Peripheral Arterial Disease
Men Women
Hormone factors adjusted for OR 95% CI p-value OR 95% CI p-value
Total testosterone**
age,BMI 0.84 (0.52,1.36) 0.48 0.79 (0.51,1.23) 0.30
age,BMl,sBP,cigs,LDL,HDL,TGs 0.75 (0.41,1.38) 0.37 0.70 (0.41,1.17) 0.19
SHBG*
age,BMI 0.43 (0.12,1.55) 0.21 0.59 (0.23,1.49) 0.27
age,BMI,sBP,cigs,LDL,HDL,TGs 0.50 (0.10,2.60) 0.44 0.72 (0.24,2.15) 0.57
Free testosterone**
age,BMI 1.21 (0.74,1.99) 0.46 1.98 (0.63,1.51) 0.92
age,BMI,sBP,cigs,LDL,HDL,TGs 1.10 (0.61,1.99) 0.77 0.77 (0.45,1.30) 0.35
Estrone*
age,BMI 3.36 (0.55,20.6) 0.20 0.69 (0.14,3.49) 0.66
age,BMI,sBP,cigs,LDL,HDL,TGs 2.13 (0.21,21.2) 0.55 0.71 (0.12,4.43) 0.73
Estradiol**
age,BMI 0.74 (0.46,1.19) 0.22 0.82 (0.53,1.28) 0.39
age,BMI,sBP,cigs,LDL,HDL,TGs 0.67 (0.36,1.26) 0.24 0.79 (0.47,1.32) 0.39
OR: *Odds ratio for a one unit increase on a log scale in steroid sex hormone.
**Odds ratio for a 1 SD increase in steroid sex hormone (total testosterone 5.22 mnol/Liter men, 0.45 nmol/Liter women; free
testosterone 148 pmol/Liter men, 12.85 pmol/Liter women; estradiol 29.54 pmol/Liter men, 14.53 pmol/Liter women).
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ever, we found no significant difference in the levels of
SHBG between men with and without peripheral arterial
disease, consistent with previous case-control19-20 and pro-
ispective16 studies on sex hormone binding concentration
and cardiovascular disease in men.
j.
Women
Postmenopausal women taking pharmacological doses of
exogenous estrogens reduce their risk of cardiovascular
disease,3 However, we did not find any significant differ¬
ence in endogenous estrone or estradiol levels between
women with and without peripheral arterial disease, sug¬
gesting that physiological doses of estrogens may not be
associated with disease. Correspondingly, no association
has been found between circulating estrone levels and prev¬
alent heart disease,21 nor between estrone or estradiol and
the development of symptomatic cardiovascular disease.22
Neither testosterone (total or free), nor SHBG levels
differed between women with and without peripheral arte¬
rial disease in the present study. Previous information on
endogenous testosterone levels and atherosclerotic disease
• in women is scarce. Although women with testosterone
excess associated with chronic anovulation had an increased
risk of myocardial infarction, in a single prospective
study,23 neither total nor free testosterone predicted fatal
cardiovascular disease in postmenopausal women.22 How¬
ever, low SHBG levels did increase the 12-year incidence of
cardiovascular disease in postmenopausal women.24
An important consideration in any negative study is
whether the study had sufficient power to detect a signifi¬
cant difference. With our sample size and at a power of 80%
i(a = 0.05), we could detect a difference in each sex hor¬
mone equivalent to approximately half a standard deviation
of its sex-specific distribution (for example, a difference in
total testosterone of 2.55 nmol/Liter in men and 0.27 nmol/
Liter in women). It is possible that smaller differences might
have been detected using larger subject numbers, but the
physiological relevance of such small differences is ques¬
tionable. It is also possible that our results could have been
affected by the sensitivity of the hormone assays; in our
laboratory, 18% and 22% of women were below the sensi¬
tivity range for estradiol and total testosterone, respectively,
but no men were below the sensitivity range of any of the
sex hormones and no women were below the sensitivity
range for estrone or SHBG. Diurnal variation in hormone
levels should not have affected the results because all sam¬
ples were taken fasting at the same time in the morning.
The population studied in this investigation was rela¬
tively elderly (mean age 71 years). The fact that exogenous
estrogens reduce cardiovascular risk in postmenopausal
women suggests that exposure to sex hormones, even in
later life, may be an important factor in determining disease.
However, the latency period of cardiovascular disease is
long, and it is also possible that any effects of endogenous
sex hormones on disease are more important earlier in life,
during the development phase of atherosclerosis. This is a
particularly important consideration in women, because es¬
trogen levels fall substantially during the menopause. Un¬
fortunately. study of premenopausal women would be dif¬
ficult due to their low risk of cardiovascular disease
(necessitating prolonged follow-up) and difficulties in de¬
termining average hormone concentrations during the men¬
strual cycle.
In conclusion, this study does not support the hypothesis
that endogenous sex hormone levels are important in deter¬
mining risk of atherosclerotic disease in elderly men and
postmenopausal women. The role of endogenous sex hor¬
mones in cardiovascular disease now needs to be addressed
in younger populations, in particular to determine the sig¬
nificance of observed associations between sex hormones
and cardiovascular risk factors
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